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Abstract

APPLICATION OF PHARMACOMETRIC METHODS TO IMPROVE PEDIATRIC DRUG
DEVELOPMENT
By Mallika A. Lala, Ph.D.
A dissertation submitted in partial fulfillment of the requirements for the degree of
Doctor of Philosophy at Virginia Commonwealth University.

Virginia Commonwealth University, 2011

Major Co-advisors: Jogarao V.S. Gobburu and F. Douglas Boudinot

Pharmacometrics is a quantitative science that is rapidly changing the landscape
of drug development, and particularly so for the pediatric population. The motivation
behind the research underlying this dissertation is to contribute towards the improvement
of pediatric drug development by the astute application of pharmacometric methods. Two
distinct research areas have been focused upon: 1- improving pediatric pharmacokinetic
(PK) trial design and 2- improving pediatric dosing of warfarin by using a genetics-based
dosing regimen.

xiv

The first project examined in detail the feasibility of and simulation-based
methodology for implementing a recent regulatory PK quality standard. The focus was on
designing pediatric PK trials that employ sparse sampling and population analysis
methods, using a simulation-estimation platform. The research provided clarity on the
impact of various trial design elements, such as PK sampling, adult data inclusion, PK
variability and analysis method on sample size adequacy to honor the standard.
The PK quality standard was found to be practically feasible in terms of sample
size adequacy. Informative sampling schedule for a given number of PK samples per
subject is assumed during trial design. Recommendations are made to: 1- use prior adult
or pediatric data for trial design and analysis, wherever possible and 2 - use one-stage
population analysis methods and biologically feasible covariate models for designing
pediatric PK studies.

The second project involved derivation of the first ever pediatric warfarin dosing
regimen, including starting dose and titration scheme, based on pharmacogenetics
(Cyp2c9 *1/*2/*3 and VKORc1 -1629 G>A polymorphisms). While extensive research
and several dosing models for warfarin use in adults exist, there is paucity of data in
pediatrics. A validated adult warfarin population PKPD model was bridged using
physiological principles and limited pediatric data to arrive at a pediatric PKPD model
and dosing regimen. Pediatric data (n=26) from an observational study conducted at the
Children’s Hospital Los Angeles (CHLA) was used to qualify the pediatric model.
A 2-step pediatric starting dose based on body weight (<20 kg and ≥20 kg) for
each of 18 (6 Cyp2c9 x 3 VKORC1) genotype categories is proposed. The titration

xv

scheme involves percentage changes relative to previous dose, based on latest patient
INR. The dosing regimen targets a major (≥ 60%) proportion of INRs within therapeutic
range of 2.0-3.0, by the second week into warfarin therapy. Simulataneously, bleeding
and thromboembolic risks are minimized via minimal proportions (≤ 10% and ≤ 20%) of
INRs > 3.5 and INRs < 2.0, respectively. In simulations, the proposed dosing regimen
performed better on target INR outcomes than the standard-of-care dosing used in the
CHLA patients. Given the challeneges in and low likelihood of conducting pediatric
warfarin clinical studies, the proposed dosing regimen is believed to be an important
advance in pediatric warfarin therapy. Prospective warfarin studies in pediatrics using the
proposed dosing regimen are recommended to refine and validate the suggested dosing
strategy.

xvi

CHAPTER 1
Pharmacometrics: Concepts and Applications to Drug
Development

ABSTRACT
Pharmacometrics is the science of quantitaive clinical pharmacology that impacts
decision-making throughouht the drug development and regulatory review process. It is
based primarily on pharmacokinetic and pharmacodynamic modeling and simulation with
applications including among others, clinical trial design and dose optimization. Through
the channel of quantitiative drug, disease and trial models, pharmacometric methods have
the unqiue ability to leverage all prior and current information from diverse sources
including clinical pharmacology, pathophysiology and statistics.
This chapter provides an introduction to the genral applications of
pharmacometrics as well as concepts and methods employed, including non-linear mixed
effects modeling and population analysis. Further, several case studies are cited, where
pharmacometric analyses played a role in drug development and/or regulatory decision
making. Finally, a future perspective on the field is provided with considerations for
wider adoption of pharmacometrics to improve the efficiency of drug development
programs.
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WHAT IS PHARMACOMETRICS?
Introduction
Pharmacometrics is the science of quantitaive clinical pharmacology that influences
decision-making throughouht the drug development and regulatory review process. It is
an amalgamation of several research areas, including among others, pharmacokinetics
(PK), pharmacodynamics (PD), pathophysiology and statistics. Pharmacometrics
comprises of an array of techniques that are primarily based on modeling and simulation
of data, which include but are not limited to population pharmacokinetic (PPK) analysis,
exposure-response (E-R, or PK-PD) determination for drug efficacy and safety, clinical
trial simulations and disease progression modeling.

Several organizations have discussed the increasing importance of modeling and
simulation for enhancing drug development [1-4]. The pharmaceutical industry has
conducted surveys to evaluate the role of pharmacometric analysis in their drug
development process. A study at Parke-Davis [5] found that in almost half (5 of 12) of
the cases reviewed, the population analysis provided information that influenced the
direction of individual development programs and may have facilitated review and
approval. A similar study at Hoffmann La Roche [6] found that a modeling and
simulation guided approach contributed toward making clinical drug development more
rational and efficient, by better dose selection for clinical trials and time savings up to
several months.

2

The following sections of this chapter describe the general applications of
pharmacometrics during drug development and regulatory review, as well as different
concepts and methods employed.

Case studies, which bring out the role that

pharmacometric analyses have played in various aspects of drug development, and a
future perspective on the field, are also provided.

Quantitative disease-drug-trial models
Disease-drug-trial models may be considered mathematical expressions of the time
course of biomarkers, clinical outcomes, placebo effects, drug effects, and trial execution
characteristics [7]. Accrual of information from across drug development programs
enables efficient future planning, for which quantified disease, drug, and trial information
can serve as a helpful guide.

Disease models quantify the relevant biological system in the absence of drug (detailed
discussion in Section 2). Drug models characterize the exposure-response relationship for
both efficacy and safety of drugs. Among other decisions, such models drive the
determination of optimal dosing regimens. Using drug models early on can reduce
unexpected safety/efficacy outcomes during the late clinical phase [8;9]. Trial models
attempt to account for patient characteristics and behaviors such as eligibility criteria,
baseline variables and their correlation, protocol adherence [10] and dropout rates, which
may significantly influence outcomes in clinical trials. Trial models have great potential
contribution towards more efficient and successful future clinical trials.

3

Applications
Pharmacometrics can be applied at all stages of the drug lifecycle, right from the preclinical phase through clinical development and regulatory review, as well as postmarketing. Potential applications range from molecule screening and identification of
biomarkers and surrogates, to dosing regimen and trial design selection and optimization,
to prognostic factor and benefit/risk evaluation. These methods have the unique ability to
leverage all prior and current information, providing a rational, scientifically sound
framework to maximize knowledge and efficiency of drug development programs. The
many and varied applications of pharmacometrics are illustrated in Figure 1.

Figure 1: Potential applications of pharmacometrics throughout drug development
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Clinical trial design
It has been observed over time that registration trials fail to demonstrate effectiveness or
safety, often due to ignorance of prior knowledge, both drug-specific and non-specific
(placebo-effect or natural disease progression) and/or employment of one-size-fits-all
dosing strategies [1;11]. Disease-drug-trial models and clinical trial simulations are
useful tools that can help reduce such trial failures. Potential benefits include upfront
comparison of candidate study designs, dose and safety outcomes selection, sample size
and power determination, and evaluation of drug interactions and co-morbidities [12].
The resources needed to perform the pharmacometric analyses are negligible compared
with the costs of unsuccessful trials.

For instance, nesiritide, developed for the treatment of acute congestive heart failure, was
initially not approved because the dosing regimen used in the first registration trial was
sub-optimal. Modeling led to suggestion of a new, optimal dosing regimen, and results of
simulated trials based on this regimen matched well with those of the second registration
trial that led to eventual approval of the drug [13]. In retrospect it appears as though an
early dose optimization could have saved three years of drug development time and one
failed clinical trial.

Another instance, is for a drug to treat type 2 diabetes mellitus [14], a semi-mechanistic
model to describe the time course of FPG and HbA1c was developed and extensive
simulations were performed to evaluate two different trial designs: genotype-stratified
and biomarker enrichment designs. The biomarker-enrichment design with a bid dosing
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regimen was proposed for future trials with an understanding that the trial results would
be used to derive an optimal dosing strategy such as genotype-based dosing. An
important resulting drug development decision was the need to develop a sustained
release formulation of the drug.

Dose optimization
Exploring several dosing strategies in clinical trials is often impractical, costly, and in
some cases, unethical. Under such circumstances, simulations can be used to explore all
competing dosing schemes and select an optimal strategy. If no single dosing scheme is
able to achieve target drug exposures in majority of patients, there may be need for dose
individualization and therapeutic drug monitoring (TDM). Modeling and simulation can
help forecast this need and provide a TDM strategy [1]. This was observed in case of an
oral suspension product for prophylaxis of invasive fungal infections in high-risk patients
[15]. E-R analysis revealed very high variability in exposures across patients and the need
for TDM to maximize effectiveness for all patients, and supported conducting a postmarketing study to evaluate benefit of proposed TDM. The analysis also supported
inclusion of administration conditions to optimize drug absorption, emphasizing the
importance of adequate plasma concentrations, in the drug label.

Usually, only dosing regimens ‘directly’ studied in clinical trials are proposed in drug
labels. However, a drug model may effectively be used to explore the suitability of
intermediate doses that are not directly studied but could potentially offer similar
effectiveness as studied dosing regimens [16;17]. But extrapolating outside the studied
6

dose range may not be feasible. The ability of a well-developed exposure-response
relationship to support approval of a dosing regimen not directly studied in clinical trials
is in fact one of the strongest merits of modeling and simulation. Unfortunately, this tool
is not being fully exploited currently.

Covariate / Prognostic factor determination
Apart from dose-ranging studies, the clinical pharmacology characterization of a new
drug involves a number of bridging studies to identify influential covariates or prognostic
factors such as body size, age, gender, food intake, co-morbidities, co-medications, and
others. While effectiveness and safety data may not be collected in bridging studies, they
could be simulated from a previously developed drug model.

For instance, Sular is a once-a-day controlled release formulation of the drug Nisoldipine,
which is approved in the United States for the treatment of hypertension. Food was found
to increase the bioavailability (Cmax increases up to 245%) of the controlled release
product. The influence of these higher drug concentrations on lowering of blood pressure
was evaluated using simulation of the drug effect under fed condition from a previously
developed exposure-response model [18]. Even though the Sular label recommends
administration on an empty stomach for optimal bioavailability, these simulations
alleviated the safety concern of a large drop in blood pressure, should the drug be
administered with food. Hence, there is no safety warning in the label for the drug to not
be administered in a fed condition.
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Special populations
Pharmacometric analyses enable the understanding of unique clinical pharmacology
features in special populations such as pediatrics, geriatrics, renal/hepatic impairment,
and others. A case in point is docetaxel, where the exposure-response relationship in
patients with cancer was successful in identifying a sub-population, patients with liver
impairment, to be more prone to grade 4 neutropenia [19]. This important finding
improved the safety profile of the drug and was the basis of the dosing recommendation
for patients with hepatic insufficiency in the label. The drug development program of
docetaxel exemplifies the value added by prospective modeling and simulation while
planning clinical trials.

The FDA offers a six month extension on the marketing exclusivity for a new drug,
should the sponsor fulfill the requirement of a written request to characterize the
exposure-response relationship of the drug in pediatrics. Hence, one of the most sought
out special populations to study for labeling changes is pediatrics. A well-defined
exposure-response relationship of a drug in adults, be it for a biomarker, surrogate or
clinical endpoint, can facilitate development of the same drug for use in pediatrics.
Modeling and simulation is a powerful tool that can be used to provide plausible trial
design, rational dosing recommendations and useful labeling information in pediatrics
when sufficient understanding of adult and pediatric pharmacology is available [20].

For instance, a pediatric population analysis [21], and further modeling and simulation
[22], provided the labeled dosing recommendations for the anti-arrhythmic agent sotalol
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in pediatrics aged 1 month to 12 years. The E-R analysis found drug effects in pediatrics to
be consistent with adults. In this case, dosing for patients < 2 years of age was selected

specifically based on modeling, and not studied directly in trials.

Regulatory considerations
The United States Food and Drug Administration (FDA) routinely utilizes
pharmacometric methods as an aid in making regulatory decisions during the
investigational new drug (IND), biologics license application (BLA) and new drug
application (NDA) review processes. The role of pharmacometric analyses in various
regulatory decisions are summarized in Table 1.

A survey of 42 NDAs submitted between 2000 and 2004, which included a
pharmacometric component, revealed that pharmacometric analyses were pivotal in
regulatory decision making in more than half of the cases. Of the 14 reviews where such
analyses were key to approval related decisions, 5 identified the need for additional trials,
while 6 identified reduction in the burden of conducting additional trials [1].

The proceedings of an advisory committee meeting for cardio-renal (CR) drug products
are noteworthy [23]. The meeting devoted 50% of the total time to discuss the role of
exposure-response in CR drug development. The advisory committee concluded that
model-dependent analysis to learn about the shape of the exposure-response curve and
more innovative designs to potentially allow both, frequentist and Bayesian types of data
analysis were needed.
9

Table 1: Summary of the types of regulatory decisions influenced by
pharmacometric analyses
Regulatory

Role of Pharmacometric Analyses

Decision

Trial design

•

Selection of dose or exposure range for registration trials

guidance

•

Derivation of optimal sampling schemes (PK and PD)

Approval

•

Development of approval criteria

•

Evaluation of:
o evidence of effectiveness
o benefit-risk
o targeted safety studies (ex: QT evaluation)
o clinical implications of failed bioequivalence studies

Labeling

•

Recommendation of dosing strategy:
o dose and regimen
o individualized doses, where required
o therapeutic drug monitoring, where required
o dosing in special populations (ex: pediatrics)
o drug interactions

Policy

•

Evidence for warnings and precautions

•

Evaluation of:
o alternative primary analysis methods
o competing recommendations for guidances
o bioequivalence criteria

10

The FDA issues guidance to industry to facilitate a smoother drug development and
approval process. The guidance to industry on population pharmacokinetics [16]
emphasizes the role of modeling and simulation in designing and analyzing trials. The
FDA Modernization Act (FDAMA) [17] has a section for “extrapolation from existing
studies” which emphasizes the ability to use knowledge from previous clinical trials for
approval of the same drug product for pediatric use, or for establishing equivalence of
alternative formulations, provided the original trial yielded well-defined exposureresponse relationships. The FDA has also implemented End-of-Phase-IIA (EOP2A)
meetings with sponsors [24] and published the Critical Path Initiative [25], which again
emphasize the usefulness of pharmacometrics in enhancing drug development. The
premise for all these regulatory initiatives is that with efficient planning, sponsors can
economize valuable drug development time and resources, which is in public health
interest, as well as reap full advantage of the resulting incentives.

DISEASE MODELS
A disease model is a mathematical representation of a given biological (or pathological)
system in the absence of drug that attempts to quantify the time course of the disease [7].
There are three major sub-models that capture the relevant aspects of disease modeling,
namely, the relationship between biomarkers and clinical outcomes, the natural disease
progression, and the placebo effect. In addition, there are three general approaches to
building any disease model: systems biology, semi-mechanistic, and empirical modeling.
The main features of the three approaches are summarized in Table 2.

11

Biomarkers and clinical outcomes
In several cases, particularly when clinical endpoints occur after prolonged periods of
time, biomarkers are used as outcomes in clinical trials rather than the actual clinical
endpoints. Characterization of the relationship between biomarkers and clinical outcomes
for both efficacy and safety for a particular disease condition, is thus a very important
aspect of disease modeling, and can help develop surrogate endpoints. Such models can
then aid in trial design optimization and risk projection based on biomarker data. Systems
biology models, although complex, are very useful for this purpose [26]. They are based
on an understanding of the underlying biological system, much like physiologicallybased models. They represent the system at the molecular level, with an ability to account
for pathological disturbances. The model parameters are estimated from multiple,
detailed in-vitro and ex-vivo experiments [7].

On the other hand, semi-mechanistic and empirical models are predominantly data driven
and tend to disregard details of related diseases [27]. Semi-mechanistic models
sufficiently simplify the biological system to be able to describe the available data well,
and could be the first step toward a systems biology model. Empirical disease models are
essentially mathematical expressions used to interpolate between observed data, and
seldom relate to the underlying biology. Even so, such models are useful, depending on
the problem at hand. Empirical models are simple and frequently all that is available, and
are often invaluable in making go/no-go decisions and designing pivotal trials. The
empirical parametric hazard model [28] that describes the relationship between the
change in tumor size and survival is one such example.
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It may be correct to say that every model will include some empirical component. For
instance, in the case of diabetes, a detailed systems biology model with more than 50
parameters [29], as well as a semi-mechanistic model [30] have been proposed. While the
systems biology model takes into account glucose and HbA1c data, as well as other
related information such as blood pressure, cardiac output, family history, cholesterol,
and smoking status, the semi-mechanistic model focuses on just the glucose and HbA1c
information. Similarly, the outputs of the systems biology model include risks of
retinopathy, nephropathy, and neuropathy, while the semi-mechanistic model is restricted
to prediction of changes in glucose and HbA1c. Having said that, the systems biology
model will still need to establish a relationship between change in blood pressure and/or
glucose and a binary event such as myocardial infarction, thus incorporating an empirical
component [7].

Natural disease progression
The natural disease progression aspect of disease modeling aims at describing the time
course of changes observed in the clinical outcome. Drug therapy may alter natural
progression of the disease, and such models can then provide insights into the
management of several diseases [31]. For this purpose, empirical models have been used
most commonly. The natural progression of Alzheimer’s disease as measured by the
Alzheimer’s Disease Assessment Scale – Cognitive score (ADAS-COG) and that of
Parkinson’s disease using total Unified Parkinson Disease Rating Scale (UPDRS) have
been described using empirical models [32-34]. However mechanistic models, which are
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more generalizable, are also being studied. A mechanistic disease progression model for
arthritis in rats has been proposed [35].

Placebo effect
The effect in a placebo group refers to the psycho-socially induced biochemical changes
in a patient’s brain and body that in turn may affect both, the natural course of a disease,
and response to therapy [36]. Thus, even though the placebo-effect is not directly related
to the disease, it can significantly impact outcomes. This is particularly true for disease
conditions that are measured symptomatically, such as pain and depression. Therefore,
modeling the magnitude and time course of placebo effect has value in discerning true
drug effects and also aids in estimating sample size during trial design. Recently, a
Bayesian model that describes the time course of the Hamilton Depression Rating scale
(HAMD-17) clinical score in the placebo arms of antidepressant trials, combined with a
dropout mechanism, has been developed [37]. This model provides new insights on the
validity of the results of several longitudinal registration trials currently used for new
drug products. A placebo model for Crohn’s disease trials [38] is also available.
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Table 2: Comparison of systems biology, semi-mechanistic and empirical
approaches to disease models

Feature

Data source

Validation

Complexity

Application

&
Approach

Resources

Systems

Wide range –

Extremely

High –

biology

underlying biology,

challenging

Diverse

models

inter-relationships with

expertise

related systems,

involved.

multiple detailed

• target
identification
• dose selection
• trial design
optimization

experiments etc.

• risk projection
based on
biomarker data
Semi-

Limited range –

mechanistic one or more
models
experiments; related

• go/no-go
Low –

systems not considered
Empirical

Limited range –

models

one or more

decisions

Relatively

Lesser

• dose selection

simple

expertise

• trial design

involved.

experiments; may not
accommodate design
variations and related
systems not considered
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optimization

POPULATION ANALYSIS
Conceptual framework
A population model typically comprises structural and statistical model components.
Structural models are deterministic in nature, and account for population or ‘fixed
effects’ (primary model parameters), but do not account for variability. The typical value
of systemic clearance (CL) for a 70 kg individual and the mean potency (EC50) of a drug
are examples of fixed effects. A population model suite would include four structural
models: PK model, PD model, covariate (or prognostic factor) model and disease
progression model.

Statistical models are stochastic in nature, and account for the variability or ‘random
effects’ seen at both, the individual and the observational levels. A population model
suite would include three statistical models: between-subject variability (BSV) model,
between-occasion variability (BOV) model, and within-subject variability (WSV) model.
Random effects models usually assume that the between-subject and between-occasion
errors (η) are normally distributed with mean zero and variance Ω2, and that the withinsubject or residual errors (ε) are normally distributed with mean zero and variance σ2.
BSV signifies deviations among different subjects and BOV signifies deviations among
different occasions. WSV signifies deviation between predicted and observed values for
each subject, and may be the result of measurement error or even model-misspecification.

Nonlinear mixed effects models are called so because they attempt to account for both,
fixed and random effects together. The “mixed effects” concept is depicted in Figure 2.
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Consider a one-compartment PK model where the drug is given as an intravenous bolus
and the volume of distribution (V) is identical in every individual (no BSV for V). Then,
the concentration in the ‘ith’ subject at the ‘jth’ time point (C ij ) can be described using the
following equations:
C ij =

Dose
⋅e
V

−

CLi
⋅t
V

+ ε ij

CLi = CL POP + η CL,i

Eqn. (i)

Eqn. (ii)

where; CL i is the estimated clearance of the ‘ith’ subject, CL POP is the estimated
population mean clearance, η CL,i is the difference between the population mean and
individual clearances and ε ij is the residual error of the ‘jth’ sample of the ‘ith’ subject.

Figure 2: Conceptual framework for nonlinear mixed effects modeling
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Analysis methods
A primary goal of population analysis is to estimate the mean value of relevant
parameters (such as CL, V and EC50) in the population of interest, the variances in these
parameters as well as residual variability of observations. Another goal is to explain the
observed BSV using patient covariates such as body size, age, genotype etc. In addition,
estimating individual PK parameters (such as CL i and V i ) is required to impute
concentrations for performing E-R analysis and any other simulations at a later stage.

The known methods for performing a population analysis are: naïve pooled, naïve
averaged, two-stage (TS), and nonlinear mixed effects (NM) or one-stage analysis. The
main features of these analysis methods are summarized in Table 3.

In naïve pooled analysis, individual observations from all subjects are pooled (as though
all data came from a single, giant subject) to obtain average PK parameters. A minor
variation of this method is the naïve averaged analysis which involves determination of
the mean of the data at each time point. Both these methods provide only the central
tendency of the model parameters and no random effects are estimated. These methods
are used more often for pre-clinical data and are appealing because of their simplicity.
However, since between-subject variability is not estimated and cannot be accounted for
using covariates, the potential applications of naïve pooled or naïve averaged analyses are
very limited.
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In two-stage analysis, the first stage involves estimation of the average parameters for
each subject from their individual observations, while the second stage involves the
estimation of the population mean and variance of the parameters, after adjusting for
covariates, if necessary. Estimates of both, the central tendency and the inter-individual
variability can be obtained reasonably well. The TS method requires collection of rich
data to have sufficient samples per subject (greater than the number of model parameters
to be estimated), which is the usual requirement with experimental data. One concern is
this method assumes that the individual parameters, estimated in stage one, are known
without any uncertainty. More serious drawbacks include the inability to model sparse
data and concentration (or dose) dependent nonlinear processes. The conventional PK
non-compartmental analysis (NCA) is a type of two-stage population analysis approach.

In non-linear mixed effects analysis, data from all subjects are simultaneously modeled to
yield estimates of both, population mean parameters as well as variance. Since both
stages of the TS method are performed in one step, the NM technique is also known as
the ‘one-stage’ method. Individual parameters are calculated post-hoc, subsequent to this
one-stage optimization. Nonlinear mixed effects modeling is perhaps the most powerful
technique for analyzing both rich and sparse data, and does not share the drawbacks of
the other methods discussed earlier. One of the main advantages of the NM method is its
ability to conduct meta-analyses which enables incorporating all data across a drug
development program. The primary disadvantage of this method is that sophisticated
software are required for the analysis, which mandates special training for its use, while
learning resources are limited. In addition, these analyses can be highly time-consuming.
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Table 3: Main features of the common population analysis methods
Feature

Covariate

Uncertainty at

Uncertainty at

Relative

exploration

observational

subject level

Complexity

level

& Time

Method

involved

Naïve

Indirect –

Pooled

A model with known
relevant covariates
can be imposed.

Ignored –
Mean estimates
will be unduly

Naïve

Indirect –

Averaged

Subjects can be

(extreme

divided into groups

observations).

closer to outliers

based on relevant

can be estimated in
stage 2.
One-stage

Convenient –

weighted
equally,

Low

regardless of
observations per

Convenient –
A covariate model

All subjects are

number of

covariates.
Two-Stage

Ignored –

subject.
Accounted –
Models will not
be unduly
influenced by

Accounted –

High -

A covariate model

extreme

Subjects with

Special

can be included in

observations.

more data are

training is

also weighted

required.

the optimization step.

more.
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Model qualification
All models are required to be qualified and credible for their wider adoption. Validation
implies a procedure of utmost robustness. However, the fact that the true model and its
parameters are not known discourages the use of the term ‘validation’ for population PKPD models. Hence, qualification may be a better suited term.

The purpose for which the model is being developed should be clearly specified as a prerequisite before undertaking any model building. Based on the purpose of the model,
qualification methods can test either the descriptive capacity or the extrapolation capacity
of a given model. Developing an acceptable descriptive model is critical for making
labeling recommendations. However, drug labels, usually, do not extrapolate results
beyond the range of data observed.

Adequate description of the data at hand will ensure that the proposed model and its
parameters are qualified to make reliable inferences, within the range of the data studied.
This can be assessed using the routine diagnostic tests such as goodness-of-fit plots
(independent variable versus observed and individual/population model predictions),
summary statistics, and precision of the parameter estimates. A model and its parameters
may be deemed ‘qualified’ to perform the particular task(s) if they satisfy certain prespecified criteria. Application of a predictive check to a model and its parameters along
with Monte-Carlo simulations [39;40] is an effective method used for qualification of
population models.
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Physiological interpretation of model parameters is one of the most important aspects of
model qualification. A model and its parameters may be deemed ‘credible’ to perform a
particular task(s) if the conceptual foundation on which the model was proposed is
satisfactory to a panel of experts. It is important to note that there is no formal means to
assess whether a model can be used for extrapolation. Hence the credibility of the model
i.e. whether the model was derived from sound mechanistic principles, which appear
reasonable to subject matter experts, is important. Thus, a model (and its parameters) may
be considered qualified to predict beyond the range of the data used for building the
model if the descriptive capacity of the model is acceptable and the model is credible.

TYPES OF DATA AND TRIAL DESIGNS
Data
Pharmacometrics data (referring to PK/PD measurements) that may be collected during
clinical trials, in general, are of two types – rich data and sparse data. Typically, rich data,
which refers to several (10-20) samples from each subject, is collected under controlled
conditions in trials conducted in a small number of patients over a short duration of time.
Data from each subject can be analyzed independent of the others, in most cases, and
then summarized. Such kind of data is the best for building structural models. Doseescalation studies, bioequivalence studies, and bridging (for prognostic factor effects)
studies are examples of trials where rich data are collected.
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On the other hand, late phase clinical trials that are conducted in a large number of
patients and for relatively longer durations, typically collect sparse data. Few (1-5)
samples are taken from each individual due to practical limitations, which makes it
challenging to analyze the data from each subject separately. Sparse data are most suited
to build statistical models. Pivotal or registration safety-efficacy trials are examples of
studies that tend to collect sparse data.

Trial Designs
Broadly, three of the most commonly used trial designs that employ population analyses
are: parallel, cross-over, and titration. In a parallel study design, subjects are randomized
to one of several treatment options, for instance, control, dose1, dose2 or dose3. Such a
design supports the estimation of population exposure-response characteristics well, but
not that of individual characteristics. In a cross-over design, each subject receives all the
treatment options. This is the most powerful study design for estimating the individual
exposure-response relationships. However, such trials are longer in duration and may
experience carry-over effects from previous treatments. The titration design is one where
patients are usually initiated at a low dose, which is then gradually increased either until
no additional benefit is observed, or until dose-limiting toxicity occurs. This design
resembles clinical practice most closely and individual exposure-response determination
is possible. However, it may so happen that patients who are less sensitive to the drug
need higher doses, making it (falsely) appear as though the response decreases after a
certain dose. In several cases, particularly for the cross-over and titration designs,
sophisticated data analysis such as mixed-effects modeling is required.
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Further, based on the assignment of randomized groups in the trial, there are different
designs possible. Subjects may be randomized to receive a particular dose or
concentration of the test drug or to a particular effect elicited by the drug. Accordingly,
such trials are referred to as Randomized Dose Controlled (RDCT), Randomized
Concentration Controlled (RCCT), or Randomized Effect Controlled (RECT) trials. An
active control group is used where a placebo control is considered unethical.

In an RDCT, the different doses of the drug to be tested are randomly administered to the
subjects. Data are then collected throughout the trial and analyzed using an appropriate
method. Such trials are the most commonly seen design due to the relatively simple
execution and analysis involved.

In an RCCT, a set of target drug concentration levels are selected based on the exposureresponse relationship established from previous studies. Subjects are then randomized to
one of these pre-specified target concentrations [41]. Such a design obviates a dosetitration period during which the dose that ensures achieving concentrations within the
selected target range (ex.: 5 ± 0.5 μg/L) is identified. A variation of the RCCT design is
when doses are pre-specified based on a certain demographic variable. For instance, body
weight adjusted doses are routinely administered in pediatric studies. Similarly, in an
RECT, subjects are randomly assigned to a pre-specified target effect level. Again, the
target effects are chosen based on prior knowledge of the drug’s exposure-response, and
the dose is titrated accordingly.
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RCCT and RECT designs have similar requirements such as prior exposure-response
relationship to select the appropriate target concentration or effect ranges, an efficient and
sensitive analytical assay method with a short turn-around time, and sufficient strengths
of the formulation to allow for any required dose adjustments. Candidate drugs for such
trial designs are those where the PK has a large unexplained variability (RCCT) and those
where the PD has a large unexplained variability (RECT). In addition, when the
measured effect (desired/undesired) is symptomatic, for instance, effects such as pain or
nausea that are ‘felt’ by patients, the RECT could be applicable. When the symptoms are
not obvious, the RCCT may be a better choice. Unfortunately, very few drug
development programs utilize RCCT or RECT designs, perhaps due to their complicated
execution and data analysis, relative to the RDCT design, as well as the cost of
implementing

TDM

if

the

drug

is

approved

[42;43].

Notably,

trials

for

immunosuppressant drugs used in transplantation generally employ the RCCT design.

CASE STUDIES
Pharmacometric analyses have been employed at various stages of the drug development
process. Several case studies where such analyses have had pragmatic value in decision
making are discussed. Table 4 summarizes all presented cases while a few selected cases
have been discussed in detail.
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Tacrolimus – liver, kidney, heart transplantation
Background:
Tacrolimus is an immunosuppressive agent indicated for the prophylaxis of organ
rejection in allogeneic liver, kidney, or heart transplants. A large amount of variability
has been observed in the PK and PD of this drug. Pharmacometric methods have been
employed throughout the drug development stages of tacrolimus, to select rational dosing
regimens and optimize therapy [44].
Key questions:
1. What is a safe and effective dosing regimen for first-time-in-man clinical studies?
2. What is a rational target therapeutic concentration range for tacrolimus?
3. What is an optimal initial dose of tacrolimus for late phase clinical trials?
4. What is an optimal TDM strategy for managing patients on tacrolimus therapy?
Role of Pharmacometrics:
The starting dose of tacrolimus (0.15 mg/kg/day IV) used in early phase clinical trials
was extrapolated from a synthesis of safe doses in two animal models (rat and dog). The
target concentration range for monitoring the drug therapy during these trials was also
based on the same animal models, augmented with in vitro PD modeling using the IC 50
values from mixed lymphocyte reactions. Collectively, all the animal models studied
were also highly predictive of the systemic toxicities observed with tacrolimus in
humans. A pilot compassionate-use early clinical study in patients with refractory liver
rejection suggested that the 0.15 mg/kg starting dose was clinically effective, but toxic in
some patients, and doses had to be individualized to the patient. A reduced starting dose
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(0.05 mg/kg/day IV) was predicted by simulations before onset of the pivotal trial, and
the need for this dose reduction was dramatically confirmed during the U.S. and
European multicenter registration trials. In addition, an Artificial Intelligent Modeling
System (AIMS) was developed to efficiently guide dosing and monitoring of patients on
tacrolimus. The AIMS-based TDM led to clinical and pharmacoeconomic benefits in a
subsequent prospective pilot clinical study.
Impact:
Pre-clinical models proved to be a reliable guide for identifying a safe and effective dose
and a therapeutic concentration range for tacrolimus. Implementation of the AIMS
improved the TDM strategy by 3-4 fold reduction in number of blood samples drawn and
a reduction in length of hospitalization after liver transplantation. Thus, modeling and
simulation enabled more efficient trial design and data analysis of the RCCTs conducted
during development of tacrolimus and improved the cost-effectiveness of therapy.

Degarelix – prostate cancer
Background:
Degarelix is indicated for the treatment of advanced prostate cancer patients. During its
clinical development, the primary end-point used in trials was suppression of testosterone
levels (< 0.5 ng/ml) from day 28 of treatment initiation through 1 year of therapy in 90%
patients. The dosing goals were to achieve this challenging end-point. The sponsor
conducted five early and late phase dose-finding clinical studies but was unable to derive
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an optimal dosing regimen. An end-of-phase 2a meeting was arranged between the FDA
and the sponsor to discuss a better drug development plan for degarelix.
Key question:
What is a rational dosing regimen that would maximize the effectiveness of degarelix in
advanced prostate cancer patients?
Role of Pharmacometrics:
Population analysis was conducted to develop an exposure-response model for degarelix
based on the five dose finding studies conducted by the sponsor [45;46]. The FDA
suggested alternative dosing strategies and clarified the regulatory expectations of the
NDA. For initial suppression of testosterone levels by day 28, a higher loading dose
requirement was explored. A lower maintenance dose was derived to sustain the
testosterone suppression through 1 year of drug therapy. Using a mechanistic E-R model
and extensive clinical trial simulations an optimal dosing regimen was derived. All
pharmacometric analyses were conducted by the sponsor, under the guidance of the FDA.
The model-based regimen was used in a registration trial that resulted in positive
outcomes and led to approval of degarelix for this indication.
Impact:
Degarelix was approved for use in advanced prostate cancer based on a registration trial
that employed a modeling and simulation derived dosing regimen, which several prior
clinical studies failed to derive. Trials in prostate cancer patients are challenging and
costly and early interaction between the sponsor and the FDA enabled more cost-efficient
drug development and a smoother review process.
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Busulfan – bone marrow transplantation
Background:
Busulfex, an intravenous formulation of the drug busulfan, is used in combination with
cyclophosphamide as an immunosuppressive conditioning regimen for bone marrow
ablation prior to hematopoietic stem cell transplantation. The drug was initially approved
for use in adults with chronic myelogenous leukemia. The dose-limiting toxicity
associated with busulfan is potentially fatal hepatic venoocclusive disease (HVOD).
Clinical studies suggested that a therapeutic window of 900-1500 umol/L/min in adults
was appropriate to balance safety (occurrence of HVOD and leukemic relapse) and
efficacy (successful engraftment). The FDA issued a written request (WR) to the sponsor
to determine the PK of busulfan in pediatrics (aged 4-17 years) and the optimal dosing
regimen for this population that would achieve target exposures.
Key question:
What is the appropriate dosing strategy for busulfex in pediatric patients?
Role of Pharmacometrics:
A population PK study was conducted to characterize the PK of intravenous busulfan in
pediatrics and provide dosing recommendations [47]. Clinical studies indicated that the
therapeutic window was similar for pediatric and adult patients. However, this was
confounded by the increased variability in the PK of oral busulfan seen in pediatric
patients compared with adults. Hence a target therapeutic window with a lower, more
conservative threshold for toxicity, than in adults, was used for pediatric patients (9001350 umol/L/min). Body weight, body surface area, age and gender were explored for
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their impact on pediatric dosing. Simulations suggested that the mg/kg and mg/m2 based
dosing regimens were similar in their efficiency. Exposures obtained by different dosing
regimens, with 1 to 7 dosing steps including various combinations of weights and doses,
were evaluated. All the dosing regimens explored had, at best, 60% patients achieving
target exposures after the first dose. Notably, the model revealed that the unexplained
between-subject variability (25%) was larger than the within-subject variability (6%),
indicating that BSV is the key determinant of therapeutic success. This finding coupled
with the narrow therapeutic window for busulfan, supported implementation of
therapeutic drug monitoring for optimizing drug therapy.
Impact:
Based on the modeling and simulation, and practical considerations, a 2-step dosing
regimen was proposed from this study: 1.1 mg/kg for patients weighing ≤ 12 kg and 0.8
mg/kg (adult dose) for patients weighing > 12 kg. In addition, considering that about 40%
patients may not achieve target exposures after the first dose, even with the optimized
regimen, a TDM strategy was proposed to enhance therapeutic targeting. These dosing
recommendations, which had not been directly tested in clinical trials, were incorporated
into the drug label.
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Table 4: Summary of case studies, where pharmacometric analysis had an impact
on decision making, during different stages of drug development.

Drug

Stage

5c8, mAb
[48]

Preclinical
Early
Clinical
Late
Clinical
EOP2A
Postmarketing

rPSGL-Ig
[49]

Preclinical
Early
Clinical
Late
Clinical
EOP2A
Postmarketing

Tacrolimus
[44]

Preclinical
Early
Clinical
Late
Clinical
EOP2A
Postmarketing

Key Questions

Decision
Impacted
Molecule
Go/no-go
screening
Dose
optimization
Trial /
experimental
Improved
design
trial design
Dose
Approval
selection
Labeling
Covariate
Special
determination
population –
Evidence of dose selection
effectiveness
Benefit/
risk evaluation
Molecule
screening
Trial /
experimental
design
Dose
selection
Covariate
determination
Evidence of
effectiveness
Benefit/
risk evaluation
Molecule
screening
Trial /
experimental
design
Dose
selection
Covariate
determination
Evidence of
effectiveness
Benefit/
risk evaluation
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Go/no-go
Dose
optimization
Improved
trial design
Approval
Labeling
Special
population –
dose selection

Comments
Perceived impact of model
developed:
• optimize sample
collection in
experiments
• anticipate exposureresponse in humans
• quantify other antigenprovoked responses
• project utility of 5c8 in
treatment of antibodymediated autoimmune
disease
• developed allometric
models across animal
species to predict PK
and dose range for firsttime-in-man clinical
trial

Go/no-go • derived early phase
Dose
trials starting dose using
optimization
two animal models
Improved • derived target conc.
trial design
range for RCCT trials
Approval
and TDM using animal
Labeling
and in-vitro PD models
Special
• derived final starting
population –
dose for pivotal trial
dose selection
using simulations
• improved TDM strategy
and cost-efficiency

Rivoglitazone
[50]

Preclinical
Early
Clinical
Late
Clinical
EOP2A
Postmarketing

Mycophenolate
mofetil
[51;52]

Preclinical
Early
Clinical
Late
Clinical
EOP2A
Postmarketing

Degarelix
[45;46]

Preclinical
Early
Clinical
Late
Clinical
EOP2A
Postmarketing

Piperacillin/
Tazobactam
[53]

Preclinical
Early
Clinical
Late
Clinical
EOP2A
Postmarketing

Molecule
screening
Trial /
experimental
design
Dose
selection
Covariate
determination
Evidence of
effectiveness
Benefit/
risk evaluation
Molecule
screening
Trial /
experimental
design
Dose
selection
Covariate
determination
Evidence of
effectiveness
Benefit/
risk evaluation
Molecule
screening
Trial /
experimental
design
Dose
selection
Covariate
determination
Evidence of
effectiveness
Benefit/
risk evaluation
Molecule
screening
Trial /
experimental
design
Dose
selection
Covariate
determination
Evidence of
effectiveness
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Go/no-go • developed a ‘best-inDose
class’ compound using
optimization
modeling and simulation
Improved • selected biomarker/endtrial design
point, dose, sampling,
Approval
washout, eligibility &
Labeling
discontinuation criteria,
Special
and forecasted trials for
population –
late clinical phase
dose selection • built disease model from
related drug information
Go/no-go • derived dosing regimen
Dose
for a late phase clinical
optimization
trial (RCCT) using E-R
Improved
model based on a pilot
trial design
study
Approval
Labeling
Special
population –
dose selection

Go/no-go • explored alternative
Dose
dosing strategies based
optimization
on five phase 1/ 2
Improved
studies
trial design
• selected final dosing
Approval
regimen for registration
Labeling
trial that eventually led
Special
to drug approval
population –
dose selection

Go/no-go • recommended 2-step
Dose
weight-based PIP/TAZ
optimization
pediatric dosing regimen
Improved
in drug label for patients
trial design
aged ≥ 2 months
Approval • verified no new safety
Labeling
concerns than those in
Special
adults
population –
dose selection

Busulfan
[1;47]

Preclinical
Early
Clinical
Late
Clinical
EOP2A
Postmarketing

Everolimus/
Cyclosporine
[15]

Preclinical
Early
Clinical
Late
Clinical
EOP2A
Postmarketing

Apomorphine
[1]

Preclinical
Early
Clinical
Late
Clinical
EOP2A
Postmarketing

Benefit/
risk evaluation
Molecule
screening
Trial /
experimental
design
Dose
selection
Covariate
determination
Evidence of
effectiveness
Benefit/
risk evaluation
Molecule
screening
Trial /
experimental
design
Dose
selection
Covariate
determination
Evidence of
effectiveness
Benefit/
risk evaluation

Go/no-go
Dose
optimization
Improved
trial design
Approval
Labeling
Special
population –
dose selection

• recommended 2-step
weight-based pediatric
dosing regimen in drug
label
• proposed TDM strategy
in label to enhance
therapeutic targeting

Go/no-go • projected likely
Dose
outcomes of altered
optimization
dosing schemes
Improved • proposed new dosing
trial design
regimen that reduced
Approval
renal toxicity while
Labeling
maintaining efficacy
Special
thus improving
population –
benefit/risk profile than
dose selection
seen in registration trial
• cardio-renal advisory
committee
recommended new
regimen to be evaluated
in future trial
Molecule
Go/no-go • demonstrated a 50%
screening
Dose
increase in exposure in
Trial /
optimization
renal impairment
experimental
Improved • derived maximum
design
trial design
recommended dose and
Dose
Approval
titration strategy and
selection
Labeling
dose adjustment in renal
Covariate
Special
impairment in drug label
determination
population –
Evidence of dose selection
effectiveness
Benefit/
risk evaluation

33

Zoledronic acid
[1]

Preclinical
Early
Clinical
Late
Clinical
EOP2A
Postmarketing

Oxcarbeazepine
[1;54]

Preclinical
Early
Clinical
Late
Clinical
EOP2A
Postmarketing

Micafungin
[15]

Preclinical
Early
Clinical
Late
Clinical
EOP2A
Postmarketing

Molecule
screening
Trial /
experimental
design
Dose
selection
Covariate
determination
Evidence of
effectiveness
Benefit/
risk evaluation
Molecule
screening
Trial /
experimental
design
Dose
selection
Covariate
determination
Evidence of
effectiveness
Benefit/
risk evaluation

Go/no-go • suggested a correlation
Dose
between risk of renal
optimization
deterioration and drug
Improved
exposure
trial design
• recommended dose
Approval
adjustments in mild and
Labeling
moderate renal
Special
impairment patients in
population –
drug label
dose selection

Go/no-go • found no important
Dose
differences in placebo
optimization
and drug effects
Improved
between adults and
trial design
pediatrics
Approval • supported evidence for
Labeling
approving drug as
Special
monotherpay in
population –
pediatric patients with
dose selection
partial seizures
• derived dosing
instructions in drug label
• saved additional
controlled trials
Molecule
Go/no-go • derived dosing
screening
Dose
recommendation and
optimization
Trial /
supported approval of
experimental
Improved
drug for esophageal
design
trial design
candidiasis
Dose
Approval • provided evidence for
selection
Labeling
label to indicate greater
Covariate
Special
potential for liver
determination
population –
toxicity at approved
Evidence of dose selection
dose
effectiveness
Benefit/
risk evaluation
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Varenicline
[15]

Preclinical
Early
Clinical
Late
Clinical
EOP2A
Postmarketing

Docetaxel
[19]

Preclinical
Early
Clinical
Late
Clinical
EOP2A
Postmarketing

Nesiritide
[1;13]

Preclinical
Early
Clinical
Late
Clinical
EOP2A
Postmarketing

Go/no-go • showed much higher
Dose
drug exposures in renal
optimization
impairment
Improved • found baseline smoking
trial design
status and age to be
Approval
prognostic of abstinence
Labeling
from smoking
Special
• found marginal dose
population –
increase to increase
dose selection
effectiveness but also
significantly increase
toxicity (nausea)
• recommended lowering
dose in case of
intolerance to adverse
effects in drug label
Molecule
Go/no-go • identified a subscreening
Dose
population (liver
optimization
Trial /
impairment patients)
experimental
Improved
more prone to grade 4
design
trial design
and febrile neutropenia
Dose
Approval • recommended reduced
selection
Labeling
dose in label for patients
Covariate
Special
with liver insufficiency
determination
population –
to improve safety profile
Evidence of dose selection
of drug
effectiveness
Benefit/
risk evaluation
Molecule
Go/no-go • explored alternative
screening
Dose
dosing regimens for
optimization
Trial /
reasonable benefit-risk
experimental
Improved
profile
design
trial design
• proposed dosing
Dose
Approval
regimen for use in
selection
Labeling
subsequent registration
Covariate
Special
VMAC (Vasodilation in
determination
population –
the Management of
Evidence of dose selection
Acute CHF) trial that
effectiveness
led to drug approval
Benefit/
risk evaluation
Molecule
screening
Trial /
experimental
design
Dose
selection
Covariate
determination
Evidence of
effectiveness
Benefit/
risk evaluation
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Sotalol
[1;21;22]

Preclinical
Early
Clinical
Late
Clinical
EOP2A
Postmarketing

Nisoldipine
[18]

Preclinical
Early
Clinical
Late
Clinical
EOP2A
Postmarketing

Oral suspension
product for
prophylaxis of
invasive fungal
infections in
high-risk
patients
[15]

Preclinical
Early
Clinical
Late
Clinical
EOP2A
Postmarketing

Molecule
screening
Trial /
experimental
design
Dose
selection
Covariate
determination
Evidence of
effectiveness
Benefit/
risk evaluation
Molecule
screening
Trial /
experimental
design
Dose
selection
Covariate
determination
Evidence of
effectiveness
Benefit/
risk evaluation
Molecule
screening
Trial /
experimental
design
Dose
selection
Covariate
determination
Evidence of
effectiveness
Benefit/
risk evaluation
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Go/no-go • found drug effects in
Dose
pediatrics to be
optimization
consistent with adults
Improved • found sponsor’s dosing
trial design
recommendations to be
Approval
acceptable for patients
Labeling
aged ≥ 2 years
Special
• derived more specific
population –
dosing for neonates and
dose selection
infants aged < 2 years in
drug label
Go/no-go
Dose
optimization
Improved
trial design
Approval
Labeling
Special
population –
dose selection

• alleviated safety concern
of large drop in blood
pressure upon
administration of drug in
fed condition, given
significant food effect
on increasing
bioavailability of
controlled-release
product

Go/no-go • revealed need for TDM
Dose
to maximize effect for
optimization
all patients
Improved • supported inclusion of
trial design
conditions to optimize
Approval
drug absorption and
Labeling
importance of ensuring
Special
adequate plasma
population –
concentrations in label
dose selection • supported need for postmarketing study to
evaluate benefit of
proposed TDM

Drug to treat
type 2 diabetes
mellitus
[14]

Preclinical
Early
Clinical
Late
Clinical
EOP2A
Postmarketing

Drug to treat a
life-threatening
rheumatologic
disorder
[1]

Preclinical
Early
Clinical
Late
Clinical
EOP2A
Postmarketing

Drug to treat a
debilitating
neurological
disorder
[15]

Preclinical
Early
Clinical
Late
Clinical
EOP2A
Postmarketing

Go/no-go • evaluated 2 trial designs:
Dose
genotype-stratified and
optimization
biomarker enrichment
Improved
designs, using semitrial design
mechanistic model for
Approval
FPG and HbA1c
Labeling
• proposed biomarkerSpecial
enrichment design for
population –
future trials that would
dose selection
help derive optimal
genotype-based dosing
• revealed need to develop
sustained release drug
formulation
Molecule
Go/no-go • showed that biomarker
Dose
screening
was predictive of
optimization
Trial /
clinical outcome but a
experimental
Improved
65% reduction would
design
trial design
achieve significance,
Dose
Approval
after two failed
selection
Labeling
registration trials
Covariate
Special
• recommended exploring
determination
population –
doses that achieve
Evidence of dose selection
greater reduction in the
effectiveness
biomarker or maximal
Benefit/
tolerated dose for future
risk evaluation
trials
Molecule
Go/no-go • showed that reduction in
screening
Dose
symptoms was related
optimization
Trial /
with drug dose while
experimental
Improved
withdrawal effects were
design
trial design
significant and
Dose
Approval
consistent, after 1 failed
Labeling
selection
and 1 successful
Covariate
Special
registration trial
determination
population –
• supported evidence of
Evidence of dose selection
effectiveness for drug
effectiveness
approval
Benefit/
• saved additional clinical
risk evaluation
trial
Molecule
screening
Trial /
experimental
design
Dose
selection
Covariate
determination
Evidence of
effectiveness
Benefit/
risk evaluation
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Drug to treat a
mild, moderate,
or severe lifethreatening
disease
[15]

Preclinical
Early
Clinical
Late
Clinical
EOP2A
Postmarketing

New class of
antivirals
[14]

Preclinical
Early
Clinical
Late
Clinical
EOP2A
Postmarketing

Drug to treat
insomnia
[14]

Preclinical
Early
Clinical
Late
Clinical
EOP2A
Postmarketing

Go/no-go • identified non-responder
Dose
sub-group: patients with
optimization
mild disease
Improved • showed consistent
trial design
effectiveness in patients
Approval
with moderate and
Labeling
severe disease
Special
• elucidated inconsistent
population –
results from previous
dose selection
trials
• recommended future
study in only moderate
and severe disease
patients
Molecule
Go/no-go • distinguished QD and
screening
Dose
BID dosing regimens
optimization
Trial /
using a mechanistic
experimental
Improved
viral-dynamic model
design
trial design
that previous models
Dose
Approval
could not achieve
selection
Labeling
• allowed assessment of
Covariate
Special
impact of variability,
determination
population –
dosing regimen, patient
Evidence of dose selection
compliance and dropout
effectiveness
on trial outcomes
Benefit/
• proposed a lower dose
risk evaluation
BID regimen for future
trials
Molecule
Go/no-go
• recommended healthy
screening
Dose
subject studies for
optimization
Trial /
selecting doses for sleep
experimental
Improved
onset but not for sleep
design
trial design
maintenance evaluation
Dose
Approval
• recommended patient
selection
Labeling
trial durations of more
Covariate
Special
than 30 days for reliable
determination
population –
identification of doses
Evidence of dose selection
and persistent sleep
effectiveness
maintenance
Benefit/
risk evaluation
Molecule
screening
Trial /
experimental
design
Dose
selection
Covariate
determination
Evidence of
effectiveness
Benefit/
risk evaluation
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Pro-drug to
treat a lifethreatening
disease
[14]

Preclinical
Early
Clinical
Late
Clinical
EOP2A
Postmarketing

Molecule
screening
Trial /
experimental
design
Dose
selection
Covariate
determination
Evidence of
effectiveness
Benefit/
risk evaluation

Go/no-go
Dose
optimization
Improved
trial design
Approval
Labeling
Special
population –
dose selection

• revealed body weight to
be prognostic for
toxicity and
effectiveness and that
per kg dosing of both
test and reference drugs
would allow more
appropriate investigation
of non-inferiority
• indirectly, also derived
optimal dosing of
reference drug for wider
application across other
development programs

PERSPECTIVE
Learn-Apply paradigm
The strongest merit of model-based drug development lies in its ability to incorporate the
entire base of relevant prior knowledge into decision-focused recommendations for the
future. A Learn-Apply paradigm is being proposed as an effective means to leverage
pharmacometric methods and enhance drug development [55]. Accordingly, learning
refers to transforming information (such as clinical trial data) into knowledge while
applying refers to utilizing this knowledge to make informed decisions (such as
confirmation of effectiveness, dose selection etc). This is an extension to the learn-andconfirm philosophy in modeling that has been promoted by Lewis Sheiner [56].

Currently, pharmacometric models are typically developed at the end of phase 3. A more
prudent way to economize time and costs to develop models is by maintaining a
progressive model building philosophy. The essence of progressive model building is to
continuously update the current model as new knowledge is accrued. The advantages are
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at least two-fold: the ability to ‘carry-forward’ knowledge all along the development of a
given drug product, and the ability to divide a big problem into several small components
that are easier to solve. For instance, in the case of developing a "best-in-class"
compound, model-based drug development can use the wealth of knowledge from
predecessor drugs with a similar mechanism of action [50]. Right from the phase 1 stage,
efficacy and safety drug models can be developed based on preclinical data of the new
drug, as well as clinical experience with predecessors. As the clinical development
advances, the models can be continually updated, and thus the characteristics of the new
drug would become increasingly well defined. However, implementation of such a
paradigm calls for more open collaboration of scientists from all disciplines and an
institutional commitment to use the ‘current’ model while designing the next trial.

Future considerations
The late-phase attrition rates in drug development are alarmingly high at both, the
registration trial and the regulatory review stages, and it is believed that timely
application of pharmacometric methods can enhance future development plans and
reduce these attrition rates [1-7;11;57].

Quantitative disease-drug-trial model suites can serve as a valuable tool for improving
future drug development and should be increasingly employed to design trials using
clinical trial simulations. The FDA has set a target to design 50% of all pediatric trials
using simulations by 2015 and 100% by 2020. Upon development of and experience with
a particular disease-drug-trial model suite, a standardized template can be created for the
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trial design, data analysis and review for all drugs under that indication. Consortia on
specific topics are perhaps effective means for developing such model suites.

Early-on interaction between the FDA and drug sponsors may help in more efficient
planning. The End-of-Phase 2A (EOP2A) meetings are a good platform to facilitate this
goal via more rational dose selection and trial design and reduction in number of cycles
involved in the NDA review [24].

However, modeling and simulation must not be viewed as a substitute for clinical trials
altogether, nor seen as a tool to salvage failed trials, which were poorly-designed, for
regulatory approval. The aim is simply to employ these techniques into a continuous
learn-apply paradigm, capitalize on prior knowledge, improve trial design, and support
evidence for approval and labeling of drugs.

Increased collaboration between the industry, academia and the FDA is essential for the
growth and wider application of pharmacometrics. In addition, increased interaction
across the board between experts, such as clinicians, pharmacometricians and statisticians
is a must for better appreciation of this field. Finally, training in this area is currently not
offered by many academic institutions, and this may be an important step forward in the
future.
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CHAPTER 2
Pharmacometric Analyses Impact Pediatric Drug Approval
and Dosing

ABSTRACT
The purpose of this article is to review case studies where pharmacometric analyses, also
known as PK/PD modeling and simulation, have contributed to decision making in
pediatric drug development and regulatory reviews. Most prominently, pharmacometric
analyses support dose selection for clinical trials, evidence of effectiveness for regulatory
approval and dosing recommendations for pediatric labeling. In addition, the article
provides a future perspective on adopting pharmacometric analyses to improve pediatric
pharmacotherapy and drug development.
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INTRODUCTION
The need to improve pediatric pharmacotherapy and drug development has a long history
with regulators and public health professionals. As the potential harm of extensive offlabel drug use in pediatrics began to surface, several legislative initiatives were
undertaken to generate pediatric-specific data. The aim was to ensure that the pediatric
patient population no longer remained a therapeutic orphan [1]. In the U.S., the Food and
Drug Administration Modernization Act (FDAMA) in 1997, the Best Pharmaceuticals for
Children Act (BPCA) in 2002 and the Pediatric Research Equity Act (PREA) in 2003,
have jointly provided an impetus to pediatric clinical studies and useful pediatric
prescribing information in drug labels [2;3]. The European Council (EC) and the
European Parliament have also promoted major regulatory changes in the way pediatric
studies are planned and conducted in Europe. The regulation provides financial
incentives, and requires a Pediatric Investigation Plan (PIP) for all new products and
some existing products (new indication, new formulation, new dosage form, etc.), similar
to the pediatric Written Request (WR) in the U.S. [4].

These initiatives have been largely successful in stimulating pediatric investigations. The
desire to generate prospectively planned data for pediatrics is now being realized. As of a
recent update, FDA has issued 386 pediatric written requests for several important
diseases. Thus far, 173 approved drugs have obtained pediatric exclusivity by fulfilling
the elements of written requests, as agreed upon by the FDA and sponsors. FDA has
made labeling changes for many drug products (n>160) and the majority of these changes
resulted in new pediatric safety and effectiveness information [5].
48

In the early 1990s, it was accepted that pediatric-specific data were either impossible or
difficult to generate. In recent times, while financial incentives have led to an increase in
the amount of information available to treat the pediatric population, there still remains a
concern regarding the generation of good quality data to guide pediatric
pharmacotherapy.

•

Off-label use of medication continues to be a major concern in pediatrics
[6;7]. According to a 2005 study (677 patients), prescribing information in all
age categories was available for less than 35% of commonly prescribed
medications [7]. There are data from a 2004 survey (7901 patients) to
indicate that 96% of cardiovascular-renal, 86% of pain, 80% of
gastrointestinal, and 67% of pulmonary and dermatologic medication
prescriptions either did not follow the prescribing recommendations or such
information was not available [6]. Additionally, younger children were more
likely to be treated with off-label strategies. For example, 92% (out of 238
patients) received one or more courses of an unapproved drug [8].

•

Many pediatric investigations fail to generate useful data due to challenges
unique to pediatric drug development. A recent study found that about half of
the pediatric antihypertensive pivotal dose-response trials failed [9]. A
retrospective analysis of such trials revealed that poor dose selection, lack of
acknowledgement of differences between adult and pediatric populations and
lack of pediatric formulations were associated with trial failures [9].
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These concerns point to the unique nature of pediatric drug development. Such drug
development programs are typically short (one or two clinical trials) and generally do not
involve mortality/morbidity end-points. Drug approval is often based on matching
systemic exposures or effect on pharmacodynamic biomarkers, to those in adults.
Another major challenge is our understanding of and ability to account for the impact of
growth and maturation on clinical pharmacology. It is expected that different drug
exposures and/or altered response to the drug would be achieved in pediatric patients as
compared with adults [10]. Altered clinical pharmacology along with ethical and
logistical constraints together pose challenges to the design and analysis of pediatric trials
as well as to pediatric therapeutics.

Towards that end, there has been a growing interest in exploring means to enhance
pediatric drug development [4;11]. Pharmacometric analysis methods are an important
tool to improve the success of pediatric clinical trials and, therefore, pediatric
pharmacotherapy. As summarized by Manolis and Pons, pharmacometric analyses
consist of characterization and prediction of pharmacokinetics/pharmacodynamics
(PK/PD), extrapolation from adults to children, interpolation between pediatric age
subsets and optimal use of scientific literature and in vitro/preclinical data.
Pharmacometric analyses can be employed to design informative studies using
knowledge about disease pathophysiology, drug pharmacology (from adults and/or
pediatrics), and organ maturation in pediatrics.
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The focus of the present article is to review case studies where pharmacometric analyses
have influenced three major areas: pediatric trial design and therapeutics guidelines,
evidence of effectiveness, and dosing recommendations for pediatric labeling. For each
of these areas, case studies are grouped according to a best fit scenario and one of the
case studies is discussed in detail. In addition, the article also provides future perspectives
for the application of modeling and simulation to improve pediatric trial design and
therapeutics.

APPLICATIONS OF PHARMACOMETRIC ANALYSES
Trial Design and Therapeutics Guidelines
A prospective clinical trial is one of the best ways to generate information to derive
useful prescribing guidelines for pediatric drug use. For several drugs, however, there are
either no data from prospectively planned clinical trials or pediatric trials have failed to
achieve their primary objective. While it is possible that some drugs approved for adults
may not be effective in the pediatric population, it is important to derive evidence-based
support. Table provides examples where pharmacometric analyses were used to design
future pediatric studies based on adult data or studies for drugs where there had been a
failed pediatric trial for the same drug.

A case in point is the antihypertensive drug esmolol. The pediatric registration trial failed
to demonstrate effectiveness of the drug [12]. However, an external clinical study of the
same drug and indication in pediatrics, that was conducted even before the registration
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trial commenced, found the drug to be effective and reported a distinct exposure-response
(E-R) relationship for reduction in blood pressure [13]. The registration trial investigated
125-500 ug/kg/min esmolol doses in spite of the external clinical study showing 700
ug/kg/min of esmolol to be effective in reducing blood pressure in pediatric patients with
acute hypertension after cardiac operations. The results of these studies clearly
demonstrate that the choice of doses studied in the registration trial was a key
determinant of trial failure. It is unlikely that a pediatric trial of esmolol will be repeated.
Thus, inefficient trial design led to a potentially effective treatment not being approved
for use in pediatrics, a common theme among antihypertensive trials conducted in the
early 2000s.

Pharmacometric analyses can provide a rational basis for making important choices while
designing pediatric trials using available information. Important trial design aspects such
as dose range to be studied, sample size and PK sampling, trial duration, and analysis
methods should be carefully selected [9;14]. A case study to systematically design a
pediatric clinical trial based on adult data (without pediatric data) for anti-hypertensive
drugs is available [14]. Presumably, such systematic use of available information may
have helped appropriate dose selection for a registration trial of esmolol (discussed
above).

On the other hand, there are several instances of drugs that have been in clinical use for
years in pediatrics, but optimal dosing strategies were unknown. In many such cases,
pharmacometric analyses have provided insights to retrospectively derive dosing
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information or to design subsequent trials to further optimize dosing strategies and
perhaps guide therapeutic decisions. Such examples are also cited in Table 1.

Table 1: Pharmacometric analyses to design pediatric trials using existing data in
pediatrics and/or adults

Drug

Problem Statement

Pharmacometric Analyses
Contributions

• Explored competing dosing

Topotecan[15],

regimens

Furosemide[16],
Vancomycin[17],

• Recommended optimal dosing

Ondansetron [18]

strategy for use in future trials
Lack of clear guidelines

and/or clinical practice

Fluconazole[11;19],

for pediatric use despite

Actinomycin-D

years of clinical

were successfully employed in

(AMD) [20]

experience

subsequent trials

• Developed dosing guidelines that

• Examined the success (in terms
of efficacy and safety) of dosing
strategies and designed a
prospective efficacy trial
Carvedilol[21-23],

Failure of pediatric trial

• Provided insights into failed trial

Esmolol [12]

for drug approved in

• Recommended optimal dosing

adults

strategy for use in future trials

• Recommended appropriate endpoint for future trials
Famciclovir[24],

Prospective clinical

Teduglutide[25]

trial design

• Recommended prospective study
design including elements such
as dose selection, sample size and
PK sampling
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Evidence of effectiveness
The primary analysis methods for drug approval (treatment vs placebo comparison using
standard hypothesis testing) and some endpoints (mortality/morbidity) used in adult trials
may not be feasible or practical in pediatrics. Occasionally, a pivotal trial may fail to
meet its primary endpoint due to avoidable reasons. Model-based endpoints may then be
used in select instances, along with prior knowledge from adults and related pediatric
data, to provide primary or supportive evidence of effectiveness for approval in
pediatrics. Model-based endpoints are expected to be more powerful than standard
hypothesis testing and hold unique value in pediatric trials due to challenges identified
above. Table 2 provides a summary of case studies where pharmacometric analyses were
considered suitable to support evidence of effectiveness for pediatric drug approval.

Under certain circumstances, regulations allow the use of well established exposureresponse knowledge from one population for the approval in another [26].
Pharmacometric analysis was useful in bridging consistent drug effect of d,l sotalol
hydrochloride on a surrogate (heart rate) in pediatrics and adults. Sotalol was originally
approved in adults to treat life-threatening ventricular fibrillation and tachycardia, and for
maintenance of sinus rhythm in patients with symptomatic atrial fibrillation and flutter. A
clinical study assessing the antiarrhythmic and beta blocking effects of sotalol on QTc
and heart rate in pediatrics ranging from neonates to 12-year-old children formed the
basis of approval for sotalol’s use in pediatric patients. A biomarker study and ensuing
pharmacometric analyses led to the judicious dosing recommendation in pediatrics [27].
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Table 2: Pharmacometric analyses to provide primary or supportive evidence of
effectiveness

Drug

Problem Statement

Pharmacometric Analyses Contributions

Oxcarbazepine

• Unethical to conduct a

• Provided evidence for approving the

(Trileptal) [28]

monotherapy trial in

drug (first ever) as monotherpay in

pediatrics

pediatric patients with partial seizures

• Drug approved without additional
controlled trials and model-derived
dosing instructions included in label
Candesartan

• Trial in patients aged

Cilexitil

6 to <17 yrs failed

(Atacand) [29]

potentially due to

• Supported evidence of effectiveness in
patients aged 6 to <17 yrs

• Provided rational dosing

poor dose selection

recommendations in drug label

and primary analysis
method

• No other approved
ARB for patients
aged <6 yrs and no
new pediatric trial
expected
Sotalol
(Betapace) [27]

• Impractical to

• Demonstrated consistent drug effect on

conduct a mortality

surrogate (heart rate) in pediatrics and

trial in pediatrics

adults

• Proposed dosing for patients aged ≥ 2
years

• Derived dosing recommendations for
neonates and infants in drug label.

55

Dosing Recommendation
The most successful application of pharmacometric analyses to pediatric drug
development has been deriving dosing recommendations [30]. In several instances these
recommendations have been successfully incorporated into the drug label (Table 3). In
others, such as voriconazole [31] and leflunomide [32], dosing strategies have been
proposed to guide therapeutic decisions. Occasionally, pediatric doses not directly studied
in trials have been approved and included in the drug labels (see Table 3 for specific
examples). In fact, in some therapeutic areas such as anti-virals and anti-infectives, drugs
are frequently approved for pediatric use by extrapolating effectiveness from adult data.
Drug exposures that are shown to be safe and effective in adults are typically considered
target exposures for pediatrics. Suitable pediatric dosing regimens are then derived based
on matching exposures between pediatrics and adults. In addition, as described
previously (Table 1) there are several cases of drugs that have already been in clinical use
for pediatrics where pharmacometric analyses have been used after-the-fact to
recommend dosing strategies in order to improve therapeutics.

Pharmacometric analyses have been used to optimize dosing recommendations after trial
results are obtained based on the therapeutic goal. According to the FDA’s pediatric
study decision tree [33] there are three broad approaches to conduct pediatric studies to
seek drug approval and dosing recommendations: the PK-Only approach, the PKBiomarker approach, and the PK-Efficacy approach. Depending upon the disease,
expected response to intervention, and prior information available (from adult or related
pediatric data), one of the three approaches is selected for the pediatric drug development
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program. Table 3 below provides a summary of case studies, categorized by approach
used, where pharmacometric analyses were employed to derive pediatric dosing
recommendations for labeling.

Table 3: Pharmacometric analyses to derive pediatric dosing recommendations for
labeling
Drug

Pharmacometric Analyses Contributions

PK-Only Approach
Piperacillin/
Tazobactam
(Zosyn) [34]

• Derived a 2-step body weight based dosing regimen to include
in the label

Busulfan
(Busulfex) [35]

• Derived a 2-step, body weight based dosing regimen to include
in the label
• Derived therapeutic drug monitoring strategy to enhance
therapeutic efficiency

Levofloxacin
(Levaquin) [36]

• Recommended dosing regimen to balance efficacy and safety
that was not directly studied in a pediatric trial

PK-Biomarker Approach
Argatroban [37]

• Provided dosing strategy for pediatrics that matched therapeutic
response and risk with adults

Levetiracetam
(Keppra) [38]

• Demonstrated that a higher dose (3 mg/kg) that was not directly
studied may offer better effectiveness than the lower dose (2
mg/kg) that was studied in the pivotal trial; Both doses
incorporated into the label

Tipranavir

• Recommended higher dose (of two doses) studied in the trial
based on benefit/risk evaluation

(Aptivus) [39]

• Explored different dosing strategies and recommended a body
weight-based dosing regimen along with original BSA-based
dosing
PK-Efficacy Approach
Fenoldopam
(Corlopam) [40]

• Recommended capping the pediatric dose (at 0.8 mcg/kg/min)
based on benefit/risk evaluation
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FUTURE PERSPECTIVE
There are several areas within the realm of pediatric drug development that could highly
benefit from future research [41]. Pharmacometric analyses have the potential to
contribute towards many of these areas.

•

Pediatric dosing decisions will gain much higher success if developmental
ontogeny is well understood and routinely incorporated. This is particularly true
for disposition pathways such as non-renal elimination pathways and transport
systems where effect of maturation is not well established.

•

Pediatric clinical trials will be much more informative with new biomarkers
(surrogates) that are well suited to the pediatric population and powerful analysis
methods (such as model based endpoints).

•

Pediatric clinical trials also need a sound rationale for sample size selection.
Established methods to derive sample size are missing for typical PK and PKPD
studies because these studies are not designed with a goal to derive statistical
significance. We are exploring methods such as defining an acceptable precision
standard to derive an objective basis for sample size selection.

•

Pediatric pharmacotherapy also needs powerful quantitative techniques to identify
safety signals to optimize treatment strategies. This may involve identification of
useful biomarkers that are predictive of adverse drug events. It is important to
enable detection of safety signals even with data from a small number of subjects.
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CONCLUSION
In summary, the case studies presented in this article exemplify that pharmacometric
analyses have had a significant impact on improving pediatric pharmacotherapy. Wider
adoption of these methods will bring objectivity to decision making during pediatric drug
development, improve trial success rates, and provide a more rational basis for decisions
in pediatric therapeutics.
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CHAPTER 3
Simulation-based Methodology for using PK Quality Standard
to Design Pediatric Trials in the Population Analysis setting

ABSTRACT
The objective of this research is to evaluate the feasibility and methodological
challenges while implementing a pharmacokinetic (PK) quality standard, in the
population analysis setting. It is important for pediatric trials to yield good quality PK
data to enable making reliable dosing decisions. The quality standard aims to ensure both,
rational pediatric PK trial design and consistency in regulatory review. A simulationbased method for designing pediatric trials to be prospectively powered to meet the
quality standard is proposed.
A simulation-estimation platform, aiming to optimize the pediatric sample size
that met the PK quality standard under different scenarios, was used to explore the impact
of several trial design elements. In general, reasonable sample sizes (range: 16 - 64
pediatric subjects) were required to meet the quality standard even with sparse sampling
schedules (2-3 samples per subject). Increasing sample size and PK samples per subject
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increased the precision of parameter estimates. Sample size requirements to achieve
target precision progressively increase with increasing between-subject PK variability
(low-30%, medium-50% and high-70%). Inclusion of rich adult data, in general, reduced
required pediatric sample sizes (eg. from N=64 to N=48 for 70% variability). However, a
ceiling effect is observed in the extent adult data can inform the model and reduce
pediatric sample size adequacy (no additional benefit of 24 vs. 12 adults). A comparison
of population mean analysis and individual post-hoc analysis methods found the former
to be more powerful and less biased. Finally, all trends were moreover the same for i.v.
and oral administration models.
In conclusion, the PK quality standard is practically feasible in terms of sample
size adequacy. A simulation-based approach to design pediatric PK trials using the
standard is described. Informative sampling schedule for a given number of PK samples
per subject is assumed during trial design. The recommendations are: 1- to use prior adult
or pediatric data for trial design and analysis, wherever possible and 2- to use one-stage
population analysis methods with biologically plausible covariate models for designing
pediatric PK studies.
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INTRODUCTION
The pediatric population has been described as a therapeutic orphan [1] because
historically, pediatric drug development was deprived of the patronage given to drug
development programs in adults [2;3]. However, over the past decade, concerns and
actions of health care professionals, researchers and regulators have together led to an
impetus in pediatric clinical research [4;5]. Recent legislative initiatives in combination
have dramatically stimulated changes in pediatric drug labeling [6]. The aim is to provide
useful prescribing information for pediatric pharmacotherapy, such as rational dosing and
identification of risks of therapies. Eventually, the hope is to amend the long drawn
deficit in pediatric drug development.

Under any pediatric drug development program, pharmacokinetic (PK) information is a
key driver of decisions including but not limited to dosing, approval or labeling.
According to the FDA’s pediatric study decision tree [7], a PK trial, where suitable, may
serve as the basis for drug approval in pediatrics. In fact in some therapeutic areas, such
as anti-virals and anti-infectives, regulatory approval of drugs for use in pediatrics is
primarily based on PK studies. In other areas, PK data from pediatric studies may have a
crucial role to play in determining the doses to be tested in pivotal safety and
effectiveness trials. Occasionally, drug doses not directly studied in pediatric trials are
approved and included in the label for pediatric use based on prior exposure-response
characterization from adults or pediatrics. PK data is also useful in supporting evidence
of effectiveness and safety related labeling decisions. Hence it is important that all
pediatric drug development programs, typically comprising only few (1-2) trials, yield
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good quality PK data. Trial design elements, particularly sample size and PK sampling
schedule, have a significant impact on the quality of the resulting PK data. Making
rational choices during the study design stages itself can save time and costs, ensure good
quality PK data and safeguard the interpretability of study results as well as pediatric
exclusivity granted to sponsors.

Despite the recent progress in pediatric drug development, there have been multiple
unexpected and disappointing results, particularly for pediatric PK studies. One case in
point is for the drug metoprolol, where data collected in pediatric trials could not be used
efficiently. Three pediatric dose levels (0.2, 1 and 2 mg/kg) were studied in the trial with
single trough PK sampling. However, 60% of the samples for dose group 0.2 mg/kg were
below LOQ. Firstly, this raised a scientific/regulatory concern due to the (avoidable)
complexity involved in the exposure-response analysis, which served as the basis for
approval of the drug. Secondly, collecting unusable data from pediatrics raises ethical
questions in its own standing.

Another, and perhaps the most important, aspect of pediatric trial design that warrants
attention is sample size selection. The pediatric PK studies submitted to the FDA have
vastly variable sample sizes. Often a clear rationale is not provided, which leads to
inconsistency and introduces subjectivity during regulatory review. There was an
instance where a pediatric written request stipulated a sample size of 24 pediatric subjects
to be studied, based on no scientific rationale. But due to challenging recruitment rate,
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that sample size requirement could not be met, adversely affecting the pediatric
exclusivity determination.

Heretofore, the choice of sample size for pediatric PK studies seems to have been a
logistic decision rather than a scientific one. Figure 1 presents the sample sizes used vs.
variability (%CV) reported on clearance, in eight randomly selected pediatric PK trials,
for illustration. One can observe that there is no correlation between sample size and
%CV, which brings out the lack of rationale behind sample size selection. Typically,
these studies have included a small number of patients, particularly in the lower age
range, which is inadequate for estimating PK parameters with good precision.

These instances draw attention to the need for rational pediatric trial design. In case of
pediatric PK studies, there is lack of objective criteria to design a trial, which are
available for mainstream efficacy trials. The consequences may be detrimental as is
apparent from the cases cited above. In recognition of need for a uniform criterion to
define PK data quality, a regulatory requirement has been recently initiated as part of the
pediatric written request [8]. The FDA recommends using a pre-defined target on the
precision of primary PK parameter estimates, such as mean clearance and volume of
distribution, as a quality standard for PK data. The requirement is to prospectively power
(at least 80%) a pediatric trial to target a 95% confidence interval within 60% and 140%
of the geometric mean estimate of primary PK parameters, for each pediatric age group
studied. The aim is to provide guidelines for bringing objectivity into pediatric PK trial
design.
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Figure 1: Sample size vs. %CV in 8 pediatric PK studies chosen randomly from the
literature and submissions to FDA.
1

Studies cover different age groups ranging from 2 days – 18 years.

2

Vertical dashed lines represent different variability levels

An objective criterion, such as the proposed PK quality standard, is one way of ensuring
more rational pediatric trial design. Implementation of the standard will lead to greater
consistency and efficiency in analysis of pediatric studies and their regulatory review.
However, there remain methodological research questions on how to select the optimal
sample size while designing pediatric trials, so as to prospectively power the study to
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meet the precision standard. Frequently, pediatric studies collect sparse PK data (1-3
samples per subject) and population analysis techniques are used for the design and data
analysis of such trials. Methods on optimizing the PK sampling schedule for population
analyses have been published previously [9-11]. The current study focuses on simulationbased methodology to derive sample size, and assess the impact of different elements,
while designing pediatric studies to meet the proposed PK quality standard, in the
population PK setting.

METHODS
A simulation-estimation method was developed for the current study. A pediatric
population was simulated in terms of demographics and PK observations under different
trial design scenarios with increasing sample sizes. The parameters of the PK model were
then estimated using the simulated data and relevant metrics for the estimates of mean
systemic clearance and central volume of distribution were determined. Figure 2 is a flow
chart describing all the computations carried out by the tool. The following sections detail
the steps involved during the simulation-estimation for a base case trial design scenario
with n=16 pediatric subjects, 2 PK samples per subject (1 and 3 hours), 30% betweensubject variability in clearance and volume, no adult data included, oral drug
administration, and using population mean estimates for analysis. 250 replicate datasets
were simulated for the analysis.
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Figure 2: Flow chart of computations carried out by the simulation-estimation tool

Answers to the following six research questions were sought through the current study:
1. What are the typical sample sizes for different trial design scenarios that achieve
80% power for target (60-140%) precision and acceptable bias?
2. What is the impact of varying the number of samples per subject?
3. What is the impact of low, medium or high PK between-subject variability?
4. What is the impact of including adult data for estimation?
5. What is the impact of the analysis method used?
6. What is the impact of i.v. vs. oral administration models?
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Nominal design
For the present study, the PK model developed previously in pediatrics for Zosyn
(piperacillin/tazobactam) [12] was adopted. The model drug used follows onecompartment, dose-proportional PK and has 100% bioavailability with fast absorption
(T max about 2 hrs) and a half-life (t 1/2 ) of 1.5 hrs. A single 100 mg/kg dose was
administered orally to the simulated pediatric subjects.

Demographics
A CDC (Center for Disease Control and prevention) database was used for the simulation
of pediatric demographics that included age, gender and weight. The database contained
ages from birth-20 yrs, in increments of 1 month, yielding n=240 unique ages. For each
unique combination of age and each gender (n=480) there are parameters, including a
variability component, to determine the distribution of body weight. Thus, 100
individuals of different body weight for each combination of age and gender were
simulated resulting in a virtual bank of n=48000 unique pediatric subjects.

For this study, the pediatric subjects were divided into four age bins as is commonly done
during recruitment in pediatric clinical trials. The age bins used were 1 mo to 2 yrs, >2 to
6 yrs, >6 to 12 yrs and >12 to 17 yrs. Subjects were randomly sampled from this bank of
pediatrics and evenly distributed into each age bin. All replicate datasets maintained the
same set of subjects in terms of covariates.
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The bank was also used to determine the “true” mean clearance and volume for each
pediatric age bin. Using the covariate model employed for the simulations, the “true”
individual clearances and volumes for each virtual subject in the bank were determined
and subsequently the geometric mean (non-parametric) of these parameters for each age
bin was arrived at. In addition, we also determined the mean (parametric) clearance and
volume predicted by the model at the median age and weight for each age bin.

Simulation-estimation models
The one-compartment model used in the present study was parameterized in terms of
total systemic clearance (CL) and volume of distribution for central compartment (Vc),
and in case of oral administration scenarios, the first-order absorption rate constant (KA).
The between-subject variability (BSV) of the model parameters was described using a
lognormal distribution.

An allometric scaling model was used for body weight effect on clearance and volume
whereas an Emax-type model was used for age effect on clearance. The covariate models
were employed for simulation and estimation as well as to determine the true individual
clearance and volume for each subject in the pediatrics bank.

⎛
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…. Eqn. 1

…. Eqn. 2

•e
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ηVci

KAi = TVKA • e

…. Eqn. 3

where; η CLi is the difference between individual (CL i ) and population mean (TVCL)
clearance on log scale, η Vci is the difference between individual (Vc i ) and population
mean (TVVc) volume of distribution on log scale, η KAi is the difference between
individual (KA i ) and population mean (TVKA) absorption rate constant on log scale,
allo CL and allo Vc are the allometirc exponents that account for the effect of body weight
(WT) on clearance and volume respectively, A 50 is the covariate parameter that accounts
for the effect of maturation on clearance and reflects the age at which clearance is half of
its maximal (or adult) value. η CLi , η Vci and η KAi were all assumed to follow a normal
distribution, independent of each other, with mean of zero and variances of Ω2 CL , Ω2 Vc
and Ω2 KA respectively.

The residual error or within-subject variability (WSV) was described using a proportional
error model as shown below:

Cp i = Cp pred

•

(1 + ε Cp )

…. Eqn. 4

where; ε Cp is the difference between the individual observed plasma concentration (Cp i )
and the individual model prediction (Cp pred ) and is assumed to follow a normal
distribution with mean of zero and variance of σ2 Cp .
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Truncated simulations were performed in order to contain the simulated parameter values
within reasonable limits. The distributions of clearance, volume, t 1/2 and KA were
truncated using the generic expression shown below, for each of these parameters:
LOLIM = exp(LnMean − 3 • SD )

…. Eqn. 5

HILIM = exp(LnMean + 3 • SD )

…. Eqn. 6

where; LOLIM and HILIM are the lower and upper limits desired for the simulated
parameters, LnMean is the mean parameter on the log scale and SD is the standard
deviation of the parameter on the log scale. For clearance, volume and KA the variances
used for simulations (Table 1) determined SD and for t 1/2 the variances of clearance and
volume were added to determine SD.

The parameter values for the “true” one-compartment model used for simulations, with
associated covariate effects, are listed in Table 1. During estimation the oral absorption
parameters, TVKA and Ω2 KA , were fixed, while all remaining model parameters were
estimated. For the population mean analysis, model predictions of mean clearance and
volume at the median age and weight, for each of the four age bins, were determined as
mean parameter estimates.
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Table 1: Values of the one-compartment model parameters used for the simulations
Parameter

Value

Units

TVCL

3.2

L/h /20kg

TVVc

6.2

L /20kg

TVKA

2 (fix)

/h

Ω2 CL (CV)

30, 50, 70

%

Ω2 Vc (CV)

30, 50, 70

%

50 (fix)

%

10

%

Ω
σ

2

2

KA

CP

(CV)

(CV)

ALLO_CL

0.75

ALLO_Vc

1

A 50

0.18

years

TVCL, TVVc, TVKA: typical values of systemic clearance, central volume of distribution and
first-order absorption rate constant
Ω2 CL , Ω2 Vc , Ω2 KA : variance in CL, Vc and KA respectively; CV: coefficient of variation
σ2 CP : variance in individual plasma concentrations
ALLO_CL, ALLO_Vc: allometric exponent for weight effect on CL and Vc respectively
A 50 : covariate parameter for effect of maturation on CL, defined as the age at which clearance is
half of the adult value

Data analysis
For each replicate, the precision and bias in the mean clearance and volume parameter
estimates were computed. The mean bias and power to achieve target precision standard
were then determined, based on all replicates.
Precision metrics
In accordance with the recent regulatory requirement, we assessed precision as a %CVlike metric but in terms of upper bound of the 95% confidence interval (UCI) rather than
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standard error (SE). Thus, precision was defined as the ratio of the upper limit of the 95%
confidence interval to the mean parameter estimate, or relative UCI (RUCI). Values close
to 1 for this ratio imply high precision (or small standard errors) while higher values
imply more imprecision (or large standard errors). Then as per the PK quality standard
defined previously, the target is for this ratio to be ≤ 140%. Given the lognormal
distribution of the parameters (CL and Vc), it is assumed that if the UCI is within 140%
of the mean, then the LCI will be within 60% of the mean. Hence we focused only on the
UCI for assessing precision.

A percentage expression was used to determine precision on clearance and volume
parameters for every replicate and the mean of this metric for all replicates was the ‘mean
imprecision’. Thus a value of 100 for the metric represents no imprecision (or a 0
standard error) and higher the value of the metric, deviant from 100, lower is the
parameter precision.

⎛ UCI ⎞
RUCI = ⎜
⎟ • 100
⎝ Mean ⎠

…. Eqn. 7

The proportion of replicates where RUCI met the target was determined to be the power
to achieve the precision standard. A trial design was considered successful if it achieved
80% power for target precision (i.e. RUCI ≤ 140 for ≥80% replicates).

In order to construct the 95%CI, for each age bin, model estimated mean parameters and
standard errors were used. Then the 2-sided t df,α statistic corresponding to the total
pediatric sample size for estimating eight model parameters (see Table 1) was used (α
=0.025, n=16, df=8, t= 2.306).
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Bias metrics
For the purpose of computing bias on the parameter estimates, reference values that may
be considered “true” estimates were used. The mean parameter estimates for each age bin
obtained from the virtual pediatrics bank, as described above were considered as the
reference values.

The metric used to compute bias in the parameter estimates was the percent deviation
from the reference value, calculated as follows:
⎛ P − Ptrue
% Deviation = ⎜⎜ est
Ptrue
⎝

⎞
⎟⎟ • 100
⎠

…. Eqn. 8

where; P est is the estimated value of the parameter by fitting the model to the simulated
data and P true is the reference value for the model parameter. The mean bias for all
replicates was determined. A deviation within 20% of the reference value was regarded
as acceptable bias. A trial design was evaluated not only in terms of precision but also
acceptable bias, for research purposes.

We also considered the bias in the covariate parameter estimates and variance estimates
(both BSV and WSV) as well as shrinkage in post-hoc estimates to assess their
reasonable estimation (results not shown). However these metrics were excluded from the
power analysis for the trial design.
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Scenarios explored

We were interested in exploring the impact of varying different trial design elements on
meeting the requirements of the PK quality standard. Table 2 provides a summary of the
different scenarios explored in our simulations. There were 756 unique scenarios
explored. Different combinations of all the following key design elements were
evaluated:

1. Between-subject variability (3 scenarios): The base case trial design was with low
(30%) between-subject variability. Scenarios with medium (50%) and high (70%)
between-subject variability were also simulated.
2. Samples per subject (3 scenarios): Three sparse sampling schedules, in terms of
number of PK samples (1, 2, or 3) per subject, were explored.
While it is recognized that single trough sampling may be irrelevant for
population PK analysis and using such sparse sampling schedules is discouarged,
this scenario has been included for research completion purposes. For the single
trough sampling scenarios the estimation was carried out differently, based on
previous recommendations [13]. Accordingly, only the TVCL, allo CL , Ω2 CL and
σ2 Cp parameters were estimated, when rich adult data was included. In absence of
adult data, even the residual variability parameter (σ2 Cp ) was not estimated.
3. Adult data inclusion (3 scenarios): The designs were varied in terms of inclusion
of rich adult data (10 samples per subject) in the estimation, exploring three
scenarios: pediatric data alone, or with additional rich PK data from 12 or 24
adults.
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4. Analysis method (2 scenarios): Two different analysis methods were assessed.
Thus all metrics were determined on both, population mean estimates (a one-stage
approach) as well as individual post-hoc estimates (similar to a two-stage
approach). For the latter analysis method, the geometric means of individual posthoc estimates of clearance and volume were empirically determined, for each age
bin. In order to construct the 95%CI, for each age bin, we used standard errors of
age- and weight-normalized post-hoc individual estimates and a 2-sided t df,α
statistic corresponding to the pediatric sample size for that particular age bin (α =
0.025, df = n-1) .
5. Drug administration (2 scenarios): Scenarios were simulated using both i.v. as
well as oral administration models, for comparison.
6. Sample size (7 scenarios): For each scenario, trial designs with increasing
pediatric sample sizes (n = 16, 24, 32, 40, 48, 64 and 80) were simulated, to
determine the design that met the quality standard.
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Table 2: Trial design scenarios explored during simulations
Design element

SAMPLING

VARIABILITY

ORAL

I.V.

•

2 per subject (1, 3 h)

•

2 per subject (0.1, 2h)

•

3 per subject (1, 3, 4 h)

•

3 per subject (0.1, 2, 3 h)

•

Single trough (4 h)

•

Single trough (3 h)

Rich sampling used for adult

Rich sampling used for adult

data: 10 per subject (0.25, 0.5,

data: 10 per subject (0.1, 0.5, 1,

1, 1.5, 2, 2.5, 3, 4, 6, 8 h)

1.5, 2, 2.5, 3, 4, 6, 8 h)

For Cl and Vc:

For CL and Vc:

•

Low (30%)

•

Low (30%)

•

Medium (50%)

•

Medium (50%)

•

High (70%)

•

High (70%)

For KA: 50% fixed for all cases
•
ADULT DATA

No adult data

•

Rich data from 12 adults

•

Rich data from 24 adults

ANALYSIS

•

Population mean estimates, for each pediatric age bin

METHOD

•

Individual post-hoc estimates, for each pediatric age bin

SAMPLE SIZE

•

16

•

24

•

32

•

40

•

48

•

64

•

80

Distributed evenly across four age bins
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Software

An R environment was employed for the simulation-estimation procedure with system
calls to NONMEM and SAS. For the simulations, random numbers were generated using
a six digit seed. 250 replicates were simulated for each trial design. NONMEM version
VI with Compaq Visual FORTRAN 6 compiler was used to conduct the simulations.
SAS version 9.2. was used for the estimations. The estimation method used in SAS was
QPOINTS=1 (equivalent to LaPlace in NONMEM). R version 2.9.1. was used to create
the automated program script and carry out data manipulation, data analysis and graphics
generation.

RESULTS
Figure 3 is a comparative display of the impact of all aspects of trial design explored on
meeting the PK quality standard.

What are the typical sample sizes for different trial design scenarios that achieve
80% power for target (60-140%) precision and acceptable bias?

As expected, power increases with increasing sample size. The trends remain similar for
both clearance and volume estimates and for all scenarios tested. Figure 4 is a
representation of the trend for power to achieve target precision against sample size, by
age bin, for a sample scenario (oral, 50% variability, 2 PK samples, no adult data).
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In general, the bias in the parameter estimates was acceptable - deviation within 20% of
reference values. This result is expected [13]. The mean bias in most scenarios tended to
be positive, and was generally higher for age bin 1 (1mo - 2yrs) than other age bins. In
general, mean bias w.r.t. simulated data was higher (up to +40% for age bin 1) than that
w.r.t. true data i.e. pediatrics bank. Figure 5 presents the mean bias, by age bin, for the
same sample scenario (oral, 50% variability, 2 PK samples, no adult data).

Figure 3 displays the smallest sample size that achieves 80% power for target precision
and acceptable bias, for all age bins, across all trial scenarios. The sample size selected as
a success for a trial design was one for which the criteria were met for all age bins.

Figure 3: Impact of all trial scenario elements explored on sample size adequacy to
meet PK quality standard.
1

Results shown are for all oral administration scenarios; i.v. scenario results were similar.

2

Where dotted lines are not visible on the graph, they overlap with solid lines.

82

Figure 4: Power to achieve target precision standard (on mean clearance) at all
sample sizes explored, by age bin, for a sample scenario (oral, 50% variability, 2 PK
samples per subject, no adult data).
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Figure 5: Mean bias (in mean clearance) at all sample sizes explored, by age bin, for
a sample scenario (oral, 50% variability, 2 PK samples per subject, no adult data).
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What is the impact of varying the number of samples per subject?

Scenarios with 3 PK samples per subject consistently achieved higher power than that
achieved with 2 PK samples per subject. However, this translated into lower sample size
requirements only in a few cases. This can be seen in Figure 3. Mean bias was not
different for 2 vs. 3 samples per subject. Shrinkage was in general ≤ 20% and was
consistently greater in cases of 2 samples per subject over 3 samples per subject, as
expected.

In this study, the results of single trough sampling scenarios are not directly comparable
to those of scenarios with 2 or 3 samples per subject because the estimation was carried
out differently for single trough sampling, as described in section 2.5. We assessed
precision and bias for only the mean clearance estimates. The power trends however
remain similar as for cases with 2-3 samples per subject. The bias was generally
acceptable at lower variability scenarios but at high (70%) variability, the mean bias in
clearance estimates was up to 30% deviation. However, post-hoc estimates are
susceptible to high shrinkage in case of such sparse data, which was observed in our
study for single trough sampling scenarios in absence of adult data (30-70% shrinkage).

What is the impact of low, medium or high PK between-subject variability?

Between-subject variability was the trial design element with maximum bearing on
power and sample size requirements to meet the precision standard. As would be the case
in conventional power analyses, higher PK variability resulted in lower power and higher

85

sample sizes, consistently in all scenarios. Variability did not have implications on bias
estimates.

The residual error estimation was dependent on variability. While a 10% proportional
residual error was used for simulations, at low and medium variability scenarios (30%,
50%) this estimate was 15-17% whereas at high (70%) variability scenarios the residual
error estimates were higher, 20-30%. In addition, the A 50 parameter estimate was more
biased at higher variability.

What is the impact of including adult data for estimation?

In case of the population mean analysis method, inclusion of adult data (rich sampling)
from 12 adults significantly improves the power to achieve target precision. This results
in a smaller number of required pediatric subjects when adult data is included in the
estimation. For instance, n=64 and n=48 met the precision standard for a 70% variability
scenario without and with adult data, respectively. However, a ceiling effect was
observed in the inclusion of adult data. In most cases, including rich data from 24 adults
did not offer significant increase in power or reduction in sample sizes over including
rich data from 12 adults.

The inclusion of adult data does not significantly impact the outcomes of the individual
post-hoc analysis method. The power/sample size to meet the precision standard, in
general, remains unaffected whether adult data is included or not. Figure 3 presents the
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impact of inclusion of adult data on minimum sample size requirements to achieve
precision standard for all scenarios.

Adult data inclusion had no significant impact on mean bias in clearance and volume
estimates. However, it did significantly reduce the bias in estimation of the A 50
parameter. Shrinkage in single trough sampling scenarios was significantly lowered
(≤20%) in presence of adult data. Adult data also significantly improved the estimation of
BSV parameters, in all cases.

What is the impact of the analysis method used?

The population mean analysis method is a more powerful analysis approach than the
individual post-hoc method i.e. allows use of smaller sample size to meet precision
standard, consistently for all scenarios. This observation is clear in Figure 3. Population
mean analysis also resulted in consistently lower mean bias in estimation, compared with
individual post-hoc analysis.

For population mean analysis, as far as the covariate parameter estimates, the allo CL and
allo V were generally well estimated (≤ ±20% deviation), although the allo CL was
generally under estimated. The A 50 parameter was always significantly over predicted
with 50-300% deviation from the reference value (0.18) used for simulations. As far as
variance, these parameters were generally reasonably estimated (≤ ± 20% deviation) but
the tendency was towards underprediction. This is expected, since we used truncated
simulations to restrict the simulated clearance and volume estimates within reasonable
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bounds. In case of single trough sampling, the BSV on clearance was considerably underestimated (-50 to -80% deviation). Adult data inclusion significantly reduced the bias in
estimation of variance (-20 to -40% deviation).

For individual post-hoc analysis, as far as shrinkage in parameter estimates, it was
generally ≤ 20%. As expected, shrinkage was greater with lesser number of PK samples
per subject and was significant (30-70%) for single trough sampling. However, this
reduced (to ≤20%) in presence of adult data.

What is the impact of i.v. vs. oral administration models?

All trends in power, sample size, and bias remained moreover similar between i.v. and
oral administration scenarios.

DISCUSSION
What are the typical sample sizes for different trial design scenarios that achieve
80% power for target (60-140%) precision and acceptable bias?

The study aimed to address the practical feasibility of implementing the precision
standard, in terms of sample size. Hence the inferences are focused on the estimates of
sample size adequacy and trends across different scenarios explored, and not on the
specific numbers arrived at for sample size. They are intended to serve as guidelines
while designing pediatric trials in keeping with the quality standard.
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In general, reasonable sample sizes were found to be adequate to meet the proposed
quality standard, ranging from 16-64 subjects, even with sparse sampling and high
between-subject variability. Hence we consider the proposed quality standard to be
practically feasible. Further, the estimation bias with these sample sizes was also found to
be acceptable (deviation from true values within 20%). While bias cannot be assessed in
real trials, it is re-assuring that the simulations do not suggest major bias in the estimates.

In absence of adult data, the sample size for trial design success was driven by both the
extreme age bins, bin 1 (1mo-2yrs) and bin 4 (12-17yrs). In presence of adult data, the
sample size was mainly driven by bin 1. Bins 2 (2-6 yrs) and 3 (6-12 yrs) invariably
complied with the criteria, for a given sample size, as long as bins 1 and 4 did. This result
is expected given the covariate model we have used, where body weight is the main
driver for clearance and volume estimates. Estimation precision is always lower at the
extreme ends of the data range. Hence precision on parameter estimates was consistently
found to be poorest for age bin 1 (also lowest body weight group), and in absence of adult
data, even for age bin 4 (also highest weight group). Thus, the total sample size that can
be used in a pediatric trial in order to be powered to meet the quality standard may be
lowered by recruiting fewer subjects in the middle age bins 2 and 3, and more subjects in
age bins 1 and 4. However, this decision is more of a regulatory issue than a research
focus of the current study.
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What is the impact of varying the number of samples per subject?

Sparse sampling schedules are most common in pediatric trials. While we explored
scenarios with either 2-3 or single trough PK sample per subject, the results are
generalizable. Increasing the number of PK samples per subject, even within the realm of
sparse sampling schedules, adds information to the model to aid better precision. If rich
pediatric PK data are available, non-compartmental analysis (NCA) may be considered,
in which case the sample size determination is fairly straightforward using variability
estimates from adult data or relevant prior pediatric data [8].

Of note is the fact that apart from number of samples, the sampling time schedule is of
critical importance during study design and has bearing on parameter precision as well.
However, several researchers have proposed methods to optimize PK sampling schedules
while designing a population study [9-11], and a thorough account of this aspect of
optimal trial design is beyond the scope of the present research. It is assumed that optimal
sampling time points for a given number of samples are pre-determined based on a
previous method.

As mentioned previously, we do not encourage the use of single trough sampling for
population PK studies, in recognition of its limitations. With only single trough data,
estimating volume parameters at all, let alone with good precision, is an unreasonable
expectation. Previous research has shown that the bias in estimation may be higher with
single trough sampling and that both between-subject as well as residual variability
parameters together may not be well estimated [13]. However, there still are cases where
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pediatric PK studies collect only single trough samples. At times practical restrictions, for
instance anemia or other health conditions in pediatric patients would only permit single
trough data to be collected. Further, large registration trials frequently collect only single
trough PK samples.

Hence we incorporated this scenario in our simulations. Only

clearance parameters may be estimated within the precision standard with reasonable
sample sizes, given the assumption that prior information on the structural model is
available.

What is the impact of low, medium or high PK between-subject variability?

PK variability is the predominant determinant of sample size as would be expected in any
power analysis. This parameter may differ considerably across drugs. We explored three
levels of between-subject-variability in order to generalize the methods to a wide range of
drugs. With sophisticated analytical methods and assays available today, we do not
anticipate the residual variability to be significantly high. Also structural PK models are
seldom severely mis-specified. Hence we did not explore the impact of varying this
parameter.

What is the impact of including adult data for estimation?

While designing a pediatric study, it is important to leverage prior information that may
be available in the form of either adult data for the same drug in question, or as relevant
adult or pediatric data from related drugs or indications. Most pediatric drug development
programs occur after the drug is approved in adults. Hence during pediatric trial design, it
is likely that a population PK model of the drug based on adult data would be available.
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For the analysis, sparse pediatric PK data may then be combined with the rich adult data
in order to estimate the relevant PK parameters in pediatrics. Hence inclusion of rich
adult data is also an important consideration while designing pediatric studies.

Rich adult data would additionally inform the structural model, leading to improved
estimation precision. Accordingly, we did observe an increase in precision and lowering
of pediatric sample size requirements, upon inclusion of adult data in the simulations.
However, the concern with including rich adult data in design or analysis of pediatric
trials would be the undue influence of the adult data on estimation, leading to perhaps
falsely high precision, simply by virtue of the large possible adult sample size. This
concern was addressed in our simulations. Importantly, we used a t df,α statistic
corresponding to only total pediatric sample size while constructing the 95% CI on
parameter estimates, avoiding an undue impact of adult sample size on precision. We
found a ceiling effect in terms of amount of adult data included. In most cases, rich data
from 24 adults did not offer a pediatric sample size advantage over using rich data from
12 adults. In the few cases this did happen, the gradient was reduced, and with more adult
data (48 adults) there was no added benefit (results not shown).

Both observations made with regard to adult data inclusion are useful. The first one reiterates the importance of using prior information where available, while the latter
alleviates the concern of adult data driving the parameter precision and leading to
unrealistically low pediatric sample size requirements.
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What is the impact of the analysis method used?

There could be different ways to assess whether the precision standard is met. For
instance, in the case of clearance, one option is to estimate the population mean clearance
for each pediatric age group to be studied while the other option could be to use the
geometric mean of individual post-hoc clearance estimates, for each pediatric age group.
Hence both analysis methods were explored. Given rich PK sampling, conventional
NCA, which is a two-stage analysis method, is comparable with the post-hoc analysis
approach used in our study. However, the body weight and age effect on post-hoc
individual estimates were normalized while determining precision so as to make the
precision assessment comparable with the population mean method. NCA and post-hoc
methods yield similar sample size outcomes at equivalent variability levels. The
population mean analysis was more precise and less biased than post-hoc analysis, which
is in fact a merit of mixed-effects modeling. Thus, the population-mean or one-stage
approach is the most powerful analysis method for pediatric data.

What is the impact of i.v. vs. oral administration models?

While an i.v. administration model is the simplest simulation template in terms of
parameters, most pediatric drugs are oral formulations. Hence both scenarios were
evaluated. However, since PK samples during the absorption phase would rarely be
available in pediatrics we chose to fix the absorption parameters (KA and BSV_KA)
based on adult values. Thus in terms of parameters estimated, the i.v. and oral scenarios
were the same. The only difference was additional variability (50%) contributed to the
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model by the KA parameter in the oral scenarios. As expected then, the outcomes and
trends were similar for both i.v. and oral cases.

Metrics used

The quality standard specifies the 95% confidence interval (CI) rather than standard error
(SE) for the precision standard. Using CI takes the combined effects of both SE and t df,α
into consideration for calculating precision. In case of small sample sizes (<30), which
are commonly used for pediatric studies, this is an important consideration for precision,
rather than using SE alone. Under an asymptotic normal distribution assumption, the
precision standard specified would be equivalent to achieving a relative standard error
(RSE) on the mean parameter estimate within 20%. In our study, we empirically
constructed the 95% CI using model-generated SE estimates and t df,α values
corresponding to the pediatric sample size used, avoiding undue influence of adult data
on precision. A non-parametric bootstrap would be the alternative way to construct the
required 95% CI, but this technique would be computationally very intensive and was not
considered justified for the scope of this study.

The bank of virtual pediatric subjects generated may be considered the true population of
interest for this study. Hence the non-parametric mean clearance and volume parameters,
for each age group, derived from the bank were used as reference values or true mean
estimates. These estimates matched well with the parametric mean estimates derived
using the covariate models for clearance and volume with median demographic values,
for each age group. Hence, we elected to use the same approach to determine the
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population mean parameter estimates, for each age group, under the population mean
analysis scenarios.

Scenarios

The aims of the study were to address the simulation methodology to design a pediatric
trial, along with the impact of different trial design elements, while targeting the
precision quality standard. Hence a simple one-compartment PK model was used in the
simulations. However, the methods used can also be applied for scenarios that differ
based on the underlying PK model, the covariate model used, the dose administered or
the number of and division into age bins, even though such scenarios were not explored
in this study. Scenarios were chosen to assess the impact of what we believe are the key
pediatric trial design elements.

Conclusions

The following are the salient findings of this research:
1. Plan well at the design stage to ensure an informative pediatric trial.
2. The PK quality standard of 60-140% precision with 80% power is practically
feasible. Reasonable sample sizes are adequate to comply with the standard and it
may be implemented using a simulation-based approach.
3. Pre-determined optimal sampling times for a given number of PK samples per
subject is important during trial design.

95

4. Use prior adult data or pediatric data for trial design and analysis, wherever
possible. Inclusion of adult data will not unduly drive precision and sample size to
achieve the quality standard.
5. Use one-stage population mean analysis methods, with biologically plausible
covariate models, for pediatric PK studies.
6. Allometric and Emax-type age-effect covariate models are feasible to use in
simulations, while designing pediatric trials to achieve the PK quality standard.
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CHAPTER 4
Covariate models – do not center at values outside the data
range

ABSTRACT
The purpose of this paper is to draw attention to a seemingly obvious concept during
centering of covariate effects in a population analysis. A simulation-estimation platform
with pediatric data was used to assess the impact of the choice of reference body weight
value at which the body weight effect on clearance and volume parameters is centered. It
was found that the reference value chosen for centering had implications for not only
parameter interpretation but also their precision. Absence of centering or in effect using
1 kg as a reference value led to 20-30% lower mean precision than centering at the
median of body weight range. In addition, centering at the upper end of the body weight
range led to 5-10% lower mean precision than centering at the median. The results can be
generally applied to all covariates underlining the recommendation that covariate effects
should be centered at an appropriate value of the covariate. Usually, using the median of
the covariate data range as the reference value will lead to most relevant interpretation of
model parameters and highest possible precision.
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INTRODUCTION
While developing covariate models in population analyses, it is good practice to center
the effect of a covariate on a model parameter at a particular reference value of the
covariate in order to make the parameter interpretable. It is perhaps a known issue, at
least among modelers, that when centering is done at a value outside the present data
range there could be instability in estimation and poor parameter precision. However, a
systematic study that accounts this phenomenon has not been published previously and
we believe it is of value to modelers in general. We used covariate models with body
weight effect centered at different reference values to demonstrate two key implications
of centering on: 1- parameter precision and 2- parameter interpretation.

METHODS
As part of a larger project, we conducted extensive simulation-estimation of pediatric
data. A pediatric population was simulated in terms of demographics and
pharmacokinetic (PK) observations under scenarios with increasing sample sizes. The
parameters of the PK model were then estimated using the simulated data and precision
and bias metrics for the estimates of mean systemic clearance and central volume of
distribution were determined. For each sample size scenario, 250 replicate simulationestimations were carried out.
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Nominal Design

A single 100 mg/kg dose of a hypothetical drug was administered intravenously (bolus)
to the simulated pediatric subjects. The drug follows one-compartment, dose-proportional
PK and has a half-life of about 1.5 hrs. A sparse sampling schedule design with 3 samples
per subject (0.1, 2 and 4 hrs) was employed. The different sample size scenarios used
were 16, 24, 32, 48 and 72 pediatric subjects.

Demographics
We used a CDC database for the simulation of pediatric demographics that included age,
gender and a relationship to determine body weight. Using this information we generated
a bank of n=48000 unique virtual pediatric subjects. The subjects were divided into four
age bins (1 mo to 2 yrs, >2 to 6 yrs, >6 to 12 yrs and >12 to 17 yrs) as is commonly done
during recruitment in most pediatric clinical trials. The weight range of simulated
subjects was 5 kg - 80 kg (median = 20 kg). For each scenario, the desired total number
of subjects was randomly sampled from this bank of pediatrics, with equal number of
subjects into each age bin.

Simulation Models

The one-compartment model used in the present study was parameterized in terms of
total systemic clearance (CL) and volume of distribution for central compartment (Vc).
The between-subject variability (BSV) of the model parameters was described using a

100

lognormal variance model. The allometric exponential covariate model was used to
account for effect of body weight on both clearance and volume.
η CLi

CLi = TVCL • WTi alloCL • e

… Eq. 1

η Vci

Vci = TVVc • WTi alloVc • e

… Eq. 2

where; η CLi is the difference between individual (CL i ) and typical value or population
mean (TVCL) clearance on log scale, η Vci is the difference between individual (Vc i ) and
typical value or population mean (TVVc) volume of distribution on log scale, allo CL and
allo Vc are the allometric exponents for the effect of individual body weight (WT i ) on
clearance and volume respectively. η CLi and η Vci were both assumed to follow a normal
distribution independent of each other, with mean of zero and variances of ω2 CL and ω2 Vc
respectively. The residual error or within-subject variability (WSV) was described using
a proportional error model as shown below:

(

Cpi = Cp pred • 1 + ε Cp

)

… Eq. 3

where; Cp i is the individual observed plasma concentration, Cp pred is the individual
model prediction and ε Cp is the residual error assumed to follow a normal distribution
with mean of zero and variance of σ2 Cp .

The parameter values for the “true” one-compartment model and associated covariate
effects used for simulations are listed in Table 1.
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Table 1: The one-compartment model parameters used for simulations
Parameter

Value

Units

Mean Clearance

3.2

L/h/20kg

Mean Volume

6.2

L/20kg

BSV_Clearance

30

% CV

BSV_Volume

30

% CV

Residual error

10

% CV

allo CL

0.75

allo V

1

BSV: between-subject variability; CV: coefficient of variation
allo CL , allo V : allometric exponent for weight effect on clearance and volume respectively

Estimation models
For the current study, for every simulated replicate, three estimation cases were carried
out, based on the centering of the body weight effect in the covariate model:
•

Case 1: Covariate effect not centered (effective reference value = 1 kg)

•

Case 2: Covariate effect centered at upper end of data range (reference value = 70 kg)

•

Case 3: Covariate effect centered at median of data range (reference value = 20 kg)

Accordingly, one of the following three covariate models was employed:

(

)

TVCL = THETACL • WTi alloCL
⎛
⎞
⎜
⎟
TVCL = THETACL • ⎜WTi ⎟
⎜
⎟
⎝ 70 ⎠

… Eq. 4

alloCL

⎛
⎞
⎜
⎟
TVCL = THETACL • ⎜WTi ⎟
⎜
⎟
⎝ 20 ⎠

… Eq. 5

allo CL

… Eq. 6
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Correspondingly, covariate models were also applied for TVVc, using the allo Vc
parameter. All model parameters were estimated.

Metrics

We assessed the resulting precision and bias of mean parameter estimates (clearance and
volume) for each replicate. The mean precision, power to achieve a target precision and
mean bias, based on all replicates, were then computed for each sample size scenario.

In accordance with a recent regulatory requirement of a precision standard on primary PK
parameter estimates [1], we assessed precision as a %CV-like metric but in terms of
upper bound of the 95% confidence interval (UCI) rather than standard error (SE). Using
CI takes the combined effects of both SE and t df,α into consideration which is important
in case of small sample sizes (<30) that are commonly used for pediatric studies rather
than considering SE alone. Thus, precision was defined as follows:
⎛ UCI ⎞
precision = ⎜
⎟ • 100
⎝ Mean ⎠

…. Eq. 7

Values close to 100 for this ratio represent high precision (or small standard errors) while
higher values, deviant from 100, represent more imprecision (or large standard errors).
We determined precision on clearance and volume parameters for every replicate and the
mean of this metric for all replicates was the “Mean Imprecision” for a particular sample
size scenario.
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In order to assess power, we used a pre-determined target on parameter precision, again
based on the regulatory requirement [1], defined as precision ≤ 140%. Under an
asymptotic normal distribution assumption, the precision target specified would be
equivalent to achieving a relative standard error (RSE) on the mean parameter estimate
within 20%. The proportion of replicates where the mean precision met the target was
determined to be the power to achieve target precision for that sample size scenario. In
order to construct the 95%CI, we used model estimated mean parameters and standard
errors and a t df,α statistic corresponding to the total pediatric sample size used at a 2-sided
α =0.05.

For the purpose of computing bias on the parameter estimates, the model parameters used
for simulation (Table 1) were considered to be the “true” estimates. The percent deviation
from the true value was the metric used, calculated as follows:
⎛ P − Ptrue
bias = ⎜⎜ est
Ptrue
⎝

⎞
⎟⎟ • 100
⎠

…. Eq. 8

where; P est is the estimated value of the parameter by fitting the model to the simulated
data and P true is the true value for the model parameter.

Software

We employed an R environment for the simulation-estimation platform with system calls
to NONMEM. For the simulations, random numbers were generated using a six digit
seed. The estimation method used was FOCEI. NONMEM version VI with Compaq
Visual FORTRAN 6 compiler was used to conduct the simulations and estimations. R
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version 2.9.1. was used to create the automated program script and carry out data
manipulation and analysis.

RESULTS
Precision and bias of mean parameter estimates

We found a dramatic improvement in the precision of the estimates of primary model
parameters (mean clearance and volume) when the body weight effect in the covariate
model was centered at the median (Case 3, reference value = 20 kg) as compared to at an
extreme value outside the data range (Case 1, reference value = 1 kg). Absence of
centering, or in effect using a 1 kg reference value, led to 20-30% lower mean precision
and up to 85% lower power, than centering at the median of body weight range. The
outcomes are less dramatic for centering at the upper end of the body weight range (Case
2, reference value = 70 kg), which led to 5-10% lower mean precision and up to 6%
lower power than centering at the median (refer Table 2).

As we can see in Table 2, when body weight effect is centered at the median of the
simulated data the precision on clearance and volume is high (100% power) at all sample
sizes. However, when 1 kg is used for centering the mean precision is poor (<50%) at
lower sample sizes and reasonable precision is obtained only at much higher sample sizes
(n>50) than would be expected.
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The bias in parameter estimates was unaltered by the choice of reference value used for
centering body weight effect on clearance and volume.

Table 2: Mean and power for precision on clearance and volume estimates in
absence and presence of appropriate centering.
Reference Value = 1 kg
Sample Size

Reference Value = 20 kg

Reference Value = 70 kg

Mean Imprecision

Power

Mean Imprecision

Power

Mean Imprecision

Power

(%)

(%)

(%)

(%)

(%)

(%)

16

156

15

114

100

125

94

24

149

22

112

100

122

98

32

142

46

110

100

120

100

48

136

78

108

100

116

100

72

131

98

107

100

114

100

16

157

15

116

100

126

94

24

150

15

115

100

122

96

32

143

42

111

100

120

100

48

137

74

109

100

117

100

72

132

98

107

100

114

100

Clearance

Volume

Age range: 1 month – 16 years; Body weight range: 5 – 80 kg
Mean imprecision = (95% UCI/Mean parameter)•100;
Power=% replicates where mean imprecision ≤ 140

106

DISCUSSION
Impact of centering on parameter precision

In most population analyses, the precision of model parameters, usually in the form of
standard error (SE), is used as a diagnostic tool for the model. A lower SE indicates
higher precision on parameter estimates, which is desirable and reflects well on the model
itself.

However, caution must be exerted while making this interpretation. The precision on a
parameter estimate is sensitive to both, sample size and the available data range, and in
turn to the reference value that a covariate effect is centered at. It is expected that any
software will run into difficulties while estimating a parameter in a data range where little
or no information is available. Hence, for instance, if a reference value of 1kg is used to
model the body weight effect on primary parameters then the parameter estimate may be
very imprecise because it will require the model to extrapolate to an extreme covariate
range relative to the data present. However, if the sample size is sufficiently large, the
imprecision may not be significant. Similarly, if centering at 70 kg (commonly used in
adult population analyses) is applied while modeling pediatric data [2-4], then the mean
parameter estimates could again have misleadingly lower precision because the observed
data would be concentrated at a lower weight range than the reference value.

Accordingly, as we found in Case 1, the precision on population mean clearance and
volume estimates was unexpectedly poor (refer Table 2) for a population analysis given
low between-subject-variability (30%) and residual variability (10%). We can attribute
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the poor precision to inappropriate choice of centering at 1 kg, which is an extreme low
value outside of the available of body weight range. In Cases 2 and 3 the parameter
precision was as expected for a population analysis. However, Case 3 (centering at the
median of the body weight range) had higher mean precision relative to Case 2 (centering
at the upper end of the weight range).

Thus, if a poor choice of reference value is made for centering a covariate effect, it may
adversely affect the parameter precision. In turn, dosing decisions can potentially be
affected - either if the parameter precision is subsequently used in simulations to derive
dosing regimens, or by erroneously rejecting reasonable model parameter estimates based
on precision. Some researchers use both mean parameter point estimate as well as
precision to conduct simulations to derive dosing recommendations, and caution must be
exerted while selecting reference values for centering covariate effects in such cases.
However, the choice of centering is irrelevant when the allometric exponent is fixed to a
constant during modeling or when sampling covariance between parameter estimates is
ignored during simulation.

We also found in our study that the choice of centering does not affect the overall model
significance (OFV) nor the precision or significance of other covariate effects. We
simulated a categorical covariate (gender) effect on clearance using a proportional model,
along with body weight effect, and then estimated the gender effect using the three
different reference values for body weight effect. Reference value had no impact on the
precision or statistical significance of the gender effect. This result is expected since in
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this case the gender effect parameter is estimated for all levels of body weight. However,
in a case where a different mean clearance parameter is estimated for each gender and the
determination of a significant gender effect depends on the difference between mean
clearance estimates, and their respective precision (95% CI), an erroneous decision about
gender effect may be made if inappropriate centering of body weight effect is used.

Interpretation of parameter estimates

The primary reason for centering covariate effects used in a population PK model is to
make the model parameters interpretable. In our study, in Case 1, absence of appropriate
centering limited the interpretability of resulting mean parameter estimates because
according to the models used (Eq. 4) the parameters represented the mean clearance and
volume for a non-existing individual weighing 1 kg. On the other hand in Cases 2 and 3,
when centering of the body weight effect was done at realistic body weight values (Eq. 5
and 6), the resulting model parameters were interpretable.

Further, if a proportional model is used to incorporate a covariate effect, for instance age
[5], according to the model depicted below (Eq. 9) then A eff is a parameter that represents
the effect of age on clearance and TVCL would be interpreted as the typical value of
clearance for an individual with age = 0 years. Again, this is an unrealistic population
mean clearance estimate that is not interpretable. The interpretation of model parameters
becomes even more complicated when multiple covariates are involved for a single
model parameter.

109

TVCL = THETACL • (1 + Aeff

•

Agei )

… Eq. 9

Hence it is good practice to center the individual covariate effects at a reference covariate
value that would make the model parameter interpretable and plausible. The proportional
model for age effect (Eq. 9) used above can be modified as follows to make TVCL
meaningful:

TVCL = THETACL • (1 + Aeff • ( Agei − 50))

… Eq. 10

TVCL now represents the typical value of clearance for an individual aged 50 years,
which is a useful interpretation of the parameter since 50 years is a plausible age for an
adult.

For most relevant interpretability of model parameter estimates, the choice of the
reference value to be used for centering covariate effects should depend not only on the
range of covariates present in the data being analyzed but also the population of interest.
For instance, in Case 2 in this study, 70 kg is a reasonable reference value for centering
body weight effect in an adult population model but, in terms of parameter interpretation,
not so suitable for pediatrics [2-4] or an adult obese population. Therefore, typically the
median or mean of the covariate range in the data available serves as a good choice for
the reference value [6-9]. In Case 3, the mean parameter estimates were for a 20 kg
pediatric subject making their interpretation most relevant for the population of interest to
this study. However, we do recognize that the advantage of using a uniform centering
reference value for all populations is the convenience of comparing mean parameter
estimates across all studies, pediatric and adult.
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In some population PK analyses, model parameters may be expressed per kg (e.g.
clearance is reported as L/h/kg), even when a centered model is used and the allometric
exponent is not 1 [10;11]. Per kg parameter expression is also implied when centering of
body weight effect is omitted [5;12]. Both these approaches not only limit the
interpretability of the clearance parameter but can also lead to erroneously determining
clearance values at higher body weights.

Other covariate effects

The choice of reference value for centering body weight effect in a population model is
perhaps most critical since it is the most commonly used covariate. However, the same
rationale applies to any continuous covariate used in the model. For categorical
covariates too, a similar rationale holds true. For instance, in case of a categorical
covariate with multiple levels, such as genotype, a mean clearance parameter for a
particular genotype category may be estimated, along with different effect parameters for
the remaining genotype categories. In such cases, the choice of genotype category for
which the mean clearance parameter (or intercept) is estimated will dictate its precision.
This is similar to choice of reference value for a continuous covariate. The genotype
category with highest number of subjects in the available data will have a mean clearance
estimate with highest precision. However, the precision of the different genotype effect
parameters (or slope) remains independent of the choice of reference genotype category.
The interpretation of a model parameter is also based on defining the reference covariate
category (or typical population) that it represents. In case of genotype, it would perhaps
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be most advisable to use the genotype with highest prevalence in the population of
interest as the reference category.

Conclusion

Centering covariate effects used in population models is important. While doing so the
choice of the reference covariate value at which its effect is centered is critical for both,
model parameter interpretation and precision. However, interpretation and presentation
may always be altered by re-parameterizing the model in terms of covariate values, as
applicable for the circumstance at hand. The model applied for estimation may not
always

directly

produce

the

parameters

desired

for

interpretation.

A

final

recommendation would be to use model parameterization that yields stable and precise
estimation, and also parameters with relevant interpretation, for which the median or
mean of continuous covariate data is an ideal choice.
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CHAPTER 5
A Genetics-based Pediatric Warfarin Dosing Regimen derived
using Pharmacometric Bridging

ABSTRACT
The objective of this research was to derive a genetics-based pediatric dosing
regimen for warfarin, including starting dose and titration scheme, using modeling and
simulation.
Whilst several algorithms have been suggested for warfarin dosing in adults,
pediatric specific dosing algortims are absent. Even so, warfarin continues to be
extensively used as an anticoagulant in the pediatric population. A model-based approach
was used to arrive at a proposed pediatric dosing regimen that was based on warfarin
dosing in adults and pharmacokinetic/pharmacodynamic (PK/PD) principles. Pediatric data
on warfarin dosing and INR came from a study conducted at the Children’s Hospital of
Los Angeles (CHLA). The dosing regimen targeted a major (≥ 60%) proportion of INRs
within therapeutic range of 2.0-3.0, by week two into warfarin therpay. Simulataneously,
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the target was to minimize bleeding and thromboembolic risk by minimizing the
proportions of INR > 3.5 (to ≤ 10%) as well as those of INR < 2 (to ≤ 20%). The targets
were set as used in adults as well as in pediatric studies.
A 2-step pediatric starting dose is proposed based on body weight (<20 kg and ≥20
kg) for each of 18 genotype categories, using differet possible combinations of individual
CYP2C9 (*1/*2/*3) and VKORC1 (-1639 G>A) genotypes. The titration scheme involves
percentage changes relative to previous dose, based on the latest patient INR. In
simulations, the propsed dosing regimen performed better than the empricial dosing used
in the CHLA patients, based on consistently maintaining target INR outcomes. To our
knowledge, this is the first ever proposed dosing regimen for using warfarin in pediatric
patients. However, the research is limited by the small sample size of available pediatric
PK/PD data and absence of prospective validation of the dosing regimen. Hence
prospective clinical studies with warfarin in pediatrics using the proposed dosing regimen
are recommended.
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INTRODUCTION
Warfarin is the most widely used oral anticoagulant. It has been used for over 50 years in
adults for the treatment and prevention of venous thromboembolism, pulmonary embolism,
and thromboembolic events associated with atrial fibrillation, myocardial infarction,
cardiac valve replacement and stroke [1;3;4]. The drug is currently not approved for
pediatric indications [1]. Management of warfarin therapy is complicated owing primarily
to two reasons – its narrow therapeutic index and high inter- and intra- individual
variability in drug response. The individualized treatment goal is to maintain patient INR
(international normalized ratio) within a therapeutic range, usually 2.0-3.0. Therapy
involves potentially fatal thromboembolic risk at lower INRs and hemorrhagic risk at
higher INRs [2-5].

Various known warfarin pharmacokinetics (PK) and pharmacodynamics (PD) factors
contribute to the observed INR variability. Figure 1 is a schematic of the PK-PD of Swarfarin, the potent enantiomer in the raceimic warfarin product administered. Most
importantly, polymorphisms in two genes – cytochrome p450 2c9 (CYP2C9) and vitamin
K epoxide reductase c1 (VKORC1), which are involved in the PK and PD of warfarin
respectively, have been shown to result in increased INRs and reduced warfarin dose
requirements [3-10]. The variant alleles *2 and *3 in the CYP2C9 gene reportedly reduce
warfarin clearance to about 30% and 15% respectively [4;8]. Patients with these variant
alleles also require a longer time to achieve stable dosing, and are at a significantly
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increased bleeding risk when compared with patients with the CYP2C9*1*1 (homozygous
wild-type) genotype [6;11-13]. Multiple polymorphisms (such as -1639 G>A and 1173
C>T) in the VKORC1 gene, which occur in linkage disequilibrium, have been shown to
increase warfarin sensitivity by about 30-50% [13;14], reducing warfarin dose
requirements. Collectively, the CYP2C9 and VKORC1 genotypes have been shown to
account for approximately 45% of the variability in warfarin dose requirements
[7;9;10;15;16]. At a clinical pharmacology advisory committee meeting of the U.S. Food
and Drug Administration (FDA) in 2005, there was consensus on existence of sufficient
mechanistic and clinical evidence to support lower doses of warfarin for patients with
certain polymorphisms in CYP2C9 and VKORC1 genes [17]. Subsequently, the warfarin
label was updated in 2007 to include recommendations to genotype subjects for CYP2C9
and VKORC1 before initiating warfarin therapy and use lower doses accordingly [1].
Notably, the prevalence of the CYP2C9 polymorphisms in Caucasians is about 35% [18]
and that of VKORC1 polymorphisms is about 40% in Caucasians and very high, i.e. about
85%, in Asians [5]. Therefore, testing for these polymorphisms is being performed to
guide dosing in adults, which may improve the clinical safety and efficacy of warfarin
[11]. Additional influential factors for warfarin dosing include but are not limited to body
weight, age, co-morbidities, drug-drug interactions (DDI) and diet. Extensive research has
been undertaken in order to account for the impact of all these factors on warfarin therapy
and several algorithms for dosing warfarin in adults have been proposed [710;12;15;16;19].
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Figure 1: PK-PD of S-warfarin

PK: two-compartment model dose-proportional PK, metabolic clearance via CYP2C9 only
PD: inhibition of synthesis of components of pro-coagulant complex activity (PCA) characterized using
inhibitory Emax model; response measured as INR, a derivative of prothrombin time
CL- clearance; V- volume of distribution; ka- first-order absorption rate constant; Cfree- free/unbound
plasma drug concentration; EC50- drug concentration to elicit half maximal inhibitory response; ksyth- zeroorder rate constant for PCA production; kout- first-order rate constant for PCA degradation [42].

As far as pediatrics, even though not approved, warfarin remains the mainstay of oral
anticoagulant therapy for patients with cardiovascular indications for prevention of
thromboembolism [20-23]. Two distinct pediatric patient populations receive warfarin
frequently; one are infants and young children with congenital heart defects who have
undergone Fontan or other surgery, and second are the adolescent patients who have valve
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replacement. Some other common pediatric indications requiring warfarin therapy include
presence of central venous lines, congenital antithrombin deficiency, and cerebral
thromboembolism. As in adults, the management of warfarin therapy is difficult in
pediatrics and adverse effects are common [20;24;25]. The bleeding rate in pediatric
patients on warfarin has been reported to be about 0.5% per patient year for major bleeding
events and to range from 1.9-2.3% per patient year for minor bleeding events [25;26].
While major bleeding may occur even at warfarin doses considered therapeutic, serious
hemorrhage risk has been shown to increase with increasing intensity of anticoagulation
[27]. The occurrence of recurrent thromboembolic events in pediatric patients while still on
warfarin therapy has been reported to range from 1.3-2.3% per patient year [25;26].

Limited clinical studies of warfarin in the pediatric population have been conducted
[26;28;29]. Body size and age have been suggested to have an influence on warfarin dose.
Some researchers also propose a maturation effect on the fundamental activity of the
human coagulation system [30;31]. In addition, the polymorphisms in CYP2C9 and
VKORC1 genes have been shown to be associated with lower pediatric warfarin dose
requirements [32-34]. It is intuitive that these genetic effects seen in adults would be
similar in pediatrics given that the mechanism of action of warfarin, and the coagulation
and drug elimination pathways, are the same in pediatrics and adults.
However, all clinically available computer-based pharmacogenetic dosing algorithms for
warfarin ignore considerations for pediatrics. In order to provide pediatric patients on
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warfarin therapy with the pharmacogenetic advances that are now being integrated into
adult care, it is important to develop and validate a pediatric warfarin dosing algorithm.
Such an algorithm should integrate the impact of CYP2C9 and VKORC1 genotype with
other factors (such as body size, ontogeny of PK-PD determinants, concomitant drugs) on
warfarin disposition and effect in pediatrics. A recent study reported enthusiasm among
pediatric hematologists for trials to develop a pediatric warfarin dosing algorithm,
incorporating pharmacogenetic effects [35]. However, patient recruitment problems have
been a severe limitation to such trials [36]. The need for efficient, novel approaches to
enable addressing pediatric warfarin dosing has been highlighted [35].

The objective of the current study is to develop a genetics-based pediatric warfarin dosing
regimen, including both starting doses and a titration scheme, which can be validated
prospectively for pediatric patients. A pharmacometric bridging approach, using modeling
and simulation along with limited available pediatric data have been used to assess the
potential usefulness of the dosing regimen. The eventual goal is to establish a new standard
of care for pediatric patients who require warfarin therapy via an optimal, validated dosing
regimen that will guide clinicians for safer and more effective warfarin use in pediatrics.

METHODS
An attempt has been made to leverage all the information previosuly available for the data
anlysis in this study, using efficient modeling and simulation methods. Prior information
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was available in the form of an accepted adult warfarin PKPD model [14] and warfarin
dosing and INR information was available from a limited number of pediatric subjects
from Children’s Hospital, Los Angeles (CHLA). Our research approach is outlined in
Figure 2. Briefly, we derived a pediatric PKPD model using the prior adult PKPD model
and knowledge of physiology. By physiology we refer to PKPD principles such as the
relation between drug clearance and body size, the maturation pattern of drug metabolizing
enzymes and the mechanism of action of warfarin. We then qualified the pediatric model
using the CHLA data, which were not used for model derivation. Initial pediatric warfarin
doses were estimated by matching target INRs for typical pediatric subjects with adults.
The pediatric dosing regimen - starting dose and titration scheme - were then optimized
using simulations of several thousand pediatric subjects.

Figure 2: Outline of research approach employed
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CHLA data

Patients
Data for the current study came from pediatric patients ≤ 18 years of age who were
followed previously (within the last 1 year) and currently (during the study period) in the
warfarin clinic of the Division of Cardiology, CHLA. Patients who had received warfarin
for less than 7 days were excluded. This was an observational study with patients receiving
standard of care warfarin therapy. The clinicians dosed and monitored patients as per their
clinical expertise, with each patient treated on a case to case basis, depending on their
condition and target INR. Warfarin dosing and INR logs (INR measurements across time)
were recorded during regular scheduled visits to monitor warfarin therapy. Informed
consent for study participation was obtained at one such routine visit along with a sample
of 1.0 ml blood in addition to the routine blood draw. The blood sample was transported to
the USC (University of Southern California) pharmacogenetics laboratory where genetic
testing was done. A vitamin K dietary intake estimate was performed from a 1-3 day food
diary. In addition to genotype and diet, data items collected were age, weight, height,
gender, warfarin dose, INR, other medical illness or medications and adverse events. The
information was obtained from the existing nurse coordinator's database and documented
under the study ID number.
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Genetic analysis
Genomic DNA samples were extracted from blood samples using a genomic DNA
extraction kit (QIAmp DNA Blood Mini kit, Qiagen, Mississauga, Ontario, Canada). The
genotypes for the CYP2C9 *2 (rs1799853) and *3 (rs1057910) and the VKORC1 -1639
G>A (rs9923231) SNPs were determined using real-time quantitative polymerase chain
reaction assay based on the 5’ nuclease allelic discrimination assay (ABI PRISM 7900
Sequence Detection System, Applied Biosystems, Foster City, California). Genomic DNA
(10 ng) was mixed with 2.5 µL of gene specific primers and probes (10X concentrated)
and 12.5 µL of polymerase chain reaction universal master mix (Applied Biosystems) to a
final volume of 25 µL. Thermal cycler parameters included 10 minutes at 95oC and 50
cycles involving denaturation at 95oC for 15 seconds and annealing/extension at 60oC for 1
minutes. For quality control of genotyping, negative and positive controls were used
whenever genotyping was performed. Distributions of the CYP2C9 and the VKORC1
genotypes were compared to the Hardy-Weinberg theoretical distribution using the chi
square test. A p-value less than 0.05 was considered statistically significant.

Pediatric warfarin model: derivation & qualification

Prior adult model
Previosuly, a group at the FDA in collaboration with Harvard Partners, Boston MA has
developed a warfarin population PKPD model and dosing scheme in adults [14]. The adult
model was based on published research on the concentration-effect relationship for
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warfarin [8;42] as well as data from an adult warfarin trial, CROWN (creating an optimal
warfarin dosing nomogram). The model was built using data from an initial 271 subjects
and subsequently validated in the same trial by using model-derived dosing in 117 subjects
(unpublished results). In the current study, a pediatric warfarin population PKPD model
was derived using the adult model and mechanistic reasoning.

Pediatric PK model
The adult PK parameters were first scaled to account for body size effects in pediatrics. A
covariate effect for body weight was included in the pediatric model, using previously
published and widely accepted allometric scaling principles [37;38]. A body weight effect
with allometric exponent of 0.75 was included on systemic and inter-compartmental free
clearances while that with an exponent of 1 was included for the central and peripheral free
volumes of distribution. Next, the impact of maturation on free warfarin clearance was
accounted for, using age as a covariate. The age effect on free clearance in the model is
based on a relationship previously developed for the maturation of CYP2C9 using warfarin
pediatric data [39]. According to the model used, CYP2C9 enzyme activity increases with
age and attains maturity by the age of 2-3 months. Finally, effects of the CYP2C9
genotype (variants *2 and *3) on clearance were included in the model as estimated for
adults [8]. These values came from a clinical PKPD study in 150 adult patients on warfarin
that included subjects of all relevant polymorphic CYP2C9 genotypes.
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Between-subject variability in our pediatric PK model was described for three model
parameters - clearance, central volume, and peripheral volume, using a lognormal
distribution. The total plasma drug concentrations were corrected for plasma protein
binding, which is reported to be 99% [1], in order to achieve free plasma drug levels. The
following equations describe the PK model we used:

⎛ WT ⎞
CLi = TVCL • CYPeff • ⎜ i ⎟
⎝ 20 ⎠

0.75

⎛ 0.821 • Agei
⎞ η
• ⎜⎜
+ 0.21⎟⎟ • e CLi
⎝ 0.01 + Agei
⎠

… Eqn. 1

1

⎛ WT ⎞
η
Vci = TVVc • ⎜ i ⎟ • e Vci
⎝ 20 ⎠
⎛ WT ⎞
Qi = TVQ • ⎜ i ⎟
⎝ 20 ⎠

… Eqn. 2

0.75

... Eqn. 3
1

η
⎛ WT ⎞
Vpi = TVVp • ⎜ i ⎟ • e Vpi
⎝ 20 ⎠

Cp =

... Eqn. 4

Cp free

... Eqn. 5

fu

where; η CLi is the difference between individual (CL i ) and population mean (TVCL)
clearance on log scale, η Vci is the difference between individual (Vc i ) and population mean
(TVVc) central volume of distribution on log scale, η Vpi is the difference between
individual (Vp i ) and population mean (TVVp) peripheral volume of distribution on log
scale, Q i and TVQ are the individual and population mean inter-compartmental clearance,

125

CYP eff is the covariate parameter that accounts for the effect of CYP2C9 genotype on
clearance, WT i and Age i are individual body weight and age and Cp, Cp free and f u are
total, free and fraction unbound plasma drug concentrations of S-warfarin. η CLi , η Vci and

η Vpi were all assumed to follow a normal distribution, independent of each other, with
mean of zero and variances of Ω2 CL , Ω2 Vc and Ω2 Vp respectively.

The pediatric model assumes that immature CYP2C9 clearance is not saturable at
therapeutic warfarin concentrations. Plasma protein binding was assumed to be unaffected
by maturation. The model does not account for the impact of drug-drug interactions and
dietary vitamin K on warfarin PK.

Pediatric PD model
There is no published study that establishes the concentration/dose-response relationship
for warfarin in the pediatric population. This relationship is assumed to be similar in
pediatrics and adults for pediatric PD model derivation. The assumption is based on two
reasons. First, the mechanism of action of warfarin is the same for pediatrics and adults,
namely inhibition of synthesis of vitamin K dependent clotting factors in the liver, and
drug response in both populations is measured clinically as INR. Second, the
concentration-response relationship has been shown to be similar between pediatrics and
adults for other anticoagulants, namely argatroban [40] and heparin and low molecular
weight heparin [41]. While these drugs have a different mechanism of action than warfarin

126

and their response is measured in terms of aPTT, the net effect is on clotting factor activity,
much as for warfarin. Hence, in absence of pediatric specific warfarin PD data, the adult
PD model [14] for warfarin was used for pediatrics as well.

Warfarin exerts anticoagulation by inhibiting synthesis of vitamin K dependent clotting
facttos, which results in a decrease in total clotting factor complex activity (PCA). This
effect is measured clinically as a subsequent increase in prothrombin time (PT). The INR is
a standardized measurement of PT, accounting for variations in lab reagents. The PD
model used describes an inhibitory effect of warfarin on INR degradation rather than on
synthesis of PCA. Given the inverse relationship between PCA and INR, and the fact that
the clinical response to warfarin therapy is measured as INR, such a representation of the
effect of warfarin is both logical and intuitive.

The PD effect in patients is driven by free drug levels and hence protein-binding corrected
plasma drug concentrations are used in the model. According to the model (Eqn. 6), INR
change is dependent on previous INR, free warfarin plasma concentration (Cp free ) and drug
potency (EC50), which may be defined as the drug concentration required for half maximal
inhibitory effect. Patient sensitivity to warfarin, which is dependent on VKORC1
genotype, was captured as differing potency of the drug (EC50 VKOR ) to elicit the same
response in subjects with different genotypes.
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⎛ ⎛
Cp free
⎜ ⎜
dINR
= K in − K out • INR • ⎜1 − ⎜
dt
⎜ ⎜ Cp free + EC 50VKOR
⎝ ⎝

⎞⎞
⎟⎟
⎟⎟
⎟⎟
⎠⎠

… Eqn. 6

Between-subject variability in our pediatric PD model was described for three parameters K in , K out , and EC50 VKOR , using a lognormal distribution. The measurement error on INR
was accounted for using an additive error model. The following equations describe the PD
stochastic models used:

η
Kini = TVKin • e Kini

… Eqn. 7

η
Kout i = TVKout • e Kout i

… Eqn. 8

η EC 50VKOR

EC 50VKOR i = TVEC 50VKOR • e

i

INRobs = INR pred + ε INR

… Eqn. 9
… Eqn. 10

where; η Kini is the difference between individual (Kin i ) and population mean (TVKin)
synthesis rate constant for INR on log scale, η Kouti is the difference between individual
(Kout i ) and population mean (TVKout) degradation rate constant for INR on log scale,

η EC50

i

VKOR

is the difference between individual (EC50 VKORi ) and population mean

(TVEC50 VKOR ) VKORC1 genotype-dependent warfarin potency on log scale and

ε INR is

the difference between observed (INR obs ) and model-predicted (INR pred ) INR. η Kini , η Kouti ,

η EC50

i

VKOR

and

ε INR were all assumed to follow a normal distribution, independent of each

other, with mean of zero and variances of Ω2 Kout , Ω2 Kin , Ω2 EC50VKOR and σ2 INR respectively.
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Pediatric model qualification
The prediction capability of the derived pediatric population PKPD model was qualified
using CHLA pediatric data. Data were used from only those subjects whose CYP2C9 and
VKORC1 genotypes and INR log information were available. We first predicted individual
CHLA patient INRs using our model, based on only the demographic and warfarin dosing
information from the CHLA data. 200 replicate simulations were performed for each
CHLA subject’s set of demographic and dosing data, to generate a distribution of predicted
INRs across time. For the validation simulations, INR distribution was truncated within
values 1.0-6.0. Thus, we generated 5th, 50th and 95th INR prediction percentiles, for each
CHLA subject over time. This step was blinded to the INR data from the CHLA study.
Next, we overlaid the observed INR-time profiles for each subject from the CHLA trial
onto the model INR prediction percentiles. If about 90% of a subject’s INR observations
fell within the 5th and 95th percentiles, the model predictions were considered reasonable.
The proportion of subjects where model predictions matched reasonably well with INR
observations were determined to qualify the model’s prediction capability.

Optimal pediatric dosing: clinical trial simulations

The pediatric PKPD model was employed to investigate optimal warfarin dosing using
clinical trial simulations. The aim was to optimize INR outcomes to clinically reasonable
targets. Figure 3 is a schematic representation of the simulation process. For purposes of
deriving starting dose, each genotype category was treated independently. Given all
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possible combinations of genotypes for CYP2C9 (*1*1, *1*2, *1*3, *2*2, *2*3 or *3*3)
and VKORC1 (GG, GA or AA), we had 18 unique genotype categories.

Broadly, a two-step approach was used for determining optimal dosing. In the first step we
narrowed the starting dosing choices based on deterministic simulations in typical subjects
within each genotype. The second step comprised of performing stochastic simulations to
derive the best starting and titration dosing.

Figure 3: Clinical trial simulations schematic
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Demographics
We used a CDC (center for disease control and prevention) database for the simulation of
pediatric demographics that included age, gender and weight. The database contained ages
from birth-20 yrs, in increments of 1 month, yielding 240 unique ages. For each unique
combination of age and gender there is a parameter set, including a variability component,
to determine the distribution of body weight. We simulated 100 individuals of different
body weight for each combination of age (1 month - 17 years) and gender resulting in a
virtual bank of about 48000 unique virtual pediatric subjects. For preliminary simulations
we considered six typical pediatric subjects, covering the entire pediatric demographic
range. The six typical subjects represent the mean body weight and age, obtained from the
virtual bank, for five different body weight/age groups. The typical demographics were:
5kg/1month; 8kg/6mo; 11kg/1.5yrs; 16kg/4yrs; 28kg/9yrs; 54kg/15yrs. For final
simulations, subjects were randomly sampled from the virtual bank of pediatrics. 1000
pediatric subjects for each genotype category were simulated.

Initial pediatric dosing: mean simulations
In the initial step, the target was to match warfarin INRs in typical pediatric subjects with
adults. Body weight based dosing (mg/kg/day) was considered suitable for pediatrics.
However, given the body-weight clearance relationship is not linear; the mg/kg dose is
expected to be different across different body weight groups (lower for subjects with
higher body weight). Thus one consideration was to arrive at a reasonable number of
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dosing steps by body weight level. We also considered the need to adjust dosing steps
based on age group. For the mean simulations all sources of variability in the pediatric
model were disregarded. INR outcomes were simulated for the first 30 days of warfarin
therapy.

Initial estimates of starting dose (mg/kg/day) for each of the six typical pediatric subjects
were derived for each genotype category. Adult starting doses and our pediatric covariate
model for clearance [8;14] were used for this purpose. Then using the initial pediatric dose
estimates we simulated INR outcomes for the average subject, within each genotype
category. The starting dose was adjusted to target, on an average, an INR of 2.5 and/or to
match the INR-time profile for typical subjects with that of adults. Doses that rendered
mean INR-time profiles closest to the target were considered for the full-fledged stochastic
simulations.

Final pediatric dosing: stochastic simulations
The next step was to perform stochastic simulations in order to optimize the pediatric
dosing scheme for the entire population. For these simulations all sources of variability
were included in the model, namely, demographic variability, between-subject PK and PD
variability and INR measurement error. For each genotype category, the dosing aim was to
target a high (≥ 60%) proportion of INRs within therapeutic range of 2.0-3.0, by week two
into warfarin therpay. Simulataneously, the target was to minimize bleeding and
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thromboembolic risk by minimizing proportions of INR > 3.5 (to ≤ 10%) as well as
proportions of INR < 2 (to ≤ 20%). While week 2 (14 days) into therapy was considred the
primary time end-point, the INR outcomes through month 1 (30 days) were evaluated for
all dosing regimens tested. The target clinical outcomes (depicted in Figure 4) are based
on those used commonly in pediatric patients on warfarin [20;24;26;28;29] as well as those
desired in adults, as per the expertise of the CROWN trial clinicians [14].

The starting dose as well as titration scheme were optimized as an iterative process,
assessing the target INR outcomes for all genotype groups. INR monitoring (and dose
titration) in our simulations was performed twice a week, as is done in regular clinical
practice. Simulations were performed for first 30 days of warfarin therapy. For the final
propsed dosing regimen INR outcomes through 90 days of warfarin therapy were also
simulated.

Figure 4: INR target outcomes for pediatric dose optimization
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Initially genotype-independent dosing was compared with genotype-based dosing. In the
former case, all subjects were given the same body weight adjusted doses as determined
for the CYP2C9*1*1 and VKORC1 GA genotype. In the latter case, dosing was as per our
proposed regimen – subjects with different genotypes were given different body weight
adjusted doses. Comparisons were made with regard to target INR outcomes for all
genotype categories.

The proposed dosing regimen was then compared with the empirical dosing as used in
subjects in the CHLA study. For the proposed dosing target INR outcomes were as
previously defined (Figure 4). However, for the CHLA dosing since the target INR varied
across patients, outcomes were in accordance with individual patient target INR range. To
maintain consistency with INR outcomes used for the proposed dosing, sub-therapeutic
INRs for CHLA dosing were those below the lower limit of the patient’s target therapeutic
INR range while supra-therapeutic INRs were considered at 0.5 value above the upper
limit of the target range.

Finally, we also evaluated the impact of restricting doses proposed by our regimen to
available strengths of warfarin formulations, on the target INR outcomes. The lowest dose
that is currently feasible to administer to pediatric patients in warfarin clinics is 0.5 mg.
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Software

Trial Simulator version 2.2.1 by Pharsight® was used for the mean and stochastic
simulations, while determining pediatric doses. NONMEM version VI with Compaq
Visual FORTRAN 6 compiler was used for simulations during model validation. For
NONMEM simulations, random numbers were generated using a six digit seed. R version
2.9.1 was used for data processing, data analysis and graphics generation. The NONMEM
model used is given in Appendix B. The drug model set-up in clinical trial simulator is
given in Appendix C.

RESULTS
CHLA Data

A total of 36 pediatric subjects were included in the CHLA study. Of these, 10 subjects
were missing genotype and/or INR log data. We were able to use data from 26 pediatric
subjects for model qualification. Cohort demographics are provided in Table 1. The mean
age of subjects was 4yrs 5mo (range 4 mo-18 yrs) and mean body weight was 23 kg (range
6.9-84 kg). The cohort included a wide range of body weight but only one subject with age
< 6 months. While there were a fair number of subjects with the VKORC1 polymorphisms
in the study cohort, the CYP2C9*2 polymorphism was rare and the *3 polymorphism was
absent. There were three sub-groups in terms of target INR range, which was dependent on
indication for warfarin therapy.
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Table 1: Description of cohort of pediatric subjects from CHLA
Characteristic

Mean (range) or Number (%)

Age (years)

4.4 (0.33-18)

Body weight (kg)

23 (6.9-84.1)

Height (cm)

107 (65-189)

BSA

0.81 (0.36-2.1)

Warfarin maintenance dose (mg/kg/day)

0.12 (0.04 - 0.3)

Gender:
Male
Female

16 (61%)
10 (39%)

Race:
Hispanic
Caucasian
African American
Mixed

16 (61%)
7 (27%)
2 (8%)
1 (4%)

Target INR:
1.5-2.5
2.0-2.5
2.5-3.5

13 (50%)
5 (19%)
8 (31%)

Indication:
Valve replacement
Fontan procedure
Kawasaki
Cardiomyopathy

8 (31%)
12 (46%)
5 (19%)
1 (4%)

CYP2C9 genotype:
*1*1
*1*2
*1*3 / *2*2 / *2*3 / *3*3

22 (85%)
4 (15%)
0

VKORC1 genotype:
GG
GA
AA

7 (27%)
8 (31%)
11 (42%)
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A wide range of doses (0.5-6.5 mg/day) were used in the pediatric subjects by the
clinicians in the CHLA study. Starting doses in particular ranged from 0.5-5 mg/day. The
dosing and titration choices did not follow a specified algorithm. For instance, two
comparable patients weighing 16 kg, with target INR 1.5-2.5, were started on doses of 0.5
mg/day and 1.5 mg/day, respectively. Further, in case of two patients with target INR 2.53.5, during monitoring at an INR of 1.4 on day 5, one patient was given a 20% increase in
dose while the other didn’t receive any dose change.

The patient charts reveal that adherence to dosing assigned was poor in 4 subjects and
prolonged times (> 60 days) were needed to arrive at stable dose in 12 (46%) subjects. The
median time to achieve stable INR was 137 days. There were 4 major bleeding and 6
minor bleeding events during the study.

Pediatric warfarin model

The parameters of the pediatric model that we derived and used for clinical trial simulation
are shown in Table 2.
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Table 2: Parameters of the warfarin pediatric population PKPD model used to
predict CHLA data and to optimize dosing.
Parameter

Value (*for a 20 kg subject)

Variability

PK: two-compartment model

TVCL

0.1207 L/h*

30 %CV

CYP eff
*1*1

100%

*1*2

68%

*1*3

55%

*2*2

28%

*2*3

31%

*3*3

15%

TVVc

3.45 L*

24 %CV

TVVp

1.65 L*

98 %CV

TVQ

0.05 L/h*

Allometric exponent
for weight effect on:
CL and Q

0.75

Vc and Vp

1

Ka

2 /h

Bioavailability

50%

Unbound fraction

1%

PD: sigmoidal Emax indirect response model

Kin

0.01953 /h

SD = 0.005

Kout

0.01698 /h

SD = 0.005
SD = 0.783

EC50 VKOR
GG

3.953 μg/L

GA

3.075 μg/L

AA

2.547 μg/L

INR residual error

SD = 0.586
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The model qualification outcomes for all 26 subjects are presented in Figure 5. The 5th,
50th and 95th perrcentiles of INR predictions by the model and observed INR values from
the CHLA subjects are shown. In about 80% cases (20/26) the observations lay moreover
within the 95% prediction intervals. No particular genotype, age or body weight group was
associated with cases where the model did not predict the INR time profile well. However,
in case of the only two African-American subjects present in the cohort, the model fails to
capture the INR profile well. Based on these results, the model was considered reasonable
for use in subsequent simulations to determine an optimal warfarin dosing regimen for
pediatrics.
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Figure 5: Model qualification outcomes: predicted and observed INR over time
P5, P50, P95 – 5th, 50th (median) and 95th percentile model predicted INR.
OBS – CHLA subjects observed INR
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Initial pediatric dosing – typical subjects

The simulated INR-time profiles for the typical subjects for four representative genotype
categories are presented in Figure 6. Based upon these profiles, as well as the clearancebody weight relationship for warafrin as per our model, we found the need to use two
different mg/kg doses for higher (≥ 20 kg) and lower (< 20 kg) body weight subjects,
within each genotype category. We did not find the need to alter mg/kg dose based on an
age cut-off. The selected initial dosing scheme allowed for targeting an INR of 2.0-2.5,
on an average, for all genotypes and moreover matched the average adult INR profiles.

Figure 6: INR vs. time profiles by genotype for mean simulations – initial dosing
scheme for typical subjects.
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Final pediatric dosing – population

For the stochastic simulations, the results were evaluted in terms of the target INR
outcomes across time. We refined the starting dose from the initial doses derived for
typical subjects, as suitable for each genotype category. We also made minor
modifications to the titration scheme from that suggested for adults [14]. Thus, we
derived an optimal pediatric warfarin dosing regimen, inclusive of starting dose and
titartion scheme to maximize desired INR outcomes. Our final proposed dosing regimen
is given in Table 3.

Table 3: Final proposed pediatric warfarin dosing regimen – starting dose and
titration scheme

The comparison of INR outcomes for genotype-independent and genotype-based dosing
are displayed in Figure 7, for four representative genotypes. The genotype-independent
dosing results in progressively worse outcomes (dramatic increase in proportions of
INR>3.5) as the number of variant CYP2C9 or VKORC1 alleles increases.
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Figure 7: Comparison of genotype-based and genotype-independent dosing on
patient INR outcomes across time.

The comparison of INR outcomes between CHLA dosing and our proposed genotypebased dosing are displayed in Figure 8 for all (six) genotypes present in the CHLA data.
There were vast differences in outcomes between genotype categories under CHLA
dosing.

In case of genotype *1*1-GG (homozygous wildtype for both genes) the proportions of
INR within target therapeutic range were high (60%) at week 2, with the CHLA dosing.
However, there is a decline in this proportion and an increase in proportions of supratherapeutic INR (to 20%) through month 1. In case of the other extreme end of genotype
*1*2-AA (heterozygous variant for CYP2C9 and homozygous variant for VKORC1)
while the proportions of INR within target therapeutic range were again high (60%) at
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week 2, there is a sharp decline in this proportion (to 30%) and an increase in proportions
of supra-therapeutic INR (to 50%) through month 1. In contrast, with the proposed
dosing, both therapeutic and supra-therapeutic INRs are consistently around 60% and
10% respectively through month 1.

In case of the remaining, intermediate genotype categories, the proportions of INR within
target therapeutic range were much lower (10-40%) at week 2 with CHLA dosing and
remain lower (upto 45%) through month 1, relative to the proposed dosing (60%). As far
as supra-therapeutic INR proportions, there is again an increase observed through month
1 (up to 10- 30%), in all cases. Notably, the proportions of sub-therapuetic INR at week 2
were much higher (40-90%) with CHLA dosing and remain considerably high (20-50%)
through month 1, relative to the proposed dosing (< 20%).
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Figure 8: Target INR outcomes across time with CHLA standard of care dosing and
proposed dosing regimen.
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Finally, we report the simulated INR outcomes for all genotype categories using our
proposed dosing but having imposed restrictions of available warfarin formulation
strengths. Here, the lowest dose administered and all dose changes (increase/decrease)
during the titration were limited to a minimum of 0.5 mg. The INR outcomes for four
representative genotypes are displayed in Figure 9. As expected, proportions of INR >3.5
increase sharply as the number of variant CYP2C9 or VKORC1 alleles increases. This is
because the doses administered tend to be higher than those proposed for certain
genotypes owing to the formulation strength limitations for low dose requirements.

Figure 9: INR outcomes across time with proposed warfarin dosing and formulation
restrictions.
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DISCUSSION
There are two primary contributions of the current study:
1- A proposed scientifically based pediatric warfarin dosing regimen that can be
reproduced across clinical settings.
2- A tool that can be used by clinicians/researchers to arrive at an optimal pediatric
warfarin dosing regimen, should INR outcomes be targeted other than those used in the
current study.
The research, in a nutshell, involved leveraging prior information in the form of adult
warfarin data, extensive research on warfarin pharmacokinetics and pharmacodynamics
and physiology to meet a clinical need. Pharmacometric methods were employed to
bridge an adult model and dosing regimen to develop a pediatric warfarin model and
propose a dosing regimen. The most relevant aspects of the research are discussed
further.

Pediatric model qualification

In perspective, a warfarin population PKPD model built with adult data was appropriately
scaled for a pediatric population and used to predict INR outcomes over time for pediatric
patients on warfarin. The INR outcomes were predicted well in about 80% of the patients,
given limitations in sample size, covaraiate distributions and individual therapeutic INR
targets.

The

mechanisms

that

the

model

represents

are

supported

by

pharmacological/physiological knowledge. The allometric and maturation models used
for scaling PK parameters from adults to pediatrics are those proposed and/or widely
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accepted in the literature. Thus, the pediatric model appears useful based on physiology,
consistency with adult data, and predictive ability in limited pediatric data.

Having said that, the available CHLA pediatric data represented limited CYP2C9
genotypes. *1*2 was the only genetic polymorphism present in the subjects. In the
general Caucasian population the prevelance of *1*2, *1*3, and *2*2/*2*3/*3*3 are
20%, 10% and 5% respectively. In addition, there were no subjects aged < 2 months in
order to assess the validity of the CYP2C9 maturation model used for pediatric clearance.

The model makes predictions for the typical subject with a given set of covariates having
fixed effects and assumes compliance with dosing regimen. However, an important
concern that contributes to INR variability and is difficult to quantify is patient adherence
to dosing regimen [2]. In fact, the INR logs of some of the patients where the model
appeared unable to predict INR well did reveal poor protocol adherence and exceptional
difficulty in achieving stable INR. In most cases, the model predictions follow the dosing
patterns (constant or increasing dose) but INR outcomes are counter-intuitive (decreasing
or steady). Such observations are classic cases of non-compliance with warfarin therapy.

The model also tended to over predict the INR outcomes for both the African-American
subjects present in the cohort. It is known that subjects of the black race have a lower
sensitivity to warfarin, requiring higher doses, owing to certain genetic polymorphisms
that were not included in the current model. Hence this observation is not surprising but
may also be confounded by non-compliance. In addition, particularly in case of
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pediatrics, diet can have an influence on INR to a greater extent than captured by the
unexplained variability model parameter. These aspects may have led to subjects in the
CHLA study straying from their predicted INR profile.

Initial pediatric dosing

The mean simulations led us to conclude that two weight bins with different mg/kg doses,
for all genotypes, would result in desired INR profiles on an average. In addition, given
that 18 different starting doses are already required based on genotype, we found it to be
of practical convenience to have a 2-step dosing regimen based on body weight. There
has been speculation about an impact of age in regard to the wide observation that
younger children require higher mg/kg warfarin doses than older children and adults, and
uncertainty has been expressed about the underlying mechanism [20;26;28;29]. However,
we would like to point out that this is neither an unexpected observation nor a
consequence of an age or maturation effect. It is an expected outcome based on the nature
of the clearance-body weight relationship for the drug. The slope of the relationship is
steeper at the lower weight range, which are mostly younger children, and gets shallower
at the higher weight range, which are mostly older children. Hence per kg dose is higher
for younger, or rather lighter weighing, pediatric subjects. Accordingly, for all genotypes
we have proposed a smaller mg/kg dose for subjects weighing ≥ 20 kg and a higher dose
for subjects < 20 kg. Notably, the absolute doses (in mg) administered to heavier children
would still be higher than absolute doses given to lighter children.
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Final pediatric dosing

Based on our pediatric warfarin PKPD model, it is expected that genotype would have a
significant effect on warfarin clearance and INR response, and thereby on required doses
for target INR. In the simulations, assuming everyone to belong to the same genotype
category (CYP2C9*1*1/VKORC1-GA) for dosing purposes resulted in adverse INR
outcomes, particularly for the homozygous variant genotypes (*2/*3 and AA). Between
the CYP2C9 (PK) and VKORC1 (PD) genetic effects, the polymorphisms altering PK
had the most significant impact on dosing. There are two reasons for this; first, the
homozygous variant CYP2C9 variant genotypes *2*2, *2*3 and *3*3 had a large
magnitude of effect (-70 to -85% on clearance) relative to the VKORC1 homozygous
variant genotype AA (-35% on potency). Second, warfarin dose is titrated by monitoring
INR, the PD response, and not the drug concentrations which reflect PK. Hence adjusting
starting dose based on genotypes relevant for PK is most crucial. Patients with the
*2*2/*2*3/*3*3 genotypes have prolonged warfarin half-life (3-6 times longer than
*1*1) and the starting dose needs to account for this effect. For patients with genetic
polymorphisms, outcomes at week 3 or 4 into therapy are more clinically relevant than
week 2. While all results have been presented for only four or six (of eighteen) genotype
categories, the conclusions for all scenarios tested remain the same for all genotypes.

In the CHLA study, the target INR range of 2.5-3.5 used for patients with valve
replacement matches with that reported in the literature. However, the choice of target
INR 1.5-2.5 and 2.0-2.5 for patients undergoing Fontan procedure or diagnosed with
Kawasaki are different from that reported widely in the literature [20;24;26;28;29].
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Hence for the proposed dosing the commonly accepted and employed target INR range of
2.0-3.0 was selected, to maintain consistency with the literature and to generalize the
outomes to most settings. However, the modeling and simulation tool developed can be
employed to derive rational pediatric warfarin dosing for optimizing clinical outcomes in
terms of any other target INR range or even another INR end-point, if desired.
Comparison of the CHLA warfarin dosing with our proposed genetics-based dosing
regimen on individual target INR outcomes reflects the erratic nature of pediatric
warfarin dosing practices, and the need for a uniform dosing regimen. The dose and
titration choices used in the CHLA study were independent of patient genotype and did
not follow a specific, reproducible algorithm. This is common practice for pediatric
warfarin dosing. Granted the dosing decisions are based on clinical experience, but this
would vary considerably across clinicians and institutions. The first clinical problem with
current dosing practices, such as those used in the CHLA study, is that even if good INR
control is obtained (which was not common in the study) the dosing employed cannot be
reproduced in another setting. The second problem is their moreover empirical nature.
Hence a rational, uniform dosing regimen that can be replicated across patients and
clinics is required.

While INR control was fairly good initially for the *1*1-GG and *1*2-AA genotype
groups with the CHLA dosing, there was an increase in supra-therapeutic outcomes
across time, and significantly so for *1*2-AA, which indicates sub-optimal starting dose
and/or titration scheme. The INR control was poor for the remaining genotype groups.
Their INR outcomes in general reflect clinician attitude to be conservative with warfarin
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therapy. In several cases, the INRs tend to remain in the sub-therapeutic range through
even a whole month into therapy. This is because there is grave concern, perhaps more so
in pediatrics, of overdosing leading to bleeding events. As a result though, the
proportions of INRs within the therapeutic window were lower than ought to be targeted.
However, while supra-therapeutic INRs remain well below 10% initially, the trend was
for these to increase significantly over time, more so in patients with genetic
polymorphisms. Thus despite the general conservative dosing, lack of an appropriate
starting dose and/or a rational and consistent dose titration scheme can lead to several
cases with risky supra-therapeutic INRs after first couple weeks into warfarin therapy.

Based on simulations, we consider our dosing regimen superior to that used in the CHLA
study, which may be regarded as the current standard of care. Our regimen succeeded
over empirical dosing in maximizing targeted INR outcomes consistently throughout the
first month into warfarin therapy. We also expect to see similar results should these
dosing regimens be compared in a clinical trial.

Finally, we make a case for the need for a suitable pediatric warfarin formulation. From
our simulations it is clear that limiting the lowest dose administered and smallest possible
dose change to 0.5 mg is not advisable for pediatric subjects, particularly those with
homozygous CYP2C9 and/or VKORC1 polymorphisms. In addition, the oral tablet is not
a well-suited dosage form for pediatric patients. In several cases where patients are
unable to swallow whole tablets, the tablets are crushed and administered with apple
sauce. Such drug administration practices, along with a limitation on lowest dose strength
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available, further contribute to the already high variabiltiy in INR outcomes. Hence a
more pediatric-friendly warfarin formulation, in terms of both strength and dosage form,
is a timely requirement.

Scope of the study

Currently there is no information available on altering warfarin dose in pediatrics based
on influential factors. In particular, quantifying the impact of polymorphisms in the
CYP2C9 and VKORC1 on pediatric warfarin dosing is of critical therapeutic relevance.
To our knowledge, our research brings forth the first ever proposed dosing regimen for
using warfarin in pediatric patients as well as a useful tool to derive such dosing. The
pediatric PKPD model used complies with what is known of warfarin and general
pharmacology, and is consistent with adult warfrain clinical data.

However, we recognize the limitations of the current research. We believe that in general
the limitations may be attributed to the paucity of available clinical data on warfarin use
in pedtarics. Firstly, we were restricted to a small sample size of pediatric subjects
(n=26), which we used to qualify the model. Hence the model was based on adult data
and physiological principles rather than pediatric data, and the proposed dosing was
based on simulations. Moreover, the available pediatric data was limited in terms of
covariate distributions, particualrly CYP2C9 polymorphisms and youngest ages.Another
limitation to our study is the absence of prospective validation of the dosing regimen. For
any dosing regimen to be widely accepted it must first be shown to be superior on
relevant clinical outcomes in a prospective controlled trial. Given the practical limitations
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to conducting pediatric warfarin interventional trials, we recommend that more
propspective observational studies and experiemntal studies be conducted in pediatrics to
update the PKPD model and hence the proposed dosing strategy. However, despite the
limitations, we believe we have made efficient use of available information and
suggested an important first step towards improving pediatric warfarin dosing.

The research was based on certain assumptions. First, that the concentration-INR
response relationship for warfarin is similar between pediatrics and adults. Some
researchers have suggested intrinsic developmental differences in the coagulation
systems [30;31], precluding extrapolation of dose-response for antithrombotic therapy
from adults to the youngest subset of the pediatric population (< 6 months). The second
assumption is that the CYP2C9 polymorphisms reduce warfarin clearance to the same
extent in pediatrics and adults. Last, we assumed no developmental changes in plasma
protein binding and dose-proportional PK throughout the entire pediatric age range.
However, again there is dearth of data regarding how ontogeny affects warfarin
pharmacokinetics and pharmacodynamics to formally challenge our assumptions. This is
particularly true for VKORC1 where the patterns of developmental expression are not yet
known.

The eventual goal of studies like ours is to establish a new standard of care for pediatric
patients who require warfarin therapy. A genetics-based warfarin dosing nomogram that
functions more efficiently than conventional arbitrary dosing at maximizing therapeutic
INR outcomes will represent a major advance in pediatric pharmacotherapy. Such a
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nomogram could be made widely available to all clinicians, and would enhance the safety
and effectiveness of warfarin therapy in pediatric patients. Hence, further research for
refining and validating the proposed model and dosing regimen would be useful. Even so,
the proposed regimen is based on rational sciene and is recommended for use in pediatric
studies and practice.
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CHAPTER 6
Conclusions and Future Research

CONCLUSIONS
Over the past decade there has been significant interest and progress in conducting
pediatric clinical research in order to directly generate information for the safe and
effective use of drugs in this special population. However, pediatric drug development is
challenging and fairly unique is several aspects. Most development programs have just
one chance to perform an informative set of trials, generally few in number. In some
cases, logistic and ethical constraints, and lack of financial incentives prevent conduct of
trials and limit the data available on drug use in pediatrics. Hence novel, efficient
approaches such as pharmacometric methods have and can be used to leverage prior and
current information and make useful decisions during pediatric drug development. The
research underlying this dissertation as well as the several case studies discussed in
chapters 1 and 2 highlight the contribution of pharmacometrics in enhancing pediatric
drug development.
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One aspect of the research undertaken provides evidence of the use of modeling and
simulation in improving pediatric trial design. With objective criteria such as the PK
quality standard in place, pharmacometric techniques can be successfully applied in
better planning of pediatric PK trials, to ensure informative trial outcomes. The other
aspect of the research undertaken represents the power of pharmacometric methods in
maximizing on limited available information and generating useful dosing guidelines in
pediatrics. A warfarin model and genetics-based dosing regimen that was originally built
using adult data and validated in a clinical trial was successfully leveraged along with
physiological principles to derive a pediatric warfarin model and dosing regimen. The
work caters to a heretofore unmet clinical need for a rational, reproducible pediatric
warfarin dosing strategy that may be applied across clinical settings.

The broader implications of the current research include, in general, improved pediatric
health care and quality of life. Parents of children requiring pharmacotherapy for various
conditions as well as the clinicians treating these patients stand to benefit considerably
from the wider adoption of such research, as described in this dissertation. The work also
represents an advance for pharmacogenetics. For instance, adults are now able to avail of
genetics-based warfarin dosing and the research aims at providing similar care for
pediatric patients as well. While clinical research historically has been focused on the
adult population, the work undertaken represents increased awareness and avenues for
bridging the gap between adults and pediatrics. The research is encouargaing for future
investments in enhancing pediatric drug development.
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FUTURE RESEARCH
The quality standard described currently applies only to pediatric PK trials. However, the
likelihood is that future regulation will introduce such standards for exposure-response
trials in pediatrics as well. Research on methodology and feasibility for pediatric trial
design to achieve good target precision on the slope of the exposure-response relationship
is a potential avenue for related future research. In general, all future clinical trials ought
to be designed rationally, using modeling and simulation.

Future clnical studies with warfarin in pediatrics would serve as a bonus to our current
research. Controlled interventional clinical trials of warfarin in pediatric patients are an
unrealistic expectation, given the age of this drug and lack of financial incentive for
future trials. However, experimental PKPD studies can help update the model and
prospective observational studies may help improve the dosing regimen. Refining and
prospectively validating the proposed dosing regimen could lead to wider adoption of
rational and standardized dosing for warfarin use in pediatrics, rather than the current
empirical standard of care dosing practices. The current research is a step forward in
enhancing the safety and effectiveness profile of the most widely used anticoagulant that
stands to benefit from future research.

Further, there are several reserach areas within pediatrics that can benefit from modeling
and simulation such as quantifying effects of ontogeny and identifying pediatric-specific
biomarkers and trial end-points. Moreover, the applications of pharmacometrics go
beyond pediatrics to all populations and to all aspects of drug development. Identification
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of risk factors for new and existing drug therapies and quantifying pharmacogenetic
information is an important research area. Pharmacometric analysis has been used for this
purpose for the anti-viral drug nevirapine. The report is presented in Appendix D of this
dissertation. In summary, a continuous Learn-Apply paradigm, if adopted, can
significantly improve pediatric and overall drug development and therapeutics. Timely
application of pharmacometric methods would be an integral part of such a paradigm.
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APPENDICES

APPENDIX A
R script, NONMEM model and SAS program files used to run
simulation-estimation for pediatric PK quality standard
evaluation (Chapter 3)

R script

#### EXECUTING SIMULATIONS IN NONMEM AND ESTIMATIONS IN SAS THROUGH R ###
### VARYING BOTH SAMPLE SIZE AND NUMBER OF SAMPLES ###

library(Hmisc)
library(grid)
library(lattice)
setwd("/home/lalam/Peds_Sim")
#setwd("W:/Peds_Sim")
## INPUT SIMULATION SCENARIO: ONE COMP. ORAL FIRST ORDER ABSORPTION ##
## PK MODEL PARAMETERS:
DOSE <- 100
anchor <- 20
CL <- 3.2
V <- 6.2
KA <- 2
FBA <- 1
ALLOCL<- 0.75
A50<- 0.18
ALLOV<-1
p<-8

#mg/kg
#kg
#L/h/20kg
#L/20kg
#/hr
#100%
#yrs

vari<-"MV"
CVCL <- 0.5
CVV <- 0.5
SDCL <-round(sqrt(log(1+CVCL**2)),2)
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SDV <-round(sqrt(log(1+CVV**2)),2)
SDTHF <- round(sqrt(SDCL**2 + SDV**2),2)
CVKA <- 0.5
SDKA <-round(sqrt(log(1+CVKA**2)),2)
sdtimes <-3
OMCL <- CVCL**2
OMV <- CVV**2
OMKA<-CVKA**2
SIG <- 0.01
COV<-c(ALLOCL,ALLOV,A50,OMCL,OMV,SIG)
lim<-20
## TRIAL CHARACTERISTICS:
nBins<-4
nAdult<-24
tAdult<- ifelse(nAdult==12,2.20, ifelse(nAdult==24,2.07, 0))
nABins <- ifelse(nAdult==0,nBins,nBins+1)
nrep1<-250
nrep2<-300
nrep <- ifelse(vari=="LV",nrep1,nrep2)
path<-ifelse(nAdult==0,
paste("/home/lalam/Peds_Sim/ORAL/SPARSE/NoAdult/",vari,"/",sep=""),
paste("/home/lalam/Peds_Sim/ORAL/SPARSE/Adult/",nAdult,"ad/",vari,"/",sep
=""))
#path<-ifelse(nAdult==0,
paste("W:/Peds_Sim/ORAL/SPARSE/NoAdult/",vari,"/",sep=""),
paste("W:/Peds_Sim/ORAL/SPARSE/Adult/",nAdult,"ad/",vari,"/",sep=""))
Nbin1<-c(4,4,4,4,nAdult)
t1<-c(3.18,3.18,3.18,3.18,tAdult)
Nbin2<-c(6,6,6,6,nAdult)
t2<-c(2.57,2.57,2.57,2.57,tAdult)
Nbin3<-c(8,8,8,8,nAdult)
t3<-c(2.36,2.36,2.36,2.36,tAdult)
Nbin4<-c(10,10,10,10,nAdult)
t4<-c(2.26,2.26,2.26,2.26,tAdult)
Nbin5<-c(12,12,12,12,nAdult)
t5<-c(2.20,2.20,2.20,2.20,tAdult)
Nbin6<-c(16,16,16,16,nAdult)
t6<-c(2.13,2.13,2.13,2.13,tAdult)
Nbin7<-c(20,20,20,20,nAdult)
t7<-c(2.09,2.09,2.09,2.09,tAdult)
N1<N2<N3<N4<N5<N6<N7<-

Nbin1[1]+Nbin1[2]+Nbin1[3]+Nbin1[4]+Nbin1[5]
Nbin2[1]+Nbin2[2]+Nbin2[3]+Nbin2[4]+Nbin2[5]
Nbin3[1]+Nbin3[2]+Nbin3[3]+Nbin3[4]+Nbin3[5]
Nbin4[1]+Nbin4[2]+Nbin4[3]+Nbin4[4]+Nbin4[5]
Nbin5[1]+Nbin5[2]+Nbin5[3]+Nbin5[4]+Nbin5[5]
Nbin6[1]+Nbin6[2]+Nbin6[3]+Nbin6[4]+Nbin6[5]
Nbin7[1]+Nbin7[2]+Nbin7[3]+Nbin7[4]+Nbin7[5]
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Nsub <- c(N1,N2,N3,N4,N5,N6,N7)

# if other than 7 sizes, also change
in modules 6,7

Tsamp1 <- c(0,4)
Tsamp2 <- c(0,1,3)
Tsamp3 <- c(0,1,3,4)
TsampR <- c(0,0.25,0.5,1,1.5,2,2.5,3,4,6,8)
Nsamp <- c(length(Tsamp2),length(Tsamp3))
# if other than 2
schedules, also change in module 2
RS<-length(TsampR)
Ntrials <- length(Nsub)*length(Nsamp)

## DEMOGRAPHICS:
# ages below entered in months
Bin1lo<-1
#1month
Bin1hi<-24
#2yrs
Bin2hi<-72.5 #6yrs
Bin3hi<-144.5 #12yrs
Bin4hi<-192.5 #16yrs
Bin5lo<- 18 # yrs
Bin5hi<- 65 # yrs
medage1<-1
medage2<-4
medage3<-9
medage4<-14
medage5<-41
medwt1<-9.9
medwt2<-16.1
medwt3<-28.9
medwt4<-50.5
medwt5<-74.7
## PREDEFINED OBJECTS:
simdataitems<-c("ID","TIME","AMT","Y","ABIN","AGE","WT","SEX")
parms<-c("CL","V")
Nparms<-length(parms)
covar<-c("ALLOCL","ALLOV","A50","OMCL","OMV","SIG")
Ncovar<-length(covar)
MEANparms<-paste("MEAN_",parms,sep="")
RSEparms<-paste("RSE_",parms,sep="")
UCIparms<-paste("UCI",parms,sep="")
BIAS1parms<-paste("BIAS1_",parms,sep="")
EQUIV1parms<-paste("EQUIV1_",parms,sep="")
BIAS2parms<-paste("BIAS2_",parms,sep="")
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EQUIV2parms<-paste("EQUIV2_",parms,sep="")
BIASparms<-c(BIAS1parms,BIAS2parms)
EQUIVparms<-c(EQUIV1parms,EQUIV2parms)
PRECparms<-paste("PREC_",parms,sep="")
ESTcovar<-paste("EST_",covar,sep="")
BIAScovar<-paste("BIAS_",covar,sep="")
PRECcovar<-paste("PREC_",covar,sep="")
popestnames<-c(PRECparms,BIASparms,EQUIVparms)
poprawnames<-c(MEANparms,RSEparms)
popest2names<-c(ESTcovar,BIAScovar,PRECcovar)
Npopest<-length(popestnames)+1
Npopraw<-length(poprawnames)+1
Npopest2<-length(popest2names)
pop1names<c("ID","AGE","WT","CL","SECL","RSE_CL","UCICL","V","SEV","RSE_V","UCIV")
Npop1<-length(pop1names)
pop2names<c("Parameter","Estimate","SE","DF","t","p","alpha","LCI","UCI","gradient"
)
Npop2<-length(pop2names)
indparms<-c("CLi","Vi")
Nindparms<-length(indparms)
MEANposthoc <-paste("MEAN_",indparms,sep="")
RSEposthoc <-paste("RSE_",indparms,sep="")
SHRINKposthoc <- paste("SHRINK_",indparms,sep="")
BIAS1posthoc <- paste("BIAS1_",indparms,sep="")
BIAS2posthoc <- paste("BIAS2_",indparms,sep="")
EQUIV1posthoc <- paste("EQUIV1_",indparms,sep="")
EQUIV2posthoc <- paste("EQUIV2_",indparms,sep="")
PRECposthoc <- paste("PREC_",indparms,sep="")
indrawnames<-c(MEANposthoc, RSEposthoc)
posthocestnames<c(PRECposthoc,BIAS1posthoc,BIAS2posthoc,EQUIV1posthoc,EQUIV2posthoc,SHRIN
Kposthoc)
Nindraw<-length(indrawnames)+1
Nposthocest<-length(posthocestnames)+1
posthocnames<c("ID","ABIN","AGE","WT","SEX","dose","CLi","SECLi","UCICLi","Vi","SEVi",
"UCIVi","KAi","SEKAi","UCIKAi","TIME","dv","PPRED","IPRED")
Nposthoc<-length(posthocnames)

## MODULE 1: CREATING BANK OF PEDS WITH CDC-BASED AGE-WT RELATIONSHIP ##
data<-read.csv("CDCwtage.csv")
names(data)
nsim<-100
sim<-c()
for (i in 1:nsim){
data$nrep<-i
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sim<-rbind(sim, data)
}
set.seed(123)
sim$rn<-rnorm(nrow(sim))
sim$wt<-sim$M*(1+sim$L*sim$S*sim$rn)**(1/sim$L)
sim$CL<-CL*((sim$wt/anchor)**ALLOCL)*(sim$Agemos/((A50*12)+sim$Agemos))
sim$V<-V*((sim$wt/anchor)**ALLOV)
sim1<-sim[sim$Agemos>Bin1lo
sim2<-sim[sim$Agemos>Bin1hi
sim3<-sim[sim$Agemos>Bin2hi
sim4<-sim[sim$Agemos>Bin3hi
sim1$AgeBin<-1
sim2$AgeBin<-2
sim3$AgeBin<-3
sim4$AgeBin<-4

&
&
&
&

sim$Agemos<=Bin1hi,c(1,2,17,18,19)]
sim$Agemos<=Bin2hi,c(1,2,17,18,19)]
sim$Agemos<=Bin3hi,c(1,2,17,18,19)]
sim$Agemos<=Bin4hi,c(1,2,17,18,19)]

#edit(bank)
bank<-rbind(sim1,sim2,sim3,sim4)
bankmean<-aggregate(log(bank[ ,parms]),by=list(bank$AgeBin),mean,na.rm=T)
bankmean<-exp(bankmean)[ ,parms]
bankvar<-aggregate(log(bank[ ,parms]),by=list(bank$AgeBin),var,na.rm=T)
bankvar<-bankvar[ ,parms]
truemean<-bankmean
meanclad<-CL*((medwt5/anchor)**ALLOCL)*(medage5/(medage5+A50))
meanvad<-V*((medwt5/anchor)**ALLOV)
adultmean<-c(meanclad,meanvad)
if(nAdult>0) bankmean<-rbind(bankmean,adultmean)

## MODULE 1A: SIMULATING COMMON DEMOGRAPHICS FOR ALL CASES ##
simb1a<-sim1a[sample(1:nrow(sim1a),Npbin[1],replace=F), ]
simb1b<-sim1b[sample(1:nrow(sim1b),Npbin[1],replace=F), ]
simb1<-sim1[sample(1:nrow(sim1),Npbin[1],replace=F), ]
simb2<-sim2[sample(1:nrow(sim2),Npbin[1],replace=F), ]
simb3<-sim3[sample(1:nrow(sim3),Npbin[1],replace=F), ]
simb4<-sim4[sample(1:nrow(sim4),Npbin[1],replace=F), ]
simbin5<-sim5[sample(1:nrow(sim5),nAdult,replace=F), ]

simbn1a<-simb1a
simbn1b<-simb1b
simbn1<-simb1
simbn2<-simb2
simbn3<-simb3
simbn4<-simb4
simdemo<-list()
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allsimdemo<-list(list())
k<-7
for (i in Npbin) {
simbin1a<-simbn1a[sample(1:nrow(simbn1a),i,replace=F), ]
simbin1b<-simbn1b[sample(1:nrow(simbn1b),i,replace=F), ]
simbin1<-simbn1[sample(1:nrow(simbn1),i,replace=F), ]
simbin2<-simbn2[sample(1:nrow(simbn2),i,replace=F), ]
simbin3<-simbn3[sample(1:nrow(simbn3),i,replace=F), ]
simbin4<-simbn4[sample(1:nrow(simbn4),i,replace=F), ]
simbn1a<-simbin1a
simbn1b<-simbin1b
simbn1<-simbin1
simbn2<-simbin2
simbn3<-simbin3
simbn4<-simbin4
simdemo[[6]]<-simbin1a
simdemo[[7]]<-simbin1b
simdemo[[1]]<-simbin1
simdemo[[2]]<-simbin2
simdemo[[3]]<-simbin3
simdemo[[4]]<-simbin4
allsimdemo[[k]]<-simdemo
k<-k-2
}
## MODULE 1B: CREATING DEMOGRAPHIC DATASETS FOR SIMULATIONS ##
k <- 1
n <- 4
for (i in Ntot) {
if(n==10) n<-12
simbin1a<-allsimdemo[[k]][[6]]
simbin1b<-allsimdemo[[k]][[7]]
simbin1<-allsimdemo[[k]][[1]]
simbin2<-allsimdemo[[k]][[2]]
simbin3<-allsimdemo[[k]][[3]]
simbin4<-allsimdemo[[k]][[4]]
simagewt<-rbind(simbin1,simbin2,simbin3,simbin4)
if(nBins==5) simagewt<rbind(simbin1a,simbin1b,simbin2,simbin3,simbin4)
simagewt<-simagewt[,c(6,2,3,1)]
names(simagewt)<-c("AgeBin","Age","Weight","Sex")
simagewt$Age<-simagewt$Age/12
if(nAdult>0) simagewt<-rbind(simagewt,simbin5)
demog <- data.frame(1:i)
names(demog) <- "ID"
demog<-cbind(demog,simagewt)
names(demog)<-c("ID","AgeBin","AGE","WT","SEX")
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demog$AGE<ifelse(demog$AGE<1,round(as.numeric(demog$AGE),2),round(as.numeric(demog$
AGE),1))
demog$WT <- round(as.numeric(demog$WT),1)
plot<-xyplot(demog$WT~demog$AGE, data=demog,xlab="AGE
(yrs)",ylab="WEIGHT (kg)",
scales=list(cex=1.5,lwd=2,x=list(log=10,at=c(0,1,2,6,12,16,25,50)))
,
panel=function(x,y,...){
panel.xyplot(x,y,type="p",...)
panel.curve(5.4095+4.6965*10^x0.7261*(10^x)^2+0.0721*(10^x)^3-0.002*(10^x)^4, from=log10(1),
to=log10(18), lty=2, col=2)
panel.curve(3.9364+4.5254*10^x0.7279*(10^x)^2+0.0649*(10^x)^3-0.0017*(10^x)^4, from=log10(1),
to=log10(18), lty=2, col=2)
panel.curve(7.5589+4.1842*10^x0.4651*(10^x)^2+0.0628*(10^x)^3-0.002*(10^x)^4, from=log10(1),
to=log10(18), lty=2,col=2)
panel.curve(3.5802+10.681*10^x-4.037*(10^x)^2,
from=log10(0.0001), to=log10(1), lty=3,col=1)
panel.curve(2.5787+9.8283*10^x-3.8735*(10^x)^2,
from=log10(0.0001), to=log10(1), lty=3,col=1)
panel.curve(4.4035+12.857*10^x-4.9702*(10^x)^2,
from=log10(0.0001), to=log10(1), lty=3,col=1)
}
)
pdf(file=paste("AgeWtPlot",n,".pdf",sep=""),width=9,height=9)
print(plot)
dev.off()
write.table(demog, file=paste("demog_N",n,".csv",sep=""),
sep=",", quote=F, row.names=F, na=".")
k <- k+2
n <- n+2
}

## MODULE 2: CREATING DATA TEMPLATES & CONTROL STREAMS FOR NM TO USE FOR
SIMULATIONS ##
ctlstrm <- scan(file="runsim_oral_trunc.mod", what="character", sep="\n")
d<-1
k <- 1
for (i in Nsub) {
for (j in Nsamp) {
if (j==Nsamp[1]) Tsamp <- Tsamp2
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if (j==Nsamp[2]) Tsamp <- Tsamp3
#demog<read.csv(file=paste("W:/Peds_Sim/DEMOGS/demog",d,"_",nAdult,"ad.csv",sep=
""))
demog<read.csv(file=paste("/home/lalam/Peds_Sim/DEMOGS/demog",d,"_",nAdult,"ad.
csv",sep=""))
demog<-demog[!duplicated(demog$ID), ]
e<-c(rep(j,each=i-nAdult),rep(RS,each=nAdult))
input<-demog[rep(demog$ID,e), ]
input$TIME <- c(rep(Tsamp, i-nAdult),rep(TsampR,nAdult))
input$AMT <- ifelse(input$TIME==0, DOSE*input$WT, 0)
input$CONC <- rep(".", nrow(input))
input<-input[ ,c(1,6,7,8,2,3,4,5)]
write.table(input,
file=paste(path,"run_sim_",nAdult,"/input",k,".csv",sep=""),
sep=",", quote=F, row.names=F, na=".")
ctlstrm[3] <- paste("$DATA input",k,".csv IGNORE=@",sep="")
ctlstrm[7] <- paste("SUBPROBLEMS = ",nrep,sep="")
ctlstrm[11] <- paste(" ",CL," FIX ; CL (L/h/20kg)",sep="")
ctlstrm[12] <- paste(" ",V," FIX ; V (L/20kg)",sep="")
ctlstrm[13] <- paste(" ",KA," FIX ; TVKA (/h)",sep="")
ctlstrm[14] <- paste(" ",ALLOCL," FIX ; ALLOCL",sep="")
ctlstrm[15] <- paste(" ",ALLOV," FIX ; ALLOV",sep="")
ctlstrm[16] <- paste(" ",A50," FIX ; A50 (YRS)",sep="")
ctlstrm[18] <- paste(" ",OMCL," FIX ; BSVCL",sep="")
ctlstrm[19] <- paste(" ",OMV," FIX ; BSVV",sep="")
ctlstrm[20] <- paste(" ",OMKA," FIX ; BSVKA",sep="")
ctlstrm[22] <- paste(" ",SIG," FIX ; CVCP",sep="")
ctlstrm[40] <- paste("
DLTACL =
",sdtimes,"*",SDCL,sep="")
ctlstrm[41] <- paste("
DLTAV = ",sdtimes,"*",SDV,sep="")
ctlstrm[42] <- paste("
DLTAKA =
",sdtimes,"*",SDKA,sep="")
ctlstrm[43] <- paste("
DLTATH =
",sdtimes,"*",SDTHF,sep="")
ctlstrm[length(ctlstrm)] <- paste("NOPRINT ONEHEADER NOAPPEND
FILE=sdtab",k,sep="")
write(ctlstrm,file=paste(path,"run_sim_",nAdult,"/runsim",k,".mod",
sep=""))
k <- k+1
}
d<-d+1
}

## MODULE 3: EXECUTE NM RUNS FOR SIMULATIONS THROUGH R ON CLUSTER ##
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execute <- character()
execute[1] <- "#!/bin/sh"
execute[2] <- paste("execute threads=32",paste("runsim",1:Ntrials,".mod",collapse=" ",sep=""),sep=" ")
setwd(paste(path,"run_sim_",nAdult,sep=""))
write(execute,"sim.pl")
system("perl sim.pl")

## MODULE 4: READ IN THE SIMULATED OUTPUT DATA (sdtab files) FROM NM ##
## SPLIT THE SIMULATED DATA FOR EACH REPLICATE AND CREATE DATASETS TO
INPUT BACK TO SAS ##
## CREATE SAS MODEL FILES FOR FITTING SIMULATED DATA ##
#model <- scan(file="W:/Peds_Sim/fit_oral_sp.sas", what="character",
sep="\n")
model <- scan(file="/home/lalam/Peds_Sim/fit_oral_sp.sas",
what="character", sep="\n")
k <- 1
test <- list()
simparms<- list()
allsim<-list(list())
for (i in Nsub) {
for (j in Nsamp) {
for(r in 1:nrep){
test[[r]] <- read.table(file=paste("sdtab",k,sep=""),
skip=(r-1)*((i*j)+(nAdult*(RSj))+1)+(r),header=T,nrows=(i*j)+(nAdult*(RS-j)))
simparms[[r]]<test[[r]][!duplicated(test[[r]]$ID),c("CL","V","ABIN","WT")]
test[[r]] <- test[[r]][ ,simdataitems]
names(test[[r]]) <c("ID","TIME","AMT","CONC","ABIN","AGE","WT","SEX")
dosing <- test[[r]][!duplicated(test[[r]]$ID), ]
dosing$TIME<-0
dosing$AMT<-DOSE*dosing$WT
dosing$CONC <- "."
test[[r]]<-test[[r]][test[[r]]$TIME>0 , ]
test[[r]] <- rbind(dosing, test[[r]])
test[[r]] <- test[[r]][order(test[[r]]$ID), ]
test[[r]]$MDV <- ifelse(test[[r]]$AMT==0,0,1)
test[[r]]$EVID <- ifelse(test[[r]]$AMT==0,0,1)
write.table(test[[r]],
file=paste(path,"fit_model/simdata",k,"rep",r,".csv",sep=""),
sep=",", quote=F, row.names=F, na=".")
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model[7]<- paste(" DATAFILE=\"",
path,"fit_model/simdata",k,"rep",r,".csv\"",sep="")
model[17]<-paste("if id=1001 then do; age=",medage1,"
wt=",medwt1,"; end;",sep="")
model[18]<-paste("if id=1002 then do; age=",medage2,"
wt=",medwt2,"; end;",sep="")
model[19]<-paste("if id=1003 then do; age=",medage3,"
wt=",medwt3,"; end;",sep="")
model[20]<-paste("if id=1004 then do; age=",medage4,"
wt=",medwt4,"; end;",sep="")
model[65]<-paste("
anchor = ",anchor,";",sep="")

;
;
;
;

model[66]<-paste("
TVKA = ",KA,";",sep="")
model[67]<-paste("
s2ka = ",OMKA,";",sep="")
model[68]<-paste("
F = ",FBA,";",sep="")
model[141] <- paste("(pTVCL=",CL,",",sep="")
model[142] <- paste("pTVV=",V,",",sep="")
model[143] <- paste("pALLOCL=",ALLOCL,",",sep="")
model[144] <- paste("pALLOV=",ALLOV,",",sep="")
model[145] <- paste("pA50=",A50,",",sep="")
model[146] <- paste("ps2cl=",OMCL,",",sep="")
model[147] <- paste("ps2v=",OMV,",",sep="")
model[148] <- paste("ps2=",SIG,",",sep="")
model[149] <- paste("repeats=",lim,")",sep="")
model[171] <- paste("proc export data=bins
outfile=\"",path,"model_output/bins",k,"rep",r,".csv\" DBMS=CSV REPLACE;
run;",sep="")
model[172] <- paste("proc export data=para
outfile=\"",path,"model_output/parms",k,"rep",r,".csv\" DBMS=CSV REPLACE;
run;",sep="")
model[173] <- paste("proc export data=posthoc
outfile=\"",path,"model_output/posthoc",k,"rep",r,".csv\" DBMS=CSV
REPLACE; run;",sep="")
write(model,file=paste(path,"fit_model/fit",k,"rep",r,".sas",sep=""
))
}
allsim[[k]]<-simparms
k <- k+1
}
}

## MODULE 5: FITTING MODEL TO SIMULATED DATA USING SAS THROUGH R ##
setwd(paste(path,"fit_model",sep=""))
runsas <- character()
runsas[1] <- "#!/bin/sh"
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k<-1
for (i in Nsub){
for (j in Nsamp) {
for (r in 1:nrep) {
runsas[2]<-(paste("/opt/sas92/SASFoundation/9.2/sas92 noterminal -log ",path,"fit_model -print ",path,"fit_model "
,path,"fit_model/fit",k,"rep",r,".sas",sep=""))
write(runsas,file=paste("fit",k,"rep",r,".bat",sep=""))
system(paste("chmod a+x fit",k,"rep",r,".bat",sep=""))
system(paste("qsub -o /home/lalam/eofiles -e
/home/lalam/eofiles fit",k,"rep",r,".bat &",sep=""))
}
k<-k+1
}
}
## MODULE 6: READ IN SAS ESTIMATION OUTPUT (lst/bin/parm files) FOR
ANALYSIS : METHOD 1 - POP.MEAN. ##
popest <- list()
popraw<-list()
popest2<-list()
pop1 <- list()
pop2<-list()
allpop1<-list(list())
allpop2<-list(list())
agebin<-1:nBins
k<-1
f<-1
g<-1
finalpop<-data.frame(matrix(NA,ncol=Npopest+2,nrow=Ntrials*nBins*2))
names(finalpop)<-c("METRIC","AgeBin",popestnames,"SCENARIO")
finalpop2<-data.frame(matrix(NA,ncol=Npopest2+2,nrow=Ntrials*2))
names(finalpop2)<-c("METRIC",popest2names,"SCENARIO")
for (i in Nsub) {
t<-qt(0.975,(i-nAdult-p))
for (j in Nsamp) {
popest[[k]]<-data.frame(matrix(NA,ncol=Npopest,nrow=nrep*nBins))
names(popest[[k]])<-c("AgeBin",popestnames)
popraw[[k]]<-data.frame(matrix(NA,ncol=Npopraw,nrow=nrep*nBins))
names(popraw[[k]])<-c("AgeBin",poprawnames)
popest2[[k]]<- data.frame(matrix(NA,ncol=Npopest2,nrow=nrep))
names(popest2[[k]]) <- popest2names
b<-1
for(r in 1:nrep){
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output <- scan(file=paste("fit",k,"rep",r,".lst",sep=""),
what="character", sep="\n")
thetaPos <- grep("Successful", output)
ifelse(length(thetaPos)==0,
pop1[[r]]<data.frame(matrix(NA,ncol=Npop1,nrow=nBins)),
pop1[[r]]<read.csv(paste(path,"model_output/bins",k,"rep",r,".csv",sep="")))
names(pop1[[r]])<-pop1names
ifelse(length(thetaPos)==0,
pop2[[r]]<data.frame(matrix(NA,ncol=Npop2,nrow=Nparms+Ncovar)),
pop2[[r]]<read.csv(paste(path,"model_output/parms",k,"rep",r,".csv",sep="")))
names(pop2[[r]])<-pop2names
allsim[[k]][[r]][ ,parms]<-log(allsim[[k]][[r]][ ,parms])
simmean<-aggregate(allsim[[k]][[r]][
,parms],by=list(allsim[[k]][[r]]$ABIN),mean,na.rm=T)
simmean<-exp(simmean[1:nBins,parms])
popmean<- pop1[[r]][ ,parms]
popRSE<-pop1[[r]][ ,RSEparms]
popprec<-(100 + t*(popRSE))
popbias1<-((popmean-truemean)/truemean)*100
popequiv1<-exp(log(popmean/truemean))
popbias2<-((popmean-simmean)/simmean)*100
popequiv2<-exp(log(popmean/truemean))
popparms <cbind(agebin,popprec,popbias1,popbias2,popequiv1,popequiv2)
popest[[k]][c(b:(nBins*r)),] <- popparms
poprawpar<-cbind(agebin,popmean,popRSE)
popraw[[k]][c(b:(nBins*r)),] <- poprawpar
popcov<-pop2[[r]][(Nparms+1):nrow(pop2[[r]]),pop2names[1:3]]
popcov$UCI<-popcov$Estimate + t*(popcov$SE)
popcov$Prec<-(popcov$UCI/popcov$Estimate)*100
popcov$Bias<-((popcov$Estimate-COV)/COV)*100
popcovpar <- c(popcov$Estimate,popcov$Bias,popcov$Prec)
popest2[[k]][r,] <- popcovpar
b<-b+nBins
}
allpop1[[k]]<-pop1
allpop2[[k]]<-pop2
pass<-c()
p.pass<-c()
for(a in agebin) {
for(p in 2:3) {
con<-is.na(popest[[k]][popest[[k]]$AgeBin==a,p])
ncon<-length(con[con==F])
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test1<ifelse(is.na(popest[[k]][popest[[k]]$AgeBin==a,p])==T,0,
ifelse(popest[[k]][popest[[k]]$AgeBin==a,p]<=140,1,0))
test2<-(length(test1[test1==1])/ncon)*100
pass[p]<-test2
}
for(p in 4:7) {
pass[p]<-NA
}
for(p in 8:11) {
pass[p]<-NA
}
p.pass<-rbind(p.pass,pass)
}
p.pass[,1]<-agebin
pass2<-c()
for(p in 1:6) {
pass2[p]<-NA
}
for(p in 7:12) {
pass2[p]<-NA
}
for(p in 13:18) {
con<-is.na(popest2[[k]][,p])
ncon<-length(con[con==F])
test1<-ifelse(is.na(popest2[[k]][,p])==T, 0,
ifelse(popest2[[k]][,p]<=140, 1,0))
test2<-(length(test1[test1==1])/ncon)*100
pass2[p]<-test2
}
meanpop <- aggregate(popest[[k]][
,popestnames],by=list(popest[[k]]$AgeBin),mean,na.rm=T)
popest[[k]][c((nrep*nBins+1):(nrep*nBins+nBins)),] <- meanpop
popest[[k]][c((nrep*nBins+nBins+1):(nrep*nBins+nBins*2)),] <p.pass
popest[[k]][,c(PRECparms,BIASparms)]<round(popest[[k]][,c(PRECparms,BIASparms)],0)
popest[[k]][,c(EQUIVparms)]<-round(popest[[k]][,c(EQUIVparms)],1)
popest[[k]]$REP <- rep(c(1:nrep,"MEAN","POWER"),each=nBins)
popest[[k]]<- popest[[k]][
,c(ncol(popest[[k]]),1:ncol(popest[[k]])-1)]
write.table(popest[[k]],
file=paste(path,"results/method1/",vari,"_Sparse_",nAdult,"ad_M1_output",
k,".csv",sep=""),
sep=",", quote=F, row.names=F, na=".")
meanraw <- aggregate(popraw[[k]][
,poprawnames],by=list(popraw[[k]]$AgeBin),mean,na.rm=T)
popraw[[k]][c((nrep*nBins+1):(nrep*nBins+nBins)),] <- meanraw
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popraw[[k]]$REP <- rep(c(1:nrep,"MEAN"),each=nBins)
popraw[[k]]<- popraw[[k]][
,c(ncol(popraw[[k]]),1:ncol(popraw[[k]])-1)]
popest2[[k]][nrep+1,] <- mean(popest2[[k]][1:nrep,],na.rm=T)
popest2[[k]][nrep+2,] <- pass2
popest2[[k]][,c(ESTcovar)]<-round(popest2[[k]][,c(ESTcovar)],3)
popest2[[k]][,c(PRECcovar,BIAScovar)]<round(popest2[[k]][,c(PRECcovar,BIAScovar)],0)
popest2[[k]]$REP <- c(c(1:nrep),"MEAN","POWER")
popest2[[k]] <- popest2[[k]][
,c(ncol(popest2[[k]]),1:ncol(popest2[[k]])-1)]
write.table(popest2[[k]],
file=paste(path,"results/method1/",vari,"_Sparse_",nAdult,"ad_M1_auxout",
k,".csv",sep=""),
sep=",", quote=F, row.names=F, na=".")

finalpop[f:(f+nBins*2-1), ]<popest[[k]][(nrep*nBins+1):(nrep*nBins+nBins*2), ]
finalpop$SCENARIO[f:(f+nBins*2-1)]<-k
f<-f+(nBins*2)
finalpop2[c(g,g+1), ]<-popest2[[k]][c(nrep+1,nrep+2), ]
finalpop2$SCENARIO[c(g,g+1)]<-k
g<-g+2
k<-k+1
}
}
finalpop<-finalpop[ ,c(ncol(finalpop),1:ncol(finalpop)-1)]
write.table(finalpop,
file=paste(path,"results/method1/",vari,"_Sparse_",nAdult,"ad_M1_summary.
csv",sep=""),sep=",", quote=F, row.names=F, na=".")
finalpop2<-finalpop2[ ,c(ncol(finalpop2),1:ncol(finalpop2)-1)]
write.table(finalpop2,
file=paste(path,"results/method1/",vari,"_Sparse_",nAdult,"ad_M1_auxsum.c
sv",sep=""),sep=",", quote=F, row.names=F, na=".")

## MODULE 7: READ IN SAS ESTIMATION OUTPUT (lst/parm/posthoc files) FOR
ANALYSIS : METHOD 2 - POSTHOC ##
posthocest <- list()
indraw<-list()
allposthoc<-list(list())
posthoc <- list()
posthoc.pkg<-list()
pop2<-list()
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agebin<-1:nABins
finalposthoc<data.frame(matrix(NA,ncol=Nposthocest+2,nrow=Ntrials*nABins*2))
names(finalposthoc)<-c("METRIC","AgeBin",posthocestnames,"SCENARIO")
k<-1
f<-1
for (i in Nsub) {
if (i==Nsub[1])
if (i==Nsub[2])
if (i==Nsub[3])
if (i==Nsub[4])
if (i==Nsub[5])
if (i==Nsub[6])
if (i==Nsub[7])

Nbin
Nbin
Nbin
Nbin
Nbin
Nbin
Nbin

<<<<<<<-

Nbin1
Nbin2
Nbin3
Nbin4
Nbin5
Nbin6
Nbin7

Nbin<-Nbin[1:nABins]
t<-qt(0.975,(((i-nAdult)/4)-1))
for (j in Nsamp) {
posthocest[[k]]<data.frame(matrix(NA,ncol=Nposthocest,nrow=nrep*nABins))
names(posthocest[[k]]) <- c("AgeBin",posthocestnames)
indraw[[k]]<- data.frame(matrix(NA,ncol=Nindraw,nrow=nrep*nABins))
names(indraw[[k]]) <- c("AgeBin",indrawnames)
b<-1
for(r in 1:nrep){
output <- scan(file=paste("fit",k,"rep",r,".lst",sep=""),
what="character", sep="\n")
thetaPos <- grep("Successful", output)
ifelse(length(thetaPos)==0,
pop2[[r]]<data.frame(matrix(NA,ncol=Npop2,nrow=Nparms+Ncovar)),
pop2[[r]]<read.csv(paste(path,"model_output/parms",k,"rep",r,".csv",sep="")))
names(pop2[[r]])<-pop2names
ifelse(length(thetaPos)==0,
posthoc[[r]]<data.frame(matrix(NA,ncol=Nposthoc,nrow=i)),
posthoc[[r]]<read.csv(paste(path,"model_output/posthoc",k,"rep",r,".csv",sep="")))
names(posthoc[[r]])<-posthocnames
if(length(thetaPos)!=0)
posthoc[[r]]<posthoc[[r]][match(unique(posthoc[[r]]$ID),posthoc[[r]]$ID), ]
posthoc.pkg[[r]]<-posthoc[[r]]
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if(length(thetaPos)!=0)
posthoc[[r]][ ,indparms]<-log(posthoc[[r]][ ,indparms])
ifelse(length(thetaPos)==0,
posthocmean<data.frame(CLi=c(rep(NA,nABins)),Vi=c(rep(NA,nABins))),
posthocmean<- aggregate(posthoc[[r]][
,indparms],by=list(posthoc[[r]]$ABIN),mean,na.rm=T))
ifelse(length(thetaPos)==0,posthocmean<posthocmean,posthocmean<- exp(posthocmean)[ ,indparms])
posthocbias1<-((posthocmean-bankmean)/bankmean)*100
posthocequiv1<-exp(log(posthocmean/bankmean))
#allsim[[k]][[r]][ ,parms]<-log(allsim[[k]][[r]][ ,parms])
simmean<-aggregate(allsim[[k]][[r]][
,parms],by=list(allsim[[k]][[r]]$ABIN),mean,na.rm=T)
simmean<-exp(simmean[ ,parms])
posthocbias2<-((posthocmean-simmean)/simmean)*100
posthocequiv2<-exp(log(posthocmean/simmean))
posthoc.pkg[[r]][ ,indparms]<posthoc.pkg[[r]][
,indparms]/c(((posthoc.pkg[[r]]$WT**ALLOCL)*(posthoc.pkg[[r]]$AGE/(postho
c.pkg[[r]]$AGE+A50))),posthoc.pkg[[r]]$WT**ALLOV)
if(length(thetaPos)!=0)
posthoc.pkg[[r]][ ,indparms]<-log(posthoc.pkg[[r]][
,indparms])
ifelse(length(thetaPos)==0,
posthocmean.pkg<data.frame(CLi=c(rep(NA,nABins)),Vi=c(rep(NA,nABins))),
posthocmean.pkg<- aggregate(posthoc.pkg[[r]][
,indparms],by=list(posthoc.pkg[[r]]$ABIN),mean,na.rm=T))
ifelse(length(thetaPos)==0,
posthocvar.pkg<data.frame(CLi=c(rep(NA,nABins)),Vi=c(rep(NA,nABins))),
posthocvar.pkg<- aggregate(posthoc.pkg[[r]][
,indparms],by=list(posthoc.pkg[[r]]$ABIN),var,na.rm=T))
ifelse(length(thetaPos)==0,
posthocsd.pkg<data.frame(CLi=c(rep(NA,nABins)),Vi=c(rep(NA,nABins))),
posthocsd.pkg<- aggregate(posthoc.pkg[[r]][
,indparms],by=list(posthoc.pkg[[r]]$ABIN),sd,na.rm=T))
posthocse<- sqrt(posthocvar.pkg/Nbin)
posthocUCI<-posthocmean.pkg+t*(posthocse)
posthocUCI<-exp(posthocUCI)[ ,indparms]
if(length(thetaPos)!=0) posthocmean.pkg<exp(posthocmean.pkg)[ ,indparms]
posthocprec<-(posthocUCI/posthocmean.pkg)*100
posthocRSE<-(posthocse[ ,indparms]/posthocmean.pkg)*100
posthocsd.pkg<-(posthocsd.pkg)[ ,indparms]
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meanvar<-pop2[[r]][(Ncovar:(Ncovar+1)),pop2names[2]]
meansdcl<-rep(sqrt(meanvar[1]),nABins)
meansdv<-rep(sqrt(meanvar[2]),nABins)
popsd<-cbind(meansdcl,meansdv)
shrinkage<- (1-posthocsd.pkg/popsd)*100
indest <cbind(agebin,posthocprec,posthocbias1,posthocbias2,posthocequiv1,posthoce
quiv2,shrinkage)
posthocest[[k]][c(b:(nABins*r)),] <- indest
indest2<-cbind(agebin,posthocmean,posthocRSE)
indraw[[k]][c(b:(nABins*r)),] <- indest2
b<-b+nABins
}
allposthoc[[k]] <- posthoc
pass<-c()
p.pass<-c()
for(a in agebin) {
for(p in 2:3) {
con<is.na(posthocest[[k]][posthocest[[k]]$AgeBin==a,p])
ncon<-length(con[con==F])
test1<ifelse(is.na(posthocest[[k]][posthocest[[k]]$AgeBin==a,p])==T,0,
ifelse(posthocest[[k]][posthocest[[k]]$AgeBin==a,p]<=140, 1,0))
test2<-(length(test1[test1==1])/ncon)*100
pass[p]<-test2
}
for(p in 4:7) {
pass[p]<-NA
}
for(p in 8:11) {
pass[p]<-NA
}
for(p in 12:13) {
pass[p]<-NA
}
p.pass<-rbind(p.pass,pass)
}
p.pass[,1]<-agebin
meanposthoc <- aggregate(posthocest[[k]][
,posthocestnames],by=list(posthocest[[k]]$AgeBin),mean,na.rm=T)
posthocest[[k]][c((nrep*nABins+1):(nrep*nABins+nABins)),] <meanposthoc
posthocest[[k]][c((nrep*nABins+nABins+1):(nrep*nABins+nABins*2)),]
<- p.pass
posthocest[[k]][,c(PRECposthoc,BIAS1posthoc,BIAS2posthoc)]<round(posthocest[[k]][,c(PRECposthoc,BIAS1posthoc,BIAS2posthoc)],0)
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posthocest[[k]][,c(SHRINKposthoc,EQUIV1posthoc,EQUIV2posthoc)]<round(posthocest[[k]][,c(SHRINKposthoc,EQUIV1posthoc,EQUIV2posthoc)],1)
posthocest[[k]]$REP <- rep(c(1:nrep,"MEAN","POWER"),each=nABins)
posthocest[[k]]<- posthocest[[k]][
,c(ncol(posthocest[[k]]),1:ncol(posthocest[[k]])-1)]
write.table(posthocest[[k]],
file=paste(path,"results/method2/",vari,"_Sparse_",nAdult,"ad_M2_output",
k,".csv",sep=""),
sep=",", quote=F, row.names=F, na=".")
meanraw <- aggregate(indraw[[k]][
,indrawnames],by=list(indraw[[k]]$AgeBin),mean,na.rm=T)
indraw[[k]][c((nrep*nABins+1):(nrep*nABins+nABins)),] <- meanraw
indraw[[k]]$REP <- rep(c(1:nrep,"MEAN"),each=nABins)
indraw[[k]]<- indraw[[k]][
,c(ncol(indraw[[k]]),1:ncol(indraw[[k]])-1)]

finalposthoc[f:(f+nABins*2-1), ]<posthocest[[k]][(nrep*nABins+1):(nrep*nABins+nABins*2), ]
finalposthoc$SCENARIO[f:(f+nABins*2-1)]<-k
f<-f+(nABins*2)
k<-k+1
}
}
finalposthoc<-finalposthoc[ ,c(ncol(finalposthoc),1:ncol(finalposthoc)1)]
write.table(finalposthoc,
file=paste(path,"results/method2/",vari,"_Sparse_",nAdult,"ad_M2_summary.
csv",sep=""),sep=",", quote=F, row.names=F, na=".")
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NONMEM model
$PROBLEM sim_NM thru R ; truncated normal wrt t1/2, cl, v, ka
; PROGRAMMER=MALLIKA
$DATA inputk.csv IGNORE=@
$INPUT ID TIME AMT DV=CONC ABIN AGE WT SEX
;TIME=HRS, DV=CONC=ug/mL, AMT=DOSE=MG, ABIN=AgeBin=1-5, AGE=YRS, WT=KG,
SEX=1=M,2=F
$SIMULATION (12345678 NEW) ONLYSIM
SUBPROBLEMS = 1
$SUBROUTINE ADVAN2 TRANS2
;1 COMP. MODEL oral
$THETA
3.2 FIX
6.2 FIX
2
FIX
0.75 FIX
1 FIX
0.18 FIX

;
;
;
;
;
;

CLTI (L/h/20kg)
VTI (L/20kg)
KATI (/h)
ALLOCL
ALLOV
A50 (years)

$OMEGA
0.49 FIX ; CVCL
0.49 FIX ; CVV
0.16 FIX ; CVKA
$SIGMA
0.01 FIX ; CVCP

$PK
IF (ICALL.EQ.4) THEN
CLTI
VTI
KATI
ALLOCL
ALLOV
A50

=
=
=
=
=
=

THETA(1)
THETA(2)
THETA(3)
THETA(4)
THETA(5)
THETA(6)

ETCL
ETV
ETKA

= ETA(1)
= ETA(2)
= ETA(3)

TVCL
TVV
TVKA

= CLTI*((WT/20)**ALLOCL)*(AGE/(AGE+A50))
= VTI*((WT/20)**ALLOV)
= KATI
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TVKE
TVTHF

= TVCL/TVV
= 0.693/TVKE

DLTACL
DLTAV
DLTAKA
DLTATH
LNMUCL
LOCL
HICL
LNMUV
LOV
HIV
LNMUKA
LOKA
HIKA
LNMUTH
LOTHF
HITHF

=
=
=
=
=
=
=
=
=
=
=
=
=
=
=
=

2*0.7
; MUST BE 3.27*SQRT(CVCL)!
2*0.7
; MUST BE 3.27*SQRT(CVV)!
2*0.4
2*0.7
LOG(TVCL)
EXP(LNMUCL-DLTACL)
EXP(LNMUCL+DLTACL)
LOG(TVV)
EXP(LNMUV-DLTAV)
EXP(LNMUV+DLTAV)
LOG(TVKA)
EXP(LNMUKA-DLTAKA)
EXP(LNMUKA+DLTAKA)
LOG(TVTHF)
EXP(LNMUTH-DLTATH)
EXP(LNMUTH+DLTATH)

CL=TVCL*EXP(ETCL)
IF (CL.GE.LOCL.AND.CL.LE.HICL) THEN
CLOK=1
ELSE
CLOK=0
ENDIF
V=TVV*EXP(ETV)
IF (V.GE.LOV.AND.V.LE.HIV) THEN
VOK=1
ELSE
VOK=0
ENDIF
KA=TVKA*EXP(ETKA)
IF (KA.GE.LOKA.AND.KA.LE.HIKA) THEN
KAOK=1
ELSE
KAOK=0
ENDIF
KE=CL/V
THF=0.693/KE
IF (THF.GE.LOTHF.AND.THF.LE.HITHF) THEN
THFOK=1
ELSE
THFOK=0
ENDIF
DOWHILE (CLOK.EQ.0.OR.VOK.EQ.0.OR.KAOK.EQ.0.OR.THFOK.EQ.0)
CALL SIMETA(ETA)
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ETCL
ETV
ETKA

= ETA(1)
= ETA(2)
= ETA(3)

CL=TVCL*EXP(ETCL)
IF (CL.GE.LOCL.AND.CL.LE.HICL) THEN
CLOK=1
ELSE
CLOK=0
ENDIF
V=TVV*EXP(ETV)
IF (V.GE.LOV.AND.V.LE.HIV) THEN
VOK=1
ELSE
VOK=0
ENDIF
KA=TVKA*EXP(ETKA)
IF (KA.GE.LOKA.AND.KA.LE.HIKA) THEN
KAOK=1
ELSE
KAOK=0
ENDIF
KE=CL/V
THF=0.693/KE
IF (THF.GE.LOTHF.AND.THF.LE.HITHF) THEN
THFOK=1
ELSE
THFOK=0
ENDIF
ENDDO
ENDIF

S2 = V/1
Cp(t)=A(t)/S2

;S2 is scaling factor to comp. 2 (for oral);

REP = IREP

$ERROR
ICP = F
IRES = ERR(1)
Y = F + F*ERR(1)

;proportional error model

$TABLE REP ID TIME AMT DV Y CL V KA THF ETCL ETV ABIN AGE WT SEX ICP IRES
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SAS program
options mlogic mprint;
*delete all datasets in work;
proc datasets lib=work kill memtype=data;
quit;
*import data;
PROC IMPORT OUT= data
DATAFILE="simdatakrepr.csv"
DBMS=CSV REPLACE;
GETNAMES=YES;
DATAROW=2;
RUN;
data dose; set data; if evid; dose=amt; keep id dose;run;
data data; merge data dose; by id; if evid=0; dv=conc; run;
*create the median age and wt combination within each age group for derived TVCL and TVV;
data newid; set data; by id ; if first.id; if id<=4; id=1000+id; dv=.;
if id=1001 then do; age=1 ; wt=9.7; end;
if id=1002 then do; age=4 ; wt=15.7; end;
if id=1003 then do; age=9 ; wt=29; end;
if id=1004 then do; age=14 ; wt=49.5; end;
run;
*attach newid to raw data;
data data; set data newid;run;
*fit model;
%let flag = 0;
%macro RunModel(pTVCL=,
pTVV=,
pALLOCL=,
pALLOV=,
pA50=,
ps2cl=,
ps2v=,
ps2=,
repeats=);
%let
%let
%let
%let
%let
%let
%let
%let
%let
%let
%let
%let

seedi = 18;
count = 0;
itvcl = &ptvcl;
itvv = &pTVV;
iallocl = &pALLOCL;
iallov = &pALLOV;
ia50 = &pA50;
is2cl = &ps2cl;
is2v = &ps2v;
is2 = &ps2;
tvclest = -1;
tvvest = -1;

185

%let
%let
%let
%let
%let
%let

alloclest = -1;
allovest = -1;
a50est = -1;
s2clest = -1;
s2vest = -1;
s2est = -1;

%do %while ((&flag = 0 or %sysevalf(&tvclest < 0) or %sysevalf(&tvvest < 0) or
%sysevalf(&alloclest < 0) or %sysevalf(&allovest < 0 ) or
%sysevalf(&a50est < 0) or %sysevalf(&s2clest < 0) or %sysevalf(&s2vest < 0) or
%sysevalf(&s2est < 0 )) and &count < &repeats);
proc nlmixed data=data QPOINTS=1;
*QPOINTS=1 is like Laplacian and METHOD=FIRO is like
FO in NONMEM;
parms
TVCL=&iTVCL
TVV=&iTVV
ALLOCL=&iALLOCL
ALLOV=&iALLOV
A50=&iA50
s2cl=&is2cl
s2v=&is2v
s2=&is2;
anchor = 20;
TVKA = 0.6;
s2ka = 0.09;
F = 1;
TVCLI= TVCL*((WT/anchor)**ALLOCL)*(AGE/(AGE+A50));
CL = TVCLI*EXP(ETACL);
TVVI=TVV*((WT/anchor)**ALLOV);
V = TVVI*EXP(ETAV);
KA = TVKA;
KE = CL/V;
TVKE = TVCL/TVV;
pred= log(((F*dose*TVKA)/(TVV*(TVKA-TVKE)))*(exp(-TVKE*time)-exp(-TVKA*time)));
ipred = log(((F*dose*KA)/(V*(KA-KE)))*(exp(-KE*time)-exp(-KA*time)));
ldv=log(dv);
model ldv ~ normal(ipred,s2);
random ETACL ETAV ~ normal([0,0],[s2cl,0,s2v]) subject=id;
*random ETACL ETAV ETAKA ~ normal([0,0,0],[s2cl,0,s2v,0,0,s2ka]) subject=id;
predict ipred out=ipred;
predict pred out=pred;
predict TVCLI out=TVCLI;
predict TVVI out=TVVI;
predict cl out=cl;
predict v out=v;
predict ka out=ka;
ods output ParameterEstimates=para;
run;
*reset inital parameter est;
data _NULL_;
set para;
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if
if
if
if
if
if
if
if
run;

_N_
_N_
_N_
_N_
_N_
_N_
_N_
_N_

=
=
=
=
=
=
=
=

1
2
3
4
5
6
7
8

then
then
then
then
then
then
then
then

call
call
call
call
call
call
call
call

symput("tvclest", Estimate);
symput("tvvest", Estimate);
symput("alloclest", Estimate);
symput("allovest", Estimate);
symput("a50est", Estimate);
symput("s2clest", Estimate);
symput("s2vest", Estimate);
symput("s2est", Estimate);

data _NULL_;
seed = &seedi;
call ranuni(seed, rannum1);
rannum = 1 + (rannum1 - 0.5) * 0.2;
TVCL = &ptvcl * rannum;
TVV = &ptvv * rannum;
ALLOCL = &pallocl * rannum;
ALLOV = &pallov * rannum;
A50 = &pa50 * rannum;
s2cl = &ps2cl * rannum;
s2v = &ps2v * rannum;
s2 = &ps2 * rannum;
call symput("seedi", seed);
call symput("itvcl", tvcl);
call symput("itvv", tvv);
call symput("iallocl", allocl);
call symput("iallov", allov);
call symput("ia50", a50);
call symput("is2cl", s2cl);
call symput("is2v", s2v);
call symput("is2", s2);
run;
data _NULL_;
set ipred;
if _N_ ^= 0 and %sysevalf(&tvclest > 0) and %sysevalf(&tvvest > 0 ) and
%sysevalf(&alloclest > 0) and %sysevalf(&allovest > 0 ) and
%sysevalf(&a50est > 0) and %sysevalf(&s2clest > 0 ) and %sysevalf(&s2vest > 0) and
%sysevalf(&s2est > 0 ) then
call symput("flag", 1);
run;
%if &flag = 0 %then
%do;
proc datasets library=work;
delete ipred;
quit;
%end;
%let count = &count + 1;
%end;
%mend RunModel;
%RunModel
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(pTVCL=13.5,
pTVV=10.4,
pALLOCL=0.75,
pALLOV=1,
pA50=0.18,
ps2cl=0.09,
ps2v=0.09,
ps2=0.01,
repeats=20)
%macro printRes;
*tailoring output structure;
%if &flag=1 %then
%do;
data _NULL_;
title "Successful";
file print;
put "Successful";
run;
data tvcliout; set tvcli; if id>1000; keep id age wt Pred StdErrPred Upper CLbin SECL CVCL
UCICL; CLbin=Pred; SECL=StdErrPred; CVCL=StdErrPred/Pred*100; UCICL=Upper; run;
data tvviout; set tvvi; if id>1000; keep id age wt Pred StdErrPred Upper Vbin SEV CVV UCIV;
Vbin=Pred; SEV=StdErrPred; CVV=StdErrPred/Pred*100; UCIV=Upper; run;
data cliout; set cl; by id; if first.id; if id<1000; CLi=Pred; SECLi=StdErrPred;
UCICLi=Upper; run;
*pred in this file is the posthoc CL estimate for each id;
data viout; set v; by id; if first.id; if id<1000; Vi=Pred; SEVi=StdErrPred; UCIVi=Upper;
run;
*pred in this file is the posthoc V estimate for each id;
data kaiout; set ka; by id; if first.id; if id<1000; KAi=Pred; SEKAi=StdErrPred;
UCIKAi=Upper; run;
*pred in this file is the posthoc KA estimate for each id;
data pred; set pred; if id<1000; PPRED=exp(Pred); run;
data ipred; set ipred; if id<1000; IPRED=exp(Pred); run;
data bins; merge tvcliout tvviout; by id; keep id age wt CLbin SECL CVCL UCICL Vbin SEV CVV
UCIV; run;
data posthoc; merge cliout viout kaiout; by id; keep id abin age wt sex dose cli secli
ucicli vi sevi ucivi kai sekai ucikai; run;
data preds; merge pred ipred; by id; keep id time abin age wt sex dose dv ppred ipred; run;
data posthoc; merge posthoc preds; by id; run;
*output;
proc export data=bins outfile="binskrepr.csv" DBMS=CSV REPLACE; run;
proc export data=para outfile="parmskrepr.csv" DBMS=CSV REPLACE; run;
proc export data=posthoc outfile="posthockrepr.csv" DBMS=CSV REPLACE; run;
%end;
%mend printRes;
%printRes
run;
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APPENDIX B
NONMEM model file used for simulations for warfarin
pediatric model qualification (Chapter 5)

$PROB WARF PEDS PKPD MODEL VALIDATION
$INPUT C ID TIME DAY CMT AMT DV TYPE EVID MDV INRO AGE WT GENO CYP VKOR
TARG
$DATA nmdata3.csv IGNORE='C'
$SIMULATION (123456 NEW) ONLYSIM
SUBPROBLEMS = 150
$SUBROUTINE ADVAN6 TOL=6
;User defined model written as differential equations
$MODEL ; DEFINES THE NO. OF COMPARTMENTS IN THE MODEL
COMP
COMP
COMP
COMP

=
=
=
=

1
2
3
4

$THETA (0,0.01698,1)
$THETA (0,0.019527,1)
$OMEGA 0.0961
$OMEGA 0.0686
$OMEGA 0.9821
$OMEGA 0.000001
$OMEGA 0.000025
$OMEGA 0.000025

; TVKOUT
; TVKIN
;BSV CL
;BSV V2
;BSV V3
;BSV EC50
;BSV KOUT
;BSV KIN

$SIGMA

;sd=0.585662

0.3429

$PK
TVKA = 2
TVCL = 0.1207
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TVV2
TVQ
TVV3
F1

=
=
=
=

ETCL
ETV2
ETV3

3.45
0.05
1.65
0.5

= ETA(1)
= ETA(2)
= ETA(3)

CLWT = TVCL*((WT/20)**0.75)*((0.821*AGE/(AGE+0.01))+0.21)*EXP(ETCL)
CL
= CLWT
IF (CYP.EQ.1) CL = CLWT*0.685
IF (CYP.EQ.2)

CL = CLWT*0.547

IF (CYP.EQ.3)

CL = CLWT*0.28

IF (CYP.EQ.4)

CL = CLWT*0.31

IF (CYP.EQ.5)

CL = CLWT*0.148

KA
V2
V3
Q

=
=
=
=

TVKA
TVV2*((WT/20)**0.75)*EXP(ETV2)
TVV3*((WT/20)**0.75)*EXP(ETV3)
TVQ*((WT/20)**0.75)

S2 = V2
; S2 is scaling factor to cmpt. 2 (for oral); Cp(t)=A(t)/S2 to get conc
in MG/L
TVKOUT = THETA(1)
TVKIN = THETA(2)
ETEC50 = ETA(4)
ETKOUT = ETA(5)
ETKIN = ETA(6)
TVEC50 = 0.003953
IF (VKOR.EQ.1)

TVEC50 = 0.003075

IF (VKOR.EQ.2)

TVEC50 = 0.002547

EC50
KOUT
KIN
BSLN
F4

=
=
=
=
=

TVEC50*EXP(ETEC50)
TVKOUT*EXP(ETKOUT)
TVKIN*EXP(ETKIN)
KIN/KOUT
; R0 baseline INR
BSLN

REP

= IREP

$DES
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DADT(1) = -KA*A(1)
DADT(2) = (KA*A(1))+((Q/V3)*A(3))-((Q/V2)*A(2))-((CL/V2)*A(2))
DADT(3) = ((Q/V2)*A(2))-((Q/V3)*A(3))
CFREE = A(2)*0.01/S2
DADT(4) = KIN - KOUT*A(4)*(1-(CFREE/(CFREE+EC50)));
;INHIBITION OF OUTPUT SINCE INR IS RESPONSE INVERSELY RELATED TO PCA
(INHIBITORY INDIRECT RESPONSE MODEL)

$ERROR
IF (ICALL.EQ.4) THEN
INR
CFRE
IPRE
RESID

=
=
=
=

A(4)
A(2)*0.01/S2
INR
ERR(1)

LOINR = 1
HIINR = 6
Y = IPRE + RESID
IF (Y.GE.LOINR.AND.Y.LE.HIINR) THEN
INROK=1
ELSE
INROK=0
ENDIF
DOWHILE (INROK.EQ.0)
CALL SIMEPS(EPS)
RESID = ERR(1)
Y = IPRE + RESID
IF (Y.GE.LOINR.AND.Y.LE.HIINR) THEN
INROK=1
ELSE
INROK=0
ENDIF
ENDDO
ELSE
INR
= A(4)
CFRE = A(2)*0.01/S2
IPRE = INR
RESID = ERR(1)
Y = IPRE + RESID
;ADDITIVE ERROR MODEL
ENDIF

$TABLE REP ID TIME DAY CMT AMT DV TYPE CFRE INR RESID Y INRO AGE WT GENO
CYP VKOR TARG CL EC50 BSLN KOUT KIN ETA1 ETA4 ETA5 ETA6
NOPRINT ONEHEADER FILE=sdtab8
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APPENDIX C
Drug Model set-up in Trial Simulator for optimizing pediatric warfarin dosing regimen (Chapter 5)
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APPENDIX D
Target INR outcomes for all genotypes (Chapter 5)
1. Proposed dosing regimen:
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2. Genotype-independent dosing:
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3. Proposed dosing regimen with formulation restrictions:
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4. Initial starting dose estimates - INR-time profile in typical subjects:
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APPENDIX E
Population Pharmacokinetic-Pharmacogenetic Analysis of
Nevirapine in HIV-infected Populations in Uganda and the U.S.
– A Covariate Exploration

ABSTRACT

The aims of this open-label, pharmacokinetic study were to characterize nevirapine
pharmacokinetics in two geographically distinct populations of HIV- infected patients and
to assess demographic and genetic covariates on drug exposures, focusing on the CYP2B6,
CYP3A4, CYP3A5, and MDR1genes.

A total of 46 HIV-infected adults underwent

nevirapine sampling under steady state conditions. All data were analyzed using nonlinear
mixed-effects modeling, and the population pharmacokinetic model was used to assess the
effects of covariates.

The following homozygous loss-of-function alleles, CYP2B6

516G>T, CYP3A5*3 and CYP3A4*1B, were associated with 35%, 25% and 18%
reductions in nevirapine clearance, respectively. These three genotypes in combination
with body weight, explained 71% of the interpatient variability in nevirapine apparent
clearance. Regardless of CYP genotype, all patients had trough nevirapine concentrations
above the 3,000 ng/mL threshold. As previously noted by others, variability in apparent
nevirapine clearance tended to be low and was heavily influenced by CYP2B6 516G>T.
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INTRODUCTION

At the beginning of 2009, approximately 33.4 million people world-wide were infected
with the human immunodeficiency virus (HIV); 22.5 million of these individuals live in
sub-Saharan Africa (1). In recent years, significant progress has been made in providing
antiretroviral therapy (ART) for HIV-infected patients residing in low and middle income
countries. Expanded ART access has resulted in a 10-fold increase in the number of
people receiving treatment in these underserved areas (2, 3). The availability of potent
ART to developing nations has been largely driven by the manufacture and distribution of
generic ART formulations. Of these, nevirapine has gained widespread use due to (a) its
status as a recommended component of combination ART for treatment-naïve individuals
who meet criteria for initiating therapy (4), (b) its ability to reduce mother-to-child
transmission (MTCT) of HIV-1 (5) and (c) its availability as an affordable fixed-dose
combination product (6).
Nevirapine is a non-nucleoside reverse transcriptase inhibitor (NNRTI) of HIV-1, which
binds directly to- and allosterically inhibits viral reverse transcriptase (RT) activity. Upon
oral administration, the drug is rapidly absorbed (T max = 2 h) with an absolute
bioavailability of 90-93%. It has a long half-life of 25-30 hours following repeated dosing
and is 60% bound to plasma proteins (7). Nevirapine undergoes oxidative metabolism by
CYP3A4 and CYP2B6 enzymes, while the role of CYP3A5 in nevirapine metabolism is not
entirely clear (8). In addition to CYP2B6 and CYP3A, nevirapine may also be a substrate
for the ABCB1 (MDR1) gene product and efflux transporter, P-glycoprotein (P-gp) (9).
Genetic polymorphisms in the CYP2B6, CYP3A4, CYP3A5, and ABCB1 genes may
contribute to interindividual differences in nevirapine pharmacokinetics among different
populations. Indeed, homozygous expression of the CYP2B6 516TT variant allele was
found by us and others to result in higher nevirapine concentrations in Ugandan and Swiss
populations,

respectively

(10,

11).

Similarly,

a

population

pharmacokinetic-

pharmacogenetic study in Cambodian patients found that CYP2B6 516TT was associated
with reduced nevirapine clearance compared with CYP2B6 516GT and 516GG genotypes
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(12). Nonetheless, there is still a general paucity of information regarding covariates
influencing nevirapine pharmacokinetics among different populations.
The purpose of this pharmacokinetic-pharmacogenetic study was to characterize
nevirapine pharmacokinetics in comparable non-Western (Uganda, Africa) and Western
(United States) HIV-infected populations. A population approach was used to identify
demographic and genetic factors that influence nevirapine disposition; genetic variability
in CYP2B6, CYP3A4, CYP3A5, and ABCB1 (MDR1) were targeted for this purpose. Nonlinear mixed-effects modeling was used to characterize the influence of all covariates on
nevirapine pharmacokinetic parameter values.

METHODS
Patients. Data from this study were sequentially acquired from two pooled cohorts of HIV-

infected patients from Uganda Africa, and the United States, respectively.

To be

considered for study inclusion, candidates had to be HIV positive, >18 years old, and in
good general health as determined by medical history, physical examination, and serum
chemistry values. There were no minimum or maximum requirements with regard to
CD4+ counts or HIV-RNA levels, although patients could not have any clinical or
laboratory evidence of an active opportunistic infection. Exclusion criteria also included
receipt of interleukin-2 within 3 months of study participation, receipt of any medications
known or suspected to modulate CYP2B6 and/or CYP3A4/5 activity, active drug or
alcohol abuse, pregnancy, chronic diarrhea or loose stools, fever > 38.5 0C within 7 days of
screening, and a history of poor adherence to antiretroviral therapy. After the Ugandan
cohort completed their portion of the study, a comparator group of U.S. subjects was
selected from the National Institutes of Allergy and Infectious Diseases (NIAID) outpatient
HIV clinic and included subjects who were matched by gender and BMI to their Ugandan
counterparts.
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The study was approved by the Joint Clinical Research Center Institutional Review Board,
the Uganda National Council for Science and Technology, and the National Institute of
Allergy and Infectious Diseases Institutional Review Board. All participants gave written
informed consent, and clinical research was conducted according to guidelines for human
experimentation as specified by the US Department of Health and Human Services.

Study procedures.

Because the study was designed to characterize nevirapine

pharmacokinetics in two different HIV-infected populations, a single nevirapine
formulation (Viramune™) Boehringer Ingelheim) was administered to both groups to
eliminate the possibility of a formulation effect on study results. As such, Ugandan
participants who were stabilized on a generic nevirapine formulation for at least 28 days
were switched to brand name nevirapine (Viramune™) 200 mg twice daily; the remainder
of their antiretroviral regimen remained unchanged. Due to the unavailability of generic
nevirapine formulations in the U.S., patients were already stabilized on a Viramunecontaining regimen (200 mg twice daily) for at least 28 days. To this end, pharmacokinetic
sampling for both groups occurred under steady state conditions for all study participants.
In the Ugandan cohort, subjects were admitted to the Clinical Research Center the night
before scheduled pharmacokinetic sampling. The evening nevirapine dose was observed
by study personnel for all subjects and the time of administration recorded. The next
morning, after an overnight fast, an intravenous catheter was placed into the forearm vein
of participants for the purposes of blood drawing. Just prior to taking their morning
nevirapine dose (12 hrs after the previous night’s dose), blood was collected into
heparinized tubes for a time 0 hr nevirapine concentration. Blood was also collected into
EDTA tubes for determination of CYP2B6, CYP3A4/5, and MDR1 genotypes as described
below. Next, subjects took their morning 200 mg dose of nevirapine with 100 mL of water
and a standardized breakfast provided by the clinic. Four hours after taking nevirapine,
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subjects were free to eat lunch. Adherence with antiretroviral medications was assessed by
patient interview and pill counts.
Sampling and bioanalysis. Blood samples (15 mL) for the determination of nevirapine

concentrations were collected in heparinized (green top) tubes immediately before (time 0),
and 2 and 6 hours after dosing. Blood was centrifuged after collection and plasma was
harvested and frozen until the time of analysis. Nevirapine concentrations in human
plasma were measured using a high-performance liquid chromatography (HPLC) liquid–
liquid extraction method. Percentage errors, as a measure of accuracy, were <10%, and the
inter- and intra-assay coefficients of variation were 4.35 – 8.55% and 3.54 – 6.52%
respectively (R2 = 0.998), and the limit of detection was 25 ng/ml.

Blood samples

collected during the study were also used to determine CYP2B6, CYP3A4/5, and
MDR1genotypes of the study subjects for further genetic analysis.
Genetic analysis. Venous blood samples were obtained from all subjects, and DNA was

isolated from peripheral leucocytes with the Qiamp system (Qiagen Inc, Valencia, CA).
CYP2B6 (516GG, 516GT and 516TT) and CYP3A4*1B genotypes, and/or the CYP3A5*3
null allele together with the MDR1 genotype at position 2677 were determined by
polymerase chain reaction restriction fragment length polymorphism (PCR-RFLP) as
previously described (23, 24, 25, 26).

Based on CYP2B6, CYP3A4*1B and the

CYP3A5*3 genotypes, subjects were phenotypically identified as “poor”, “intermediate”
and “extensive” nevirapine metabolizers.

No ultrarapid metabolizers were identified.

Further, based on the MDR1 genotype, subjects were phenotypically identified as “poor”,
“intermediate” and “extensive” nevirapine transporters.
Pharmacokinetic analysis. A population approach was used for the current

pharmacokinetic analysis. Previously, population PK models for nevirapine have been
published (13, 14, 15) that are consistent with regard to the base structural, onecompartment body model with first order absorption. The primary objective of this study
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was to mainly update the covariate model. While we tested for effects of all available
covariates, the focus was on the effects of four genes – CYP2B6, CYP3A4, CYP3A5 and
MDR1.

All analyses were carried out using the non-linear mixed-effects modeling

software NONMEM version VI. All graphics were generated using R version 2.9.1.
Prior base model. The available pharmacokinetic data were sparse such that we could not

estimate the oral absorption parameters. We used prior information on the base model
from a previous study (13) and fixed the parameter values for the first-order absorption rate
constant (Ka) and its variability (Ω2 Ka ) accordingly. The prior model included a linear
body weight effect parameter (WT eff ) on clearance, using a proportional model. Betweensubject variability (BSV) was explained using a proportional error model while withinsubject or residual variability (WSV) was accounted for using an additive error model. We
adapted our base model from this prior as follows:

(
Vc i = TVVc • (1 + η Vc )

)(

CLi = TVCL • 1 + WTeff • (WTi − 70 ) • 1 + η CL i

(

(2)
(3)

i

Ka i = TVKa • 1 + η Ka i

)

)

(4)

Cp i = Cp pred + ε Cp

(5)

where; η CLi is the difference between individual (CL i ) and population mean or typical
value (TVCL) of clearance for a 70-kg individual, η Vci is the difference between individual
(Vc i ) and population mean or typical value (TVVc) of volume of distribution and η Kai is
the difference between individual (Ka i ) and population mean or typical value (TVKa) of
absorption rate constant, while Cp i is the individual observed plasma concentration and
Cp pred is the individual model predicted plasma concentration. η CLi , η Vci and η Kai were all
assumed to follow a normal distribution with mean of zero and variances of Ω2 CL , Ω2 Vc
and Ω2 Ka respectively, and with η CLi and η Vci having a correlated distribution. ε Cp is the
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residual error assumed to follow a normal distribution with mean of zero and variance of
σ2 Cp .
We fit the prior model, without modification, to our study data to determine if it describes
the observed individual level data well. We also tested use of an exponential error model
for explaining BSV on all model parameters rather than a proportional model.

We

explored estimating BSV on volume with and without a covariance with clearance. We
also considered fixing the BSV on volume to the value from the prior model, or leaving
this parameter out of the model altogether.
Covariate exploration. We first tested the inclusion of each genetic and demographic

covariate individually into the model.

Covariate significance was assessed based on

mechanistic plausibility, decrease in model objective function value (ΔOFV ≥ -4), and
graphical inspection of overall model fit and covariate plots. While testing for covariate
effects, we estimated all model parameters other than mean Ka and its variability.
We explored retaining the weight effect parameter on clearance as per the prior
proportional model and estimating a weight effect parameter. We also considered an
allometric scaling model for weight effect. We then modified the clearance model as
described in the Results section above. Based on mechanism, effects of the three CYP450
isoforms were tested on nevirapine clearance and that of the MDR1 gene on bioavailability.
We used a stepwise approach for inclusion of multiple gene effects into the model, based
upon the significance of individual effects. This approach is outlined in Table 3.
Initially, we ran the model with no gene effect included. Upon inspection of covariate
plots for the four genes (vs. predicted apparent clearance (CL/F) residuals) we observed
gene effects only for the homozygous variant genotypes. Residuals were similar for the
wild type (“extensive” metabolizer) and heterozygous (“intermediate” metabolizer)
genotypes.

Hence for analysis of all gene effects, subjects were categorized into 2
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genotype groups – “extensive” metabolizers (or transporters in case of MDR1) including
wild type and heterozygous genotypes or “poor” metabolizers (or transporters in case of
MDR1) including only the homozygous variant genotype. Since the two MDR1 genotypes
(2677G>T/A and 3435C>T) on which data were available occur in linkage disequilibrium
we focused our analysis for gene effects only on the MDR1 2677 polymorphism since
there were more subjects (n = 4) with this variation than for the silent mutation MDR1
3435 (n = 2).
Although our study population was comprised of two cohorts, we considered the influence
of covariate effects based on race (White vs. Black) rather than region (U.S vs. Uganda).
Gender, age, height and BMI were the other covariates we considered for effects on both
clearance and volume, although previously published work on nevirapine population
pharmacokinetics only found either body weight or gender to be of significance.

RESULTS

Patients

A total of 46 patients met inclusion criteria and were included in the final analysis (24 and
22 subjects from the U.S. and Ugandan cohorts, respectively). Cohort demographics are
provided in Table 1.

Table 1 Characteristics of 46 HIV infected participants in this population
pharmacokinetic analysis from the U.S. and Uganda

UGANDAN
U.S. SUBJECTS
SUBJECTS
(mean
values
and
range)
(mean values and range)
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Total

N
AGE
HEIGHT
(cm)
WEIGHT
(kg)
BMI
GENDER
F
M
RACE
BLACK
WHITE
GENOTYPE
CYP2B6-516
Extensive
metabolizers
GG
Intermediate
metabolizers
GT
Poor
metabolizers
TT
CYP3A4*1B
Extensive
metabolizers
AA
Intermediate
metabolizers
AG
Poor
metabolizers
GG
CYP3A5*3
Extensive
metabolizers
AA

22
37.23 (21-50)

24
35.75 (27 - 64)

46
36.9 (21-64)

164.27 (145.7 - 184.8)

166.65 (155.3 - 195)

165.6 (145.7 - 195)

72.18 (47.4 - 98.5)
26.82 (22.01 - 37.75)

65.33 (40 - 87.5)
23.57 (14.3 - 29.7)

68.5 (40-98.5)
25 (14.3 - 37.76)

14 (63.6%)
8 (36.4%)

16 (66.7%)
8 (33.4%)

30
16

9
13

24

11 (50%)

13 (54.2%)

24 (52%)

8 (36.4%)

7 (29.2%)

15 (33%)

3 (13.6%)

4 (16.7%)

7 (15%)

12 (54.5%)

0

12 (26%)

3 (13.6%)

15 (62.5%)

18 (39%)

7 (31.8%)

9 (37.5%)

16 (35%)

6 (27.3%)

14 (58.3%)

20 (44%)
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Intermediate
metabolizers
AG
Poor
metabolizers
GG
MDR1-2677
Extensive
transporters
GG
Intermediate
transporters
GT
Poor
transporters
TT

5 (22.7%)

8 (33.3%)

13 (28%)

11 (50%)

2 (8.3%)

13 28%)

11 (50%)

23 (95.8%)

34 (74%)

7 (31.9%)

1 (4.2%)

8 (17%)

4 (18.2%)

0

4 (9%)

Pharmacokinetic analysis
Prior base model.

The sparseness of the available pharmacokinetic data precluded

estimation of oral absorption parameters. Hence, the base model was adapted from a
previous study (13). The prior model, without modification, fit the individual observed
data well.

Using an exponential error model for between-subject variability (BSV)

resulted in an increase in objective function value (OFV); hence we retained the
proportional error model to describe BSV on all primary model parameters. We also found
that estimating BSV on volume of distribution along with a covariance with clearance
yielded the best fit in terms of OFV, standard error (SE) on mean volume estimate and
predicted volume residual plots (data not shown).
Covariate exploration. We could not estimate a weight effect parameter for clearance
since the effective body weight range in both cohorts was limited (60-90 kg). Nonetheless,
removing the weight effect on clearance adversely impacted the overall model fit; hence
we chose to retain this covariate in our model. However, we used a physiologically more
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plausible allometric scaling model, with an exponent of 0.75 for body weight effect, rather
than the proportional model used previously. Besides weight, we did not find any other
demographic covariate to be of significance. Thus, our modified base clearance model is
as follows:

⎞
⎛
⎟
⎜
CLi = TVCL • ⎜WTi ⎟
⎟
⎜
⎝ 70 ⎠

0.75

(

• 1 + η CL

i

)
(1)

where; η CLi is the difference between individual clearance (CL i ) and population mean or
typical value (TVCL) of clearance for a 70-kg individual.
Genetic covariates were initially assessed individually for their effect on nevirapine
clearance. The CYP2B6 variant genotype was found to be most significant (31% reduction
in clearance, Decrease in Objective Function Value (ΔOFV) = -8) followed by the CYP3A5
variant genotype (19% reduction in clearance, ΔOFV= -4).

As lone covariates, the

CYP3A4 and MDR1 variant genotypes were not found to significantly affect nevirapine
clearance.
Table 2 summarizes our findings of gene effects on nevirapine clearance. The plots of

individual and population predicted vs. observed plasma concentrations are depicted in
Figure 1. Improved model fits can be observed for the population predictions upon

addition of significant gene effects. Figure 2 shows the covariate plots (individual population mean predicted apparent clearance (CL/F) residuals vs. covariate levels) for the
relevant genotype effects.

Table 2 Step-wise inclusion of gene-effects into model

STEP

GENE

EFFECT*
CL)
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(on 95%CI

OFV

1
2
3
4

5

NONE
CYP2B6
CYP2B6
CYP3A5
CYP2B6
CYP3A5
CYP3A4
CYP2B6
CYP3A5
CYP3A4
MDR1

-31%
-31%
-19%
-35%
-25%
-18%
-36%
-21%
-18%
+22% (eff. on F)
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-18 to -44%
-19 to -43%
-5 to -32%
-24 to -46 %
-13 to -37%
-5 to 31%
-26 to -46%
-6 to -36%
-1 to -39%
-14 to +65%

247
239
235

231

230

Figure 1: Observed vs. predicted nevirapine plasma concentrations
(a) No gene effect included

(b) CYP2B6, CYP3A5 and CYP3A4 gene effects included

Figure 2: Covariate plots showing individual vs. population mean predicted apparent
clearance (CL/F) residuals for genotype effects
(a) No gene effect included

(b) CYP2B6 gene effect included

(c) CYP2B6 and CYP3A5 gene effects included (d) CYP2B6, CYP3A5 and CYP3A4 gene effects included
*Extensive metabolizers reflect pooled wild and heterozygous genotypes. Poor metabolizers reflect
homozygous variant genotypes alone.
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In the absence of any gene effect in the model, the covariate plots were indicative of a
genotype effect for CYP2B6 and CYP3A5 genes (Figure 2a). Hence, we first included the
CYP2B6 variant genotype effect on nevirapine clearance in our model and found statistical
significance (ΔOFV = -8, Table 2) and improved graphical model fit.

The average

exposures (C avg ) were 8.63 ug/ml and 6.33 μg/ml in poor and extensive metabolizers
respectively.
Following inclusion of CYP2B6 in the model, the covariate plots were still indicative of a
genotype effect for the CYP3A5 gene (Figure 2b). We included the CYP3A5 variant
genotype effect next and found this covariate to be marginally statistically significant
(ΔOFV= -4, Table 2). The covariate plots now revealed a CYP3A4 genotype effect that
was absent earlier (Figure 2c) and a mild, if any, MDR1 genotype effect (not shown).
Hence the third genetic covariate we added to our model was the CYP3A4 variant genotype
and again found it to be marginally statistically significant (ΔOFV= -4, Table 2). Finally,
the MDR1 genotype effect on bioavailability was tested, since the covariate plots still
indicated a mild signal (Figure 2d); however, the effect was not found to be statistically
significant (ΔOFV= -1, Table 2) and did not improve the graphical model fit.
We considered differences in nevirapine clearance across race (White vs. Black). In
absence of any gene effect in the model, the covariate plots indicate a potential ‘race
effect’. However, upon inclusion of the three CYP450 isoforms into the covariate model
for clearance, this apparent race effect was no longer present in the covariate plots and the
variability in apparent clearance residuals within each race was also relatively reduced
(Figure 3).
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Figure 3: Covariate plots showing individual vs. population mean predicted apparent
clearance (CL/F) residuals for race effects
(a) No gene effect included

(b) CYP2B6, CYP3A5 and CYP3A4 gene effects included

*Extensive metabolizers reflect pooled wild and heterozygous genotypes. Poor metabolizers reflect
homozygous variant genotypes alone.

Final model parameters are presented in Table 3. While our parameter estimate for
volume of distribution (287 L) is higher when compared with previous models (70-210 L),
of note is the fact that this parameter estimate appears to vary considerably between
different models (12, 13, 14, 15). When mean volume was fixed to the prior model value
(106 L) (13), there was bias seen in the predicted volume residual (η Vci ) plots. Estimating
the mean volume parameter eliminated such bias yielding uniformly distributed residuals.

Table 3 Final model parameters
Parameter
Mean Clearance (TVCL)
Mean Volume (TVVc)

Estimate (RSE %)
3.62 L/h/70kg (6.6)

287 L (19.8)
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Variability (RSE %)

29% (22.2)
46% (24.8)

Absorption rate constant (TVKa)
WTeff_CL
CYP2B6 effect on CL
CYP3A5 effect on CL
CYP3A4 effect on CL
Residual error

1.68 /h [fixed]
0.75 [fixed]
-35% (16.1)
-25% (24.8)
-18% (36)
0.63 ug/ml (43.9)

38% [fixed]

RSE%: Relative Standard Error percentage

DISCUSSION

The base model parameters from our population model of nevirapine pharmacokinetics in
this study are in agreement with previously published accounts (12, 13, 14, 15) and they
represent the first covariate model to identify significant genotype effects on nevirapine
disposition in an African cohort. Our data are in line with prior findings that have linked
low body weight to an increase in nevirapine exposure (13, 15, 16). In fact, body weight
was the only demographic covariate with a significant impact on drug exposure, as no
differences in nevirapine pharmacokinetics were observed based on race (White vs. Black),
when accounting for the effects of the CYP genotypes in the model.

Thereby, any

observed differences in nevirapine exposure among patients of different racial (or regional)
backgrounds are likely due to differential distribution of variant genotypes among different
races, particularly CYP2B6 and CYP3A5. Highlighting this point, the CYP2B6 516TT
genotype, which is associated with minimal metabolic activity of the CYP2B6 enzyme,
was more prevalent among White subjects (24%) compared with Black subjects (12%),
while the CYP3A5*3 genotype, which is associated with minimal CYP3A5 activity, was
predominant in White subjects (85%) and negligible among Blacks (6%).

The

CYP3A4*1B variant genotype was absent among Whites and 50% prevalent in the Black
race.
In an initial study of nevirapine trough concentrations in the same Ugandan cohort reported
herein, we observed a significant association between nevirapine pre-dose concentration
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and CYP2B6 genotype (10).

Consistent with these findings, our population analysis

revealed that the CYP2B6 genotype was the most significant covariate of the population
model, being associated with a 35% reduction in nevirapine clearance. After CYP2B6,
CYP3A5*3 and CYP3A4*1B variant genotypes were identified as secondary covariates,
each of which explained 25% and 18% reductions in nevirapine clearance, respectively.
The identification of CYP2B6 and CYP3A5 variant alleles as contributors to nevirapine
clearance is consistent with previously published data (12). However, this is the first
nevirapine population model that included CYP3A4*1B. Even though the reduction in
variability in nevirapine clearance explained by CYP3A4*1B was relatively minor,
inclusion of this polymorphism improved the fit of our model and may be considered in
future studies assessing the influence of genetic covariates on nevirapine clearance.
Finally, our analysis indicated a non-significant increase of 20% in nevirapine
bioavailability in patients with the MDR1 2677TT variant genotype, when tested in context
of all genes. However, inclusion of the MDR1 gene effect did not improve the graphical
model fit. This is likely because nevirapine exhibits high oral bioavailability (> 90%),
suggesting that drug concentrations in the gastrointestinal tract would likely exceed those
necessary to saturate P-gp –assuming the nevirapine is in fact a P-gp substrate (17). To
this end, any alteration in nevirapine bioavailability due to MDR1 genotype would appear
to carry little, if any, clinical significance.
Perhaps the most important concern with reduced nevirapine clearance is the risk of
persisting subtherapeutic concentrations. This is particularly relevant to pregnant women
who receive a single dose of nevirapine for the prevention of mother-to-child-transmission
(MTCT) of HIV in Africa. Indeed single-dose nevirapine administered intrapartum, has
been associated with detectable concentrations of the drug in plasma between 1-3 weeks
after drug administration (18, 19, 20). Mothers with the CYP2B6 516TT genotype, which
is associated with reduced nevirapine clearance, may be at particular risk for persisting
nevirapine concentrations and development of NNRTI resistance mutations (K103N and
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Y181C) (21). However, a recent investigation assessed the influence of CYP2B6 516G>T
on nevirapine concentrations in HIV-infected Thai women and found that this
polymorphism had only a minor impact on nevirapine concentrations following a single
intrapartum nevirapine dose (22).
This study has several limitations. Our study design employed a limited sampling strategy
of 3 samples per subject with one pre-dose trough sample (time 0), and two post-dose
samples at 2 and 6 hours, respectively. As a result, our data was missing information on
the absorption phase of nevirapine and we could not estimate oral absorption parameters.
Hence we were unable to generate a complete model de novo, so we used a Bayesian-like
approach where we adopted prior information on these base model parameters from
previous nevirapine models.

Notably, leveraging prior information where possible is

considered good practice in model building. Next, we recognize that our sample size of 46
is comparatively smaller than other nevirapine population pharmacokinetic studies.
However, our results are consistent with previously reported findings from nevirapine
population pharmacokinetic studies, and the mechanistic reasoning for including the
selected genetic covariates is based on solid scientific rationale. Lastly, since all of our
HIV-infected patients were in good general health, we did not consider creatinine
clearance or co-morbidities as factors potentially impacting nevirapine apparent clearance.
Yet, absence of significant co-morbidities in our patient population allowed us to isolate
the influence of the genetic polymorphisms on nevirapine disposition.
Despite these limitations, data from this study show that the three genetic polymorphisms,
CYP2B6, CYP3A4*1B and CYP3A5*3 and body weight collectively explained 71% of
variability in nevirapine clearance.
Pharmacogenetic-pharmacokinetic data explaining the impact of genetic polymorphisms
on nevirapine clearance have not been previously reported in a Ugandan - U.S. cohort.
These data were largely consistent with those recently reported in HIV-infected
Cambodian patients where CYP2B6 also had the greatest impact on nevirapine clearance
215

(12). Also similar to patients from other studies, all of our patients had nevirapine trough
concentrations in excess of 3,000 ng/mL compared to 95% of patients in the Chou et al.
investigation (12). The main theoretical concern in individuals with the three genetic
polymorphisms mentioned above, particularly the CYP2B6 516TT variant, is the potential
for increased risk of nevirapine toxicity or development of nevirapine resistance due to
higher and/or persisting plasma concentrations when the drug is used for prevention of
MTCT. Further study into the pharmacogenetics and pharmacokinetics of nevirapine in
diverse patient populations will likely illicit information that will allow clinicians to
optimize the use of this agent in developing nations. Model-based dose adjustments may
also be considered for future study in homozygous variant genotype individuals to avoid
toxicity due to higher drug exposures.
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Mallika Lala
DOB: September 4, 1984
Place of birth: Mumbai, India
Citizenship: Indian
Email: Mallika.Lala@fda.hhs.gov
lalama@vcu.edu
mallika.lala@gmail.com

Current position
May 2011

Virginia Commonwealth University (VCU/School of Pharmacy)

Richmond, VA

Ph.D. candidate in Dept. of Pharmacotherapy and Outcomes Science

June 2009

Food and Drug Administration (FDA/CDER/OTS/Office of Clinical Pharmacology)

to May 2011

Silver Spring, MD
Fellow in Division of Pharmacometrics ‐ completing research for Ph.D. dissertation
• Research interests: pharmacometrics, pharmacogenetics, pediatric pharmacotherapy
• Dissertation work: Application of Pharmacometric Methods to Improve Pediatric Drug

Development. Encompasses mainly two projects:
1. Simulation‐based methodology for designing pediatric clinical trials to meet the
regulatory PK quality standard
• Objective: to evaluate the feasibility and methodological challenges while designing
a pediatric study to comply with a recent regulatory requirement.
2. A Genetics‐based pediatric warfarin dosing regimen
• Objective: to derive the first ever dosing guidelines for pediatric warfarin use,
including starting dose and titration scheme for dose individualization, focusing on
CYP2C9 and VKORC1 genetic polymorphisms.
• Major co‐advisers: Dr. Joga Gobburu (FDA) and Dr. Douglas Boudinot (VCU)
• Cumulative GPA : 4.0

Publications and Presentations
Manuscripts
• Population Pharmacokinetic‐Pharmacogenetic Analysis of Nevirapine in HIV‐infected
Populations in Uganda and the U.S. – A Covariate Exploration
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M Lala*, KM Vanevski*, JVS Gobburu, G Kabuye, P Mugyenyi, V Natarajan, RM Alfaro, H
Masur, JJL Lertora and SR Penzak
*Denotes equal contribution
Original research paper ‐ submitted to Clinical Pharmacology and Therapeutics, Feb. ’11
• CLARIFICATION ON USING THE 20% SE CRITERIA WHEN DESIGNING PEDIATRIC PK STUDIES

Wang Y, Lala M, Jadhav PR and Gobburu JVS
Short communication ‐ submitted to Journal of Clinical Pharmacology, April ’11.
• Covariate models – Do not center at values outside the data range.

Lala M, Gobburu J and Wang Y
Short communication ‐ submitted to Journal of Clinical Pharmacology, April ’11.
• Pharmacometric Analyses Impact Pediatric Drug Approval and Dosing

Mallika Lala and Pravin R Jadhav
Review article – to be submitted to Journal of Pediatrics, April ’11.
• Simulation‐based Method for using PK Quality Standard to Design Pediatric Trials in the

Population Analysis Setting
Mallika Lala, Yaning Wang, Pravin Jadhav, Joga Gobburu
Original research paper – to be submitted to Journal of Pharmacokinetics and
Pharmacodynamics, April ’11.
Book Chapter
• Pharmacometrics: Concepts and Applications to Drug Development
Mallika Lala and Jogarao V. S. Gobburu
In process for publication in Immunotherapy in Transplantation: Principles and Practice by
Wiley‐Blackwell publishers, April ’11.
Posters
• Implementation of a Pharmacokinetic Quality Standard to Improve Pediatric Trial Design.
Presented at:
• ACOP (American Conference on Pharmacometrics), April 2011
• Research and Career Day, VCU School of Pharmacy, October 2010.
• Population Pharmacokinetic‐Pharmacogenetic Analysis of Nevirapine in HIV‐infected
patients in Uganda and the U.S. – A Covariate Exploration. Presented at:
• ACOP, April 2011.
• Research and Career Day, VCU School of Pharmacy, October 2010.
• Covariate models – Do not center at values outside the data range. Presented at ACOP,
April 2011.
• Cost‐effectiveness Analysis of implementing warfarin dosing using a pharmacogenetic
model. Presented at AACC annual conference, July 2009.
• Comparison of Pharmacogenetic Models for prediction of Indivdualized Warfarin Dosing.
Presented at:
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• AACC (American Association for Clinical Chemistry) annual conference, July 2008.
• Research and Career Day, VCU School of Pharmacy, October 2008.

Academic History
Aug. 2006
to date

School of Pharmacy, VCU

Richmond, VA

• Awarded full tuition waiver based on undergraduate academic profile and experience.
• SmartWarf Clinical study: PI ‐ Dr. Bonny Bukaveckas
• Objective: to build an adult warfarin‐dosing model using retrospective multiple

•
•

•

•

regression analysis of patient data including CYP2C9 and VKORC1 genetic
polymorphisms, age, weight, gender, race and INR; and to test clinical effectiveness of
dosing model over standard of care warfarin management in the anticoagulation clinic
at MCV.
• Contributions: involved with study design, patient recruitment and data collection and
fully responsible for data archiving and analysis.
• Study was terminated prematurely due to patient recruitment problems.
Workshop on PK‐PD Modeling conducted by Dr. Jurgen Venitz, Dept. of Pharmaceutics.
Gained experiential training in modeling completed the course for credit with grade A.
Workshop on Population PK Modeling conducted by Dr. Joga Gobburu, Dr. Pravin Jadhav,
Dr. Christopher Tornoe and Dr. Yaning Wang from Division of Pharmacometrics, FDA.
Conceptual and hands‐on training in population modeling. Completed the course with a
journal club presentation to the group from FDA.
Pharmacoeconomic project on cost‐effectiveness analysis of implementing warfarin
dosing using a pharmacogenetic model under supervision of Dr. David Holdford, Dept. of
Pharmacotherapy and Outcomes Science. Involved thorough understanding and
implementation of cost‐effectiveness studies, writing of project report and poster
presentations.
Departmental Research Seminars:
• Spring ’07: “Individualized warfarin dosing, the time has come”. Literature review
seminar, covering the past work done on warfarin pharmacogenetics, the current
state of the field, its merits and limitations.
• Spring ’08: “Individualizing warfarin dosing, building the right model”. Research design
seminar, covering the hypothesis, specific aims and planned methods for the adult
warfarin PGx project.
• Spring ’09: “Pharmacogenetics: the present and the future, warfarin and beyond”.
Literature review seminar, covering the current successful clinical applications of
pharmacogenetics and future avenues, as well as a summary of the warfarin PGx
project and the potential for newer methods, mainly pharmacometrics, to improve
dosing of warfarin and other drugs.
• Spring ’10: “Approaches to assess quality of PK data for designing pediatric trials”.
Research design seminar, covering rationale, aims and methods for a simulations‐
based pediatric trial design project, proposed as part of dissertation research at FDA.
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July ’02 to
May ’06

University of Mumbai, Institute of Chemical Technology (UICT)
Degree earned: Bachelor of Pharmaceutical Sciences (B. Pharm. Sci.)

Mumbai, India

• Cumulative grade: Distinction (75% aggregate score)
• Research Seminar on ‘Estrogen as a neuroprotective’. The work entailed a comprehensive

literature review and was presented at the Dept. of Pharmaceutical Sciences &
Technology, UICT (Jan. ’05).
• Member of the TB Fact Card Project group ‐ the pioneer project of its kind in India
initiated by the IPSF & IPA ‐ for creating awareness about the course & gravity of the
disease and helping in the implementation of proper drug therapy via co‐ordination with
various retail pharmacists all over the city of Mumbai. (May 2005‐06)
• Participant in workshop on Bioinformatics and Drug Design at SIES‐Institute of
Environmental Management, Mumbai. (April 2005).

Employment Record
June ’09
to date

FDA (Office of Clinical Pharmacology)
Silver Spring, MD
FELLOW in Division of Pharmacometrics
• Undertaken two major research projects as part of Ph.D. dissertation.
• NIH collaboration research project: derived a population pharmacokinetic‐
pharmacogenetic model for the drug Nevirpaine used as HIV treatment. Wrote and
submitted manuscript on the project in collaboration with researchers from National
Instititutes of Health (July’10‐Feb’11).
• Conducted six pediatric IND reviews.
• Additional assignments by supervisors.

Aug. ’06 to
Aug. ‘09

Virginia Commonwealth University (VCU)
Richmond, VA
TEACHING ASSISTANT in Dept. of Pharmacy
st
nd
• Skills Labs: Trained 1 and 2 year Pharm.D. students in pharmacy skills ‐ role playing
(patient counseling, tele‐ prescription filling with physician etc), services (measuring blood
pressure, cholesterol, blood glucose etc), parenteral nutrition bag preparation under
aseptic conditions.
• Courses and Labs: Prepared quizzes, posted quizzes to blackboard, administered paper
quizzes and exams in class, administered clicker quizzes in class, graded quizzes, exams
and homework assignments, both MCQ type and subjective essay‐type, posted grades to
blackboard.
• Assisted with overall conduct of classes and labs and co‐ordination of course activities,
maintained blackboard course websites and handled course, instructor, and peer
evaluations.
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June‐July ’05 Pfizer
Mumbai, India
STUDENT INTERN
• Exposure to the sophisticated working environment of a multinational pharmaceutical
company.
• Overview training of operations in various departments of the industry viz. Production,
Quality Control, cR&D Pilot Plant, Engineering & Maintenance, Pharmacy, Stores and
P.P.I.C.
• Conducted a comprehensive study and presentation of how a large‐scale pharmaceutical
plant functions, to support the knowledge heretofore gained by coursework and small‐
scale laboratory work at school.

Technical Skills
• Data analysis and simulation software programs –

NONMEM, R, SAS, Trial Simulator, DATA (cost‐effectiveness modeling)
• Laboratory techniques for genetic testing –

PCR and Microarray

Achievements
• Selected as Phi Kappa Phi Graduate School Scholarship Recipient from School of

Pharmacy, VCU for two years – 2008 and 2010.
• Invited to membership of the Honor Society of Phi Kappa Phi for academic excellence ‐

October 2007.
• Elected to the post of Vice President for the Graduate Student Association of the
Dept. of Pharmacy, VCU School of Pharmacy ‐ 2007.
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